fingolimod hydrochloride has been researched along with Multiple Sclerosis in 789 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 33 (4.18) | 29.6817 |
| 2010's | 432 (54.75) | 24.3611 |
| 2020's | 324 (41.06) | 2.80 |
| Authors | Studies |
|---|---|
| Kolontareva, YM; Krasnov, VS | 1 |
| Bianco, A; Centonze, D; De Arcangelis, V; De Fino, C; De Luca, G; Di Lemme, S; Di Tommaso, V; Evangelista, L; Fantozzi, R; Lucchini, M; Mirabella, M; Pastorino, R; Presicce, G; Totaro, R | 1 |
| Gaughan, M; Lally, A; McGuigan, C; O'Higgins, L | 1 |
| Homann, T; Huwiler, A; Imeri, F; Kleuser, B; Stark, H; Stepanovska Tanturovska, B; Zivkovic, A | 1 |
| Abouelfath, A; Blin, P; Bosco-Lévy, P; Brochet, B; Debouverie, M; Diez, P; Droz-Perroteau, C; Guillemin, F; Heinzlef, O; Lassalle, R; Lignot, S; Louapre, C; Maillart, E | 1 |
| Häusler, D; Häusser-Kinzel, S; Ochs, J; Quendt, C; Weber, MS | 1 |
| Correale, J; Halfon, MJ; Jack, D; Rubstein, A; Villa, A | 1 |
| Berthele, A; Bussas, M; Eichinger, P; Gaser, C; Grahl, S; Hemmer, B; Kirschke, J; Mühlau, M; Wiestler, B; Zimmer, C | 1 |
| Battaglia, MA; Brichetto, G; Caleri, F; Callari, G; Carmisciano, L; Clerico, M; Cordera, S; Cordioli, C; Da Rin, G; Di Sapio, A; Ferrò, MT; Franciotta, D; Frau, J; Gandoglia, I; Gazzola, P; Inglese, M; Iodice, R; Landi, D; Lapucci, C; Laroni, A; Liberatore, G; Mannironi, A; Marinelli, F; Pasquali, L; Perego, G; Repice, AM; Salvetti, M; Schiavetti, I; Serrati, C; Signoriello, E; Sormani, MP; Stromillo, ML; Tassinari, T; Uccelli, A; Ulivelli, M | 1 |
| Anagnostouli, M; Chrousos, GP; Dalakas, M; Evangelopoulos, ME; Gontika, M; Markoglou, N; Skarlis, C; Stefanis, L; Velonakis, G | 1 |
| Alroughani, R; Barnett, M; Boz, C; Butler, E; Butzkueven, H; Buzzard, K; Duquette, P; Eichau, S; Girard, M; Grammond, P; Gresle, M; Hodgkinson, S; Jokubaitis, VG; Kalincik, T; Karabudak, R; Kermode, AG; Kuhle, J; Laureys, G; Lechner-Scott, J; Macdonell, R; McCombe, P; Monif, M; Prevost, J; Skibina, O; Slee, M; Stankovich, J; Taylor, B; van der Walt, A; Van Hijfte, L; van Pesch, V; Yeh, W; Zhong, M | 1 |
| Amato, MP; Banwell, B; Chitnis, T; Deiva, K; Hemingway, C; Krupp, L; Pohl, D; Rostasy, K; Sandesjö, F; Wassmer, E; Waubant, E; Wickström, R | 1 |
| Álvarez-Cermeño, JC; Fernández, O; Hernández, MA; Marzo, ME; Meca-Lallana, JE; Meca-Lallana, V; Montalbán, X; Muñoz, D; Olascoaga, J; Oreja-Guevara, C; Pato, A; Ramió-Torrentà, L; Rodríguez-Antigüedad, A | 1 |
| Aaberge, IAS; Aarseth, J; Andersen, JT; Berge, T; Celius, EG; Harbo, HF; Holmøy, T; König, M; Lorentzen, ÅR; Lund-Johansen, F; Munthe, LA; Mygland, Å; Myhr, KM; Nygaard, GO; Schikora-Rustad, S; Søraas, A; Torgauten, HM; Torkildsen, Ø; Tran, TT; Vaage, EB; Vaage, JT; Wergeland, S | 1 |
| Del Giovane, C; Filippini, G; Kruja, J | 1 |
| Cai, T; Chitnis, T; Dahal, K; Hou, J; Kim, N; Weiner, H; Xia, Z | 1 |
| Ara, JR; Fernandez, FJ; Garcia-Martin, E; Gil-Arribas, L; Jarauta, L; Martin, J; Rodrigo, MJ; Ruiz de Gopegui, E; Satue, M; Vilades, E | 1 |
| Bai, X; Beard, K; Chaudhary, D; Khalid, SH; Lisak, RP; Srivastava, S; Sriwastava, S; Wen, S | 1 |
| Berger, J; Campbell Cree, BA; DeLasHeras, V; Greenberg, BM; Hach, T; Hemmer, B; Kilaru, A; Kundu, U; Sullivan, R; Ward, BJ | 1 |
| Bianco, A; Capone, F; Cicia, A; Cortese, A; Cruciani, A; De Arcangelis, V; De Giglio, L; Di Lazzaro, V; Ferraro, E; Lucchini, M; Mirabella, M; Motolese, F; Rossi, M; Sancetta, B | 1 |
| Barragan, JA; Brown, J; Cervantes, JL; Everett, C; Gadad, BS; Nichols, F; Vargas-Medrano, J | 1 |
| Acosta, C; Alroughani, R; Boz, C; Butzkueven, H; De Luca, G; Dort, T; Duquette, P; Ferraro, D; Freudensprung, U; Grammond, P; Grand'Maison, F; Granella, F; Havrdova, E; Herring, WL; Horakova, D; Hupperts, R; Hyde, R; Izquierdo, G; Jokubaitis, VG; Kalincik, T; Lechner-Scott, J; Lugaresi, A; Oreja-Guevara, C; Pearson, I; Pucci, E; Rozsa, C; Sola, P; Spelman, T; Tempest, M; Terzi, M; Trojano, M; van der Walt, A; Van Pesch, V; Zhang, Y | 1 |
| Audoin, B; Bensa, C; Bourre, B; De Seze, J; Januel, E; Louapre, C; Maarouf, A; Maillart, E; Moisset, X; Pelletier, J; Pique, J; Vermersch, P; Vukusic, S | 1 |
| Cai, XH; Guo, C; He, Y; Huang, Z; Ikuta, T; Inoue, A; Kawakami, K; Kise, R; Qian, Y; Sun, MX; Xia, R; Xu, Z; Zhang, A | 1 |
| Awan, S; Eckert, SP; Farooq, O; Jakimovski, D; Weinstock-Guttman, B | 1 |
| Ekuma, O; Evans, C; Fisk, JD; Kingwell, E; Marrie, RA; Ng, HS; Svenson, LW; Tremlett, H; Yao, S; Zhao, Y; Zhu, F | 1 |
| Gu, ZC; Lv, Y; Ma, CL; Zhao, Z; Zhong, MK | 1 |
| Ahle, G; Bigaut, K; Collongues, N; Courtois, S; de Seze, J; Fabacher, T; Fleury, M; Gaultier, C; Goudot, M; Kremer, L | 1 |
| Albrecht, H; Ettle, B; Haas, J; Klotz, L; Lang, M; Lang, S; Lassek, C; Schmidt, S; Schulze-Topphoff, U; Winkelmann, VE; Ziemssen, T | 1 |
| Hartung, HP; Korsen, M; Meuth, SG; Pfeuffer, S; Rolfes, L | 1 |
| Dimitri, D; Pourcher, V | 1 |
| Conlon, N; Dunne, J; Gaughan, M; Holden, D; Redenbaugh, V; Redmond, J; Reynolds, A | 1 |
| Akbayır, E; Baliç, N; Erol, R; Kızılay, T; Türkoğlu, R; Tüzün, E; Yılmaz, V | 1 |
| Amato, MP; Battaglia, MA; Brambilla, L; Brescia Morra, V; Capobianco, M; Cavalla, P; Comi, G; De Luca, G; Ferraro, D; Filippi, M; Granella, F; Iaffaldano, P; Lepore, V; Lucisano, G; Lugaresi, A; Lus, G; Malucchi, S; Maniscalco, GT; Manni, A; Moiola, L; Montepietra, S; Mosconi, P; Paolicelli, D; Patti, F; Pesci, I; Petracca, M; Ponzio, M; Ragonese, P; Sola, P; Tedeschi, G; Toscano, S; Totaro, R; Trojano, M; Vianello, M | 1 |
| Duchesneau, ED; Jonsson Funk, M; Kinlaw, AC; Lund, JL; Pate, V | 1 |
| Bielen, I; Draganić, P; Klepac, N; Košćak Lukač, J; Sremec, J; Tomasović, S | 1 |
| Alonso, R; Barboza, A; Burgos, M; Carra, A; Chertcoff, A; Fernandez Liguori, N; Gaitán, MI; Halfon, MJ; Lazaro, L; Liwacki, S; Luetic, G; Mainella, C; Menichini, ML; Miguez, J; Orzuza, G; Palavecino, A; Pappolla, A; Patrucco, L; Pierdabuena, R; Pigretti, S; Pita, C; Recchia, L; Ruiz, E; Silva, B; Steinberg, J; Tkachuk, VA; Ysrraelit, MC; Zanga, G; Zentil, G | 1 |
| Askari, M; Ghaffary, EM; Ghajarzadeh, M; Ghoshouni, H; Mirmosayyeb, O; Shaygannejad, V | 1 |
| Andrade, M; Boldrini, VO; Brandão, CO; Carneiro, RPD; Damasceno, A; Farias, AS; Ferrari, B; Longhini, ALF; Marques, AM; Moraes, AS; Quintiliano, RPS; Santos, I; Santos, LMB; Stella, CRAV | 1 |
| Berger, E; Bourre, B; Cabre, P; Camdessanché, JP; Casey, R; Casez, O; Ciron, J; Clavelou, P; Couturier, J; De Sèze, J; Debouverie, M; Defer, G; Edan, G; Gout, O; Hankiewicz, K; Labauge, P; Laplaud, DA; Lebrun-Frenay, C; Leray, E; Maillart, E; Maurousset, A; Montcuquet, A; Moreau, T; Nasr, HB; Neau, JP; Pelletier, J; Pottier, C; Rollot, F; Ruet, A; Stankoff, B; Thouvenot, E; Vukusic, S; Wiertlewski, S; Zephir, H | 1 |
| Achiron, A; Dolev, M; Dreyer-Alster, S; Falb, R; Flechter, S; Gurevich, M; Harari, G; Magalashvili, D; Mandel, M; Menascu, S; Sonis, P | 1 |
| Adamkova, J; Ampapa, R; Hanulikova, P; Horakova, D; Hradilek, P; Mares, J; Meluzinova, E; Pavliska, L; Stetkarova, I; Stourac, P; Vachova, M; Valis, M; Woznicova, I; Zapletalova, O | 1 |
| Altieri, M; Bisecco, A; Capuano, R; Chianese, A; Conte, M; Coppola, N; Donnarumma, G; Franci, G; Galdiero, M; Gallo, A; Grimaldi, E; Tedeschi, G | 1 |
| Bovis, F; Buttari, F; Cellerino, M; Centonze, D; Cola, G; Fantozzi, R; Grimaldi, A; Inglese, M; Landi, D; Lucchini, M; Lus, G; Marfia, GA; Mataluni, G; Mirabella, M; Nicoletti, CG; Ponzano, M; Signoriello, E | 1 |
| Aparasu, RR; Chikermane, SG; Earla, JR; Hutton, GJ; Li, J | 1 |
| Alroughani, R; Butzkueven, H; Buzzard, K; Eichau, S; Grammond, P; Havrdova, EK; Hodgkinson, S; Horakova, D; Izquierdo, G; Kalincik, T; Kappos, L; Lechner-Scott, J; Malpas, CB; Patti, F; Roos, I; Sharmin, S; Skibina, O | 1 |
| Aydemir, A; Bezemer, I; Butzkueven, H; Korhonen, P; Moore, N; Sabidó, M; Sõnajalg, J | 1 |
| Dahlke, F; Häring, DA; Kappos, L; Kropshofer, H; Kuhle, J; Leppert, D; Meinert, R; Patil, A; Tomic, D | 1 |
| Počíková, Z; Štěpánová, R; Tichá, V; Vytlačil, J | 1 |
| Bar-Haim, E; Hellmann, MA; Karni, A; Karussis, D; Miller, A; Milo, R; Staun-Ram, E | 1 |
| Celius, EG; Høgestøl, EA; Myhr, KM; Nygaard, GO; Skattebøl, L; Sowa, P; Torgauten, H; Torkildsen, Ø | 1 |
| Bakshi, R; Gillani, RL; Klawiter, EC; Manzano, GS; Mateen, FJ; Matiello, M; Rice, DR; Tauhid, SS | 1 |
| Atula, S; Järvinen, E; Kuusisto, H; Rauma, I; Ryytty, M; Sipilä, JOT; Soilu-Hänninen, M; Viitala, M | 1 |
| Gębka-Kępińska, B; Sowa, P; Zięba, N | 1 |
| Boekel, L; Brinke, AT; Duurland, M; Eftimov, F; Hagen, RR; Killestein, J; Konijn, VAL; Kuijpers, TW; Kummer, LYL; Palomares Cabeza, V; Rispens, T; Stalman, EW; Steenhuis, M; Tas, SW; van Dam, KPJ; van de Sandt, CE; van Ham, SM; van Kempen, ZLE; Verstegen, NJM; Wieske, L; Wolbink, G | 1 |
| Chandran, S; Connick, P; Foley, P; Glasmacher, SA; Hassan, Z; Kearns, PK; Reetz, K; Tauber, S | 1 |
| Bove, RM; Gelfand, JM; Green, AJ; Guo, CY; Hsu, WY; Li, A; McPolin, K; Merrill, S; Rowles, WM | 1 |
| Al-Khedr, A; Alroughani, R; Andersen, JB; Ben Nasr, H; Berger, E; Bourre, B; Boz, C; Bramow, S; Butzkueven, H; Buzzard, K; Cabre, P; Camdessanché, JP; Casey, R; Casez, O; Ciron, J; Clavelou, P; Csepany, T; De Sèze, J; Debouverie, M; Defer, G; Dimitri-Boulos, D; Duquette, P; Edan, G; Eichau, S; Ferraro, D; Frederiksen, JL; Girard, M; Gout, O; Grammond, P; Grand'Maison, F; Granella, F; Hankiewicz, K; Havrdova, EK; Heinzlef, O; Hilt Christensen, CC; Horakova, D; Izquierdo, G; Jensen, MB; Kalincik, T; Karabudak, R; Koch-Henriksen, N; Labauge, P; Laplaud, DA; Lebrun-Frenay, C; Lechner-Scott, J; Lefort, M; Leray, E; Lugaresi, A; Magyari, M; Maillart, E; Maimone, D; Mathiesen, HK; Maubeuge, N; Maurousset, A; McCombe, P; Montcuquet, A; Moreau, T; Nifle, C; Onofrj, M; Ozakbas, S; Patti, F; Pelletier, J; Pottier, C; Prat, A; Prevost, J; Rasmussen, PV; Ruet, A; Schreiber, KI; Sellebjerg, F; Sharmin, S; Shaygannejad, V; Skibina, O; Slee, M; Soerensen, PS; Sola, P; Spitaleri, D; Stankoff, B; Terzi, M; Thouvenot, E; Trojano, M; Turkoglu, R; Van der Walt, A; Van Wijmeersch, B; Vucic, S; Vukusic, S; Wahab, A; Yamout, B; Zephir, H | 1 |
| Abduljabar, H; Al-Yafeai, Z; Arvas, M; Carvajal-González, A; Patel, N; Patel, S | 1 |
| Aliomrani, M; Dayani, L; Dinani, MS; Hashempour, H; Taheri, A; Varshosaz, J | 1 |
| Annovazzi, P; Bonavita, S; Caleri, F; Cavalla, P; Clerico, M; Cocco, E; Cola, G; Conte, A; Cordioli, C; Di Filippo, M; Di Sapio, A; Docimo, R; Ferraro, D; Immovilli, P; Iodice, R; Lanzillo, R; Laroni, A; Liberatore, G; Pasquali, L; Patti, F; Rilla, MT; Ruscica, F; Salvetti, M; Schiavetti, I; Signoriello, E; Sormani, MP; Stromillo, ML; Teresa Ferrò, M; Ulivelli, M | 1 |
| Cannizzaro, M; Clarelli, F; Colombo, B; Comi, G; Esposito, F; Ferré, L; Filippi, M; Giordano, A; Martinelli, V; Moiola, L; Sangalli, F | 1 |
| Acar Ozen, P; Anlar, B; Parlak, S; Solmaz, I; Tuncer, A | 1 |
| Eisele, P; Gass, A; Platten, M; Schirmer, L; Weber, CE; Wittayer, M | 1 |
| Bravo, GÁ; Casadevall, MP; Cedeño, RR; Ramió-Torrentà, L | 1 |
| Bellmann-Strobl, J; Böttcher, C; Braginets, A; Braun, J; de la Rosa, K; Dingeldey, M; Fauchere, F; Giesecke-Thiel, C; Henze, L; Holenya, P; Jürchott, K; Klein, F; Kruse, B; Loyal, L; Mangold, M; Maraj, A; Meyer-Arndt, L; Nitsche, A; Paul, F; Ratswohl, C; Reimer, U; Sander, LE; Sawitzki, B; Thiel, A; Vanshylla, K | 1 |
| Abyadeh, M; Amirkhani, A; Basavarajappa, D; Chick, JM; Chitranshi, N; Fitzhenry, MJ; Graham, SL; Gupta, V; Gupta, VK; Haynes, PA; Klistorner, A; Mirshahvaladi, SSO; Mirzaei, M; Paulo, JA; Turner, AJ; Wall, RV; You, Y | 1 |
| Altieri, M; Bisecco, A; Capuano, R; Conte, M; Coppola, N; d'Ambrosio, A; Donnarumma, G; Galdiero, M; Gallo, A; Grimaldi, E; Medici, N; Tedeschi, G | 1 |
| Butler, E; Butzkueven, H; Buzzard, K; Eichau, S; Girard, M; Hodgkinson, S; Jokubaitis, V; Kalincik, T; Lechner-Scott, J; Monif, M; Oh, J; Prevost, J; Skibina, O; van der Walt, A; Van Pesch, V; Zhong, M | 1 |
| Callens, A; Coustans, M; Edan, G; Jourdain, A; Lallement, F; Laplaud, D; Le Page, E; Leblanc, S; Leray, E; Michel, L; Videt, D; Wiertlewski, S | 1 |
| Boyko, AN | 1 |
| Al-Iedani, O; Lea, R; Lechner-Scott, J; Ramadan, S; Ribbons, K | 1 |
| Li, F; Li, Y; Ling, L; Zhang, W | 1 |
| Affinito, G; Berera, G; Brescia Morra, V; Carotenuto, A; Lanzillo, R; Marrazzo, G; Moccia, M; Palladino, R; Petracca, M; Piscitelli, R; Triassi, M | 1 |
| Apóstolos, SLP; Boaventura, M; Campana, IG; Mendes, NT; Teixeira, LS | 1 |
| Aguera-Morales, E; Al-Asmi, A; Alroughani, R; Amato, MP; Ampapa, R; Bakchine, S; Barnett, MH; Ben, NH; Berger, E; Bourre, B; Boz, C; Butler, EG; Butzkueven, H; Buzzard, K; Cabre, P; Cartechini, E; Casey, R; Castillo-Trivino, T; Ciron, J; Clavelou, P; Csepany, T; de Gans, K; De Seze, J; Debouverie, M; Edan, G; Eichau, S; Fragoso, YD; Gerlach, O; Girard, M; Gouider, R; Gout, O; Grammond, P; Grand'Maison, F; Havrdova, EK; Heinzlef, O; Hodgkinson, S; Horakova, D; Izquierdo, G; Kalincik, T; Kappos, L; Khoury, SJ; Labauge, P; Labeyrie, C; Laplaud, DA; Laureys, G; Lebrun-Frenay, C; Lechner-Scott, J; Leray, E; Macdonell, RA; Maillart, E; Malpas, C; Maubeuge, N; McCombe, PA; Moreau, T; Ozakbas, S; Patti, F; Pelletier, J; Prat, A; Prevost, J; Ramo-Tello, CM; Roos, I; Sánchez-Menoyo, JL; Shaygannejad, V; Sidhom, Y; Skibina, O; Slee, M; Sotoca, J; Soysal, A; Spitaleri, DLA; Stankoff, B; Terzi, M; Thouvenot, E; Turkoglu, R; Van der Walt, A; Van Hijfte, L; Van Pesch, V; Vucic, S; Vukusic, S; Wahab, A; Yamout, BI; Zephir, H | 1 |
| Al-Araji, SA; Chard, DT; Ciccarelli, O; Sahi, N; Trip, SA | 1 |
| Esfandiary, E; Ghanadian, M; Ghasemi, N; Moradi, V; Rashidi, B | 1 |
| de Aguiar, PHP; Duarte, JÁ; Finkelsztejn, A; Franceschini, PR; Morillos, MB; Piccini, CD | 1 |
| Baba, C; Cevik, S; Dogan, Y; Kaya, E; Ozakbas, S; Ozcelik, S; Ozdogar, AT; Samedzada, U | 1 |
| De Sèze, J; Edan, G; Kerbrat, A; Laplaud, DA; Le Page, E; Lebrun-Frenay, C; Lefort, M; Leguy, S; Leray, E; Lescot, L; Michel, L; Vukusic, S; Wiertlewski, S | 1 |
| Apóstolos-Pereira, SL; Callegaro, D; Castrillo, BB; Silva, GD | 1 |
| Cano, S; Elliott, E; Jivraj, F; Kang, S; Kapadia, S; Reedie, S; Rock, M; Strzok, S | 1 |
| Carmagnini, D; Carta, E; Castiglia, P; Chessa, P; Cocco, E; Cucca, F; Delogu, G; Devoto, M; Farina, G; Fiorillo, E; Floris, M; Frau, J; Fronza, M; Idda, ML; Lobina, M; Lodde, V; Loizedda, A; Lorefice, L; Marini, MG; Masala, M; Mingoia, M; Pilotto, S; Pitzalis, M; Solla, P; Steri, M; Uzzau, S; Virdis, F; Zarbo, RI; Zoledziewska, M | 1 |
| Doi, Y; Ide, T; Isobe, R; Jinno, R; Kawabe, Y; Muramatsu, E; Ritsuno, Y; Sakurai, A; Sasaki, T; Tsutsumi, Y | 1 |
| Chan, A; Diem, L; Friedli, C; Hammer, HN; Hoepner, R; Kamber, N; Salmen, A; Wagner, F; Wiest, R | 1 |
| Bajeux, E; Chappuis, M; Edan, G; Kerbrat, A; Laplaud, D; Le Page, E; Michel, L; Rousseau, C; Wiertlewski, S | 1 |
| Ataei, S; Esfahani, ME; Jenabi, E; Sahraian, MA; Salehi, AM | 1 |
| Alasmari, AF; Alharbi, M; Alshammari, A; Assiri, MA; Kalfin, R; Kapoor, T; Kumar, N; Mehan, S; Narula, AS; Sharma, N; Suri, M | 1 |
| Haug, U; Kollhorst, B; Platzbecker, K; Wentzell, N | 1 |
| Aykaç, S; Eliaçık, S | 1 |
| Calabrese, P; Chiavi, D; Dressel, H; Haag, C; Horn, AB; Kamm, CP; Kaufmann, M; Pot, C; Sieber, C; von Wyl, V; Zecca, C | 1 |
| Yukitake, M | 1 |
| Davani, DN; Ghajarzadeh, M; Najdaghi, S; Shaygannejad, V | 1 |
| Dababneh, D; Montalban, X; Muccilli, A; Rotstein, D; Saab, G; Shah, P; Solomon, JM; Sormani, MP; Ye, XY | 1 |
| Cristiano, E; Pappolla, A; Patrucco, L; Rojas, JI; Sánchez, F | 1 |
| Akgün, K; Constantinescu, V; Ziemssen, T | 1 |
| Alroughani, R; Barnett, M; Boz, C; Butzkueven, H; Hodgkinson, S; Horakova, D; Izquierdo, G; Jokubaitis, V; Kalincik, T; Karabudak, R; Khoury, SJ; Kubala Havrdova, E; Kuhle, J; Lechner-Scott, J; Macdonell, R; Merlo, D; Monif, M; Onofrj, M; Ozakbas, S; Patti, F; Prat, A; Prevost, J; Roos, I; Skibina, O; Slee, M; van der Walt, A; Van Pesch, V; Zhou, Z; Zhu, C | 1 |
| Akbayir, E; Engevik, MA; Haag, AM; Haidacher, SJ; Hoch, KM; Horvath, TD; Kürtüncü, M; Oezguen, N; Palacio, J; Thapa, S; Türkoğlu, R; Tüzün, E; Versalovic, J; Yılmaz, V | 1 |
| Chang, X; Dong, Q; Huang, W; Lu, C; Lu, J; Ngew, KY; Quan, C; Tan, H; Wang, L; Wang, M; Wu, M; Wu, X; Xiao, Y; Yu, J; ZhangBao, J; Zhao, C; Zhou, L | 1 |
| Fu, J; Hong, X; Rang, X; Xu, C; Yin, X; Zhou, Y | 1 |
| Al-Iedani, O; Alshehri, A; Khormi, I; Koussis, N; Lea, R; Lechner-Scott, J; Ramadan, S | 1 |
| Cabañas-Cotillas, M; Calahorra, L; Camacho-Toledano, C; Castillo-Triviño, T; Clemente, D; Comabella, M; Costa-Frossard, L; García-Arocha, J; García-Domínguez, JM; Machín-Díaz, I; Midaglia, L; Ortega, MC; Otaegui, D; Villar, LM | 1 |
| Comabella, M; Fissolo, N; Gutierrez, L; Montalban, X; Pappolla, A; Perez-Hoyos, S; Rio, J; Sanchez, A; Villar, LM | 1 |
| Benet, LZ; Liu, W; Wang, Z; Waubant, EL; Yu, Z; Zhai, S | 1 |
| Bigaud, M; Ekici, A; Enders, M; Kapitza, C; Kirchner, P; Kuerten, S; Weier, A; Wörl, J | 1 |
| Al-Asmi, A; Alroughani, R; Altintas, A; Ampapa, R; Blanco Morgado, Y; Butzkueven, H; Gerlach, O; Hodgkinson, S; Horakova, D; Kalincik, T; Kuhle, J; Laureys, G; Lechner-Scott, J; Macdonell, R; Oh, J; Ozakbas, S; Patti, F; Sanchez-Menoyo, JL; Soysal, A; Spelman, T; Spitaleri, D; Terzi, M; Tundia, N; Van Der Walt, A; van Pesch, V; Wong, SL; Yamout, B | 1 |
| Barritt, AW; Berger, JR; Das, E; Dizdarevic, S; Fisniku, LK; Morley, N; Nicholas, R; Saha, R; Seymour, M; Vera, J; Vundavalli, S | 1 |
| Bigaud, M; Brinkmann, V; Dahlke, F; de Micco, M; Graham, G; Hach, T; Nicoletti, F; Petricoul, O; Piani-Meier, D; Shakeri-Nejad, K; Turrini, R | 1 |
| Baker, D; Forte, E; Giovannoni, G; James, LK; Kang, AS; Pryce, G; Schmierer, K | 1 |
| Al-Mujaini, AS; Al-Rashdi, AA; Sabt, BI | 1 |
| Ali, MM; Arif, A; Ashkar, A; Ashkar, R; Baig, MMA; Yousuf, F | 1 |
| Ciccone, A; Debouverie, M; Mathey, G; Prunis, C | 1 |
| Abhari, AP; Eighani, N; Etemadifar, M; Nouri, H; Salari, M; Sedaghat, N | 1 |
| Agrati, C; Aiello, A; Altera, AMG; Bettini, A; Bevilacqua, N; Coppola, A; Cuzzi, G; Farroni, C; Galgani, S; Garbuglia, AR; Gasperini, C; Goletti, D; Haggiag, S; Lapa, D; Meschi, S; Nicastri, E; Petrone, L; Prosperini, L; Puro, V; Quartuccio, ME; Ruggieri, S; Salmi, A; Tortorella, C; Vanini, V | 1 |
| Anvari, K; Huehnchen, P; Kriedemann, H; Müller-Jensen, L; Siffrin, V | 1 |
| Aguglia, U; Amato, MP; Angelucci, E; Boffa, G; Brescia Morra, V; Caniatti, LM; Cocco, E; Conte, A; Cottone, S; De Luca, G; Filippi, M; Galgani, S; Gasperini, C; Granella, F; Iaffaldano, P; Inglese, M; Lugaresi, A; Lus, G; Mancardi, GL; Mariottini, A; Massacesi, L; Meletti, S; Moiola, L; Nistri, R; Patti, F; Repice, AM; Romano, S; Saccardi, R; Salemi, G; Sbragia, E; Signori, A; Sola, P; Sormani, MP; Trojano, M; Zaffaroni, M | 1 |
| Hashimoto, T; Hatano, T; Matsuyoshi, A; Miyata, T; Shiraishi, W; Yamada, Y | 1 |
| Can Demirdöğen, B; Erel, Ö; Kiliç, OO; Mungan, S; Neşelioğlu, S; Yilmaz, AA | 1 |
| Barcellini, L; Capello, E; Cellerino, M; Franciotta, D; Inglese, M; Lapucci, C; Laroni, A; Schiavetti, I; Sormani, MP; Tazza, F; Uccelli, A | 1 |
| Fabbrocini, G; Fornaro, L; Megna, M; Noto, M | 1 |
| Agan, K; Baba, C; Balcı, BP; Boz, C; Demirkıran, M; Efendi, H; Guler, S; Karabudak, R; Karahan, SZ; Kıylıoğlu, N; Köseoğlu, M; Ozakbas, S; Sevim, S; Soysal, A; Terzi, M; Tuncer, A; Turan, ÖF; Turkoglu, R; Yetkin, MF; Yüceyar, N | 1 |
| Fukumoto, S; Isobe, N; Masaki, K; Matsushita, T; Tanaka, E; Watanabe, M; Yamasaki, R | 1 |
| Che, Y; Kim, YH; Lock, CB; Narala, S; Rieger, KE; Saleem, A | 1 |
| Alroughani, R; Boz, C; Butzkueven, H; Csepany, T; Grammond, P; Grand'Maison, F; Granella, F; Horakova, D; Kalincik, T; Lechner-Scott, J; Onofrj, M; Ozakbas, S; Patti, F; Prat, A; Spelman, T; Terzi, M; van der Walt, A; Zhu, C | 1 |
| Alizadeh, AA; Borhannejad, B; Dastmalchi, S; Kandjani, OJ; Vahdati, SS; Yaqoubi, S | 1 |
| Aguera-Morales, E; Al-Asmi, A; Al-Harbi, T; Alroughani, R; Altintas, A; Ampapa, R; Barnett, M; Bergamaschi, R; Blanco, Y; Boz, C; Butzkueven, H; Buzzard, K; Cartechini, E; Castillo-Triviño, T; Csepany, T; de Gans, K; Deri, N; Diouf, I; Duquette, P; Eichau, S; Ferraro, D; Fragoso, Y; Gerlach, O; Girard, M; Gouider, R; Grammond, P; Grand'Maison, F; Granella, F; Gray, O; Havrdova, EK; Hodgkinson, S; Horakova, D; Hughes, S; Izquierdo, G; Kalincik, T; Karabudak, R; Laureys, G; Lechner-Scott, J; Lugaresi, A; Maimone, D; Malpas, C; McCombe, P; McGuigan, C; Moore, F; Onofrj, M; Ozakbas, S; Patti, F; Petersen, T; Prat, A; Prevost, J; Ramo-Tello, C; Roos, I; Sa, MJ; Sanchez-Menoyo, JL; Schepel, J; Sempere, AP; Sharmin, S; Shaw, C; Shaygannejad, V; Skibina, O; Sola, P; Solaro, C; Soysal, A; Spitaleri, D; Terzi, M; Trevino-Frenk, I; Turkoglu, R; van der Walt, A; van Pesch, V; Van Wijmeersch, B; Yamou, B | 1 |
| Berger, É; Bigaut, K; de Sèze, J; Debouverie, M; Gauer, L; Moreau, T | 1 |
| Berger, T; Di Pauli, F; Enzinger, C; Guger, M; Kalcher, S; Kraus, J; Kvas, E; Leutmezer, F | 1 |
| Fakih, AU; Naser Moghadasi, A; Paybast, S; Sahraian, MA | 1 |
| Chitsaz, A; Etemadifar, M; Ghasemi Movaghar, A; Lotfi, N; Salari, M; Sayahi, F; Sedaghat, N | 1 |
| Dardiotis, E; Doskas, T; Fakas, N; Grigoriadis, N; Iliopoulos, I; Karageorgiou, K; Maltezou, M; Mitsikostas, DD; Orologas, A; Vikelis, M | 1 |
| Bakkioui, S; Brieva, L; Gil Sánchez, A; González-Mingot, C; Peralta, S; Quibus, L; Ruiz-Fernández, E; San Pedro-Murillo, E; Sancho-Saldaña, A; Solana, MJ; Torres, P | 1 |
| Akçalı, A; Akman, FG; Altunrende, B; Balcı, FB; Balgetir, F; Beckmann, Y; Birday, E; Boz, C; Cantürk, İA; Çelik, RGG; Demir, CF; Demirkıran, DM; Efendi, H; Ekmekçi, Ö; Eraksoy, M; Gazaloğlu, GB; Göncüoğlu, C; Işık, N; Kabay, SC; Kamişli, Ö; Karabudak, R; Kıylıoğlu, N; Kızılay, F; Köseoğlu, M; Kürtüncü, M; Mavi, K; Ölmez, Ç; Özcan, A; Özen, NPA; Saip, S; Sarıahmetoğlu, H; Sarıkaya, C; Sevim, MS; Siva, A; Soysal, A; Terzi, M; Toprak, MK; Tuncer, MA; Turan, ÖF; Türkoğlu, R; Uygunoğlu, U; Yüceyar, AN; Yüksel, S | 1 |
| Comabella, M; Hurtado-Navarro, L; Malhotra, S; Montalban, X; Pappolla, A; Pelegrin, P; Río, J; Villar, LMM | 1 |
| Abbadessa, G; Bonavita, S; Cavalla, P; De Martino, A; Lavorgna, L; Marfia, GA; Miele, G; Simeon, V; Valentino, P; Vercellino, M | 1 |
| Cocco, E; Fenu, G; Lorefice, L; Pilotto, S; Zoledziewska, M | 1 |
| Endres, T; Gottmann, K; Kartalou, GI; Leßmann, V; Pawlitzki, M | 1 |
| Fujita, H; Ikumi, N | 1 |
| Angelucci, F; Klimová, B; Krejsek, J; Novotny, M; Pavelek, Z; Peterka, M; Sejkorova, I; Sobisek, L; Soucek, O; Stourac, P; Valis, M; Vysata, O | 1 |
| Affinito, G; Brescia Morra, V; Carotenuto, A; Di Gennaro, M; Fumo, MG; Giordana, R; Lanzillo, R; Mercogliano, M; Moccia, M; Palladino, R; Petracca, M; Triassi, M | 1 |
| Bellen, HJ; Chung, HL; Kanca, O; Lee, HK; Lu, S; Mok, JW; Park, YJ; Perrimon, N; Tattikota, SG; Ye, Q; Zuo, Z | 1 |
| Chou, CH; Lin, W; Lin, YK; Sung, YF; Tsai, CK; Yang, FC | 1 |
| Chun, J; Kihara, Y | 1 |
| Battaglia, MA; Brichetto, G; Caleri, F; Clerico, M; Conte, A; Cordera, S; Ferrò, MT; Franciotta, D; Frau, J; Gandoglia, I; Gazzola, P; Grimaldi, L; Inglese, M; Marinelli, F; Pasquali, L; Rilla, MT; Salvetti, M; Schiavetti, I; Signoriello, E; Sormani, MP; Stromillo, ML; Uccelli, A; Ulivelli, M | 1 |
| Aparasu, RR; Earla, JR; Hutton, GJ; Johnson, ML; Li, J | 1 |
| Celius, EG; Chopra, A; Harbo, HF; Holmøy, T; Høgestøl, EA; Jørgensen, KK; Kjønstad, IF; König, M; Lund-Johansen, F; Mjaaland, S; Munthe, LA; Nygaard, GO; Ravussin, A; Solum, G; Syversen, SW; Vaage, JT; Wolf, AS; Øverås, MH | 1 |
| Altieri, M; Bisecco, A; Boffa, L; Capuano, R; Cavalla, P; Cocco, E; Cordioli, C; De Luca, G; Di Gregorio, M; Fantozzi, R; Gajofatto, A; Gallo, A; Gasperini, C; Guaschino, C; Lorefice, L; Nociti, V; Paolicelli, D; Pinardi, F; Prosperini, L; Radaelli, M; Ragonese, P; Solaro, C; Torri Clerici, V; Tortorella, C | 1 |
| Cheng, X; Huang, W; Huang, Y; Nie, G; Qiu, W; Shen, S; Wang, H; Wu, S; Zhang, J; Zhao, Y | 1 |
| Canpolat, M; Kum, YE; Pamukçu, Ö | 1 |
| Wilbur, C; Yearwood, C | 1 |
| Ciplea, AI; Gold, R; Hellwig, K; Hemat, S; Langer-Gould, AM; Thiel, S; Timmesfeld, N; Tokic, M | 1 |
| Akçin, R; Arslan, G; Baba, C; Beckmann, Y; Bilge, U; Boz, C; Bünül, SD; Demir, S; Dinç, Ö; Doğan, İG; Efendi, H; Elverdi, T; Gezen, O; Gümüş, H; Gündüz, T; Karabudak, R; Koç, R; Kocazeybek, B; Köseoğlu, M; Kürtüncü, M; Özakbaş, S; Özen, PA; Saip, S; Şen, S; Siva, A; Terzi, M; Tezer, DÇ; Tuncer, A; Turan, ÖF; Tütüncü, M; Uygunoğlu, U; Uzunköprü, C | 1 |
| Chitnis, T; Gonzalez-Martinez, A; Healy, BC; Lokhande, H; Patel, R; Paul, A; Polgar-Turcsanyi, M; Saxena, S; Weiner, HL | 1 |
| Everest, E; Gorkey, OD; Gulec, B; Koc, M; Saip, S; Siva, A; Tutuncu, M; Uygunoglu, U | 1 |
| Al-Naqshbandi, M; El Ayoubi, NK; Ghanim, Z; Habahbeh, M; Hatem, A; Joudi, H; Raki, A; Sahraian, MA | 1 |
| Belin, L; Charbonnier-Beaupel, F; Hippolyte, A; Ibrahim, M; Januel, E; Jeantin, L; Louapre, C; Malet, I; Marcelin, AG; Marot, S; Pourcher, V; Rosenzwajg, M; Soulié, C; Zafilaza, K | 1 |
| Aydinlar, A; Gullu, G; Gunay-Polatkan, S; Koc, ER; Sigirli, D; Turan, OF | 1 |
| Marulanda, E; Tornes, L | 1 |
| Brownlee, WJ; Duncan, J; Haghikia, A; Harty, GT; Hayward, B; Kayaniyil, S; Khan, Z; Millar, S; Waser, N | 1 |
| Aaen, G; Abrams, A; Benson, L; Casper, TC; Chitnis, T; Gorman, M; Goyal, M; Krupp, L; Liu, T; Lotze, T; Malani Shukla, N; Manlius, C; Mar, S; Ness, J; Rensel, M; Rodriguez, M; Rose, J; Schreiner, T; Tillema, JM; Waltz, M; Waubant, E; Weinstock-Guttmann, B; Wheeler, Y | 1 |
| Gombolay, GY; Kaufmann, C; Morris, M | 1 |
| Aguera-Morales, E; Al-Asmi, A; Al-Harbi, TM; Alroughani, R; Altintas, A; Ampapa, R; Bergamaschi, R; Boz, C; Butzkueven, H; Cartechini, E; Castillo-Trivino, T; Csepany, T; de Gans, K; Diouf, I; Duquette, P; Eichau, S; Ferraro, D; Gerlach, O; Gouider, R; Grammond, P; Grand'Maison, F; Granella, F; Gray, O; Hodgkinson, S; Horakova, D; Hughes, S; Iuliano, G; Kalincik, T; Kappos, L; Karabudak, R; Kubala Havrdova, E; Laureys, G; Lechner-Scott, J; Lugaresi, A; Malpas, CB; McCombe, PA; McGuigan, C; Onofrj, M; Ozakbas, S; Patti, F; Prat, A; Roos, I; Sa, MJ; Sánchez-Menoyo, JL; Sempere, AP; Sharmin, S; Shaw, C; Shaygannejad, V; Sidhom, Y; Slee, M; Sola, P; Solaro, C; Stuart, EA; Terzi, M; Treviño Frenk, I; van der Walt, A; Vucic, S; Yamout, B | 1 |
| Koca, N; Seferoğlu, M | 1 |
| Bhise, V; Bushnell, G; Dave, CV; Henderson, M; Horton, DB; Pal, G | 1 |
| Aguera-Morales, E; Al-Asmi, A; Alroughani, R; Atkins, H; Blanco, Y; Bo, L; Burman, J; Butzkueven, H; Cartechini, E; Castillo-Triviño, T; Csepany, T; de Gans, K; Duquette, P; Fragoso, Y; Freedman, MS; Garber, J; Gerlach, O; Gouider, R; Grigg, A; Havrdova, EK; Hodgkinson, S; John, N; Kalincik, T; Karabudak, R; Kermode, A; Khoury, SJ; Kozak, T; Krasulova, E; Kuhle, J; Laureys, G; Lechner-Scott, J; Lehmann, AK; Lugaresi, A; Macdonell, R; Maimone, D; Massey, J; McCombe, P; Mrabet, S; Ozakbas, S; Patti, F; Roos, I; Sa, MJ; Sanchez-Menoyo, JL; Sharmin, S; Sharrack, B; Skibina, O; Slee, M; Snowden, JA; Spitaleri, D; Sutton, I; Taylor, B; Torkildsen, Ø; Trnený, M; Turkoglu, R; van der Walt, A; Van Hijfte, L; van Pesch, V; Weinstock-Guttman, B; Willekens, B; Withers, B | 1 |
| Al-Habahbeh, S; Al-Shudifat, AE; Al-Smadi, A; Alqudah, A; Bjørk, MH; Ennab, W; Gammoh, OS; Weshah, F | 1 |
| Akçalı, A; Altunan, B; Altunrende, B; Balcı, FB; Bingöl, A; Boz, C; Efendi, H; Güler, S; Günal, Dİ; Köseoğlu, M; Kotan, D; Sunter, G; Tamam, Y; Terzi, M; Turan, ÖF; Turgut, N; Ünal, A; Yildirim, KA | 1 |
| Engin, E; Günal, D; Sünter, G; Vural, E; Yıldırım, KA | 1 |
| Cha, E; Gotina, L; Hwang, H; Joo, J; Kang, M; Kim, HJ; Kim, J; Lee, J; Lim, SM; Pae, AN; Park, JE; Park, JH; Park, KD; Seo, SH | 1 |
| Axelsson, M; Brandt, AF; Carlin, G; Gafvelin, G; Grönlund, H; Hessa, T; Högelin, KA; Khademi, M; Kockum, I; Lycke, J; Malmeström, C; Olsson, T; Piehl, F; Rabenstein, M; Thomas, OG | 1 |
| Ahle, G; Bigaut, K; Collongues, N; Courtois, S; de Seze, J; Dentel, C; Fickl, A; Fleury, M; Gaultier, C; Kolitsi, I; Kremer, L; Lanotte, L; Moreau, A; Mostoufizadeh, S; Sellal, F | 1 |
| Boudot de la Motte, M; Garmendia, A; Gassama, S; Lejeune, FX; Louapre, C; Maillart, E; Papeix, C; Roux, T | 1 |
| Achiron, A; Angelucci, F; Halusková, S; Hartung, HP; Mareš, J; Pavelek, Z; Štourač, P; Tichá, V; Vališ, M | 1 |
| El-Adawy, AF; Elmasry, M; Hamed, M; Meshref, M; Nashwan, AJ; Ramadan, A; Shaheen, A; Shaheen, N; Younis, H | 1 |
| Bonnan, M; Courtade, H; Debeugny, S | 1 |
| Gonzales, EG; Langer-Gould, AM; Li, BH; Piehl, F; Smith, JB | 1 |
| Baradaran, B; Barpour, N; Dabbaghi, R; Hosseinpourfeizi, M; Rahmani, S; Rajabi, A; Safaralizadeh, R | 1 |
| Schwab, N; Wiendl, H | 1 |
| Chamova, T; Chervenkov, V; Ivanova, S; Kaprelyan, A; Kipriyanovska, K; Milanov, I; Slavov, G; Tournev, I | 1 |
| Benedetti, MD; Capobussi, M; Castellini, G; Featherstone, R; Filippini, G; Frau, S; Gonzalez-Lorenzo, M; Lucenteforte, E; Perduca, V; Tramacere, I; Virgili, G | 1 |
| Ghasemi-Kasman, M; Hashemian, M; Parsian, H; Sadeghi, F | 1 |
| Banwell, B; Chitnis, T; Deiva, K; Gärtner, J; Huppke, P; Krupp, L; Merschhemke, M; Pearce, GL; Stites, T; Waubant, E | 1 |
| Jaafar, N; Massouh, J; Yamout, BI; Zeineddine, M | 1 |
| Dasgupta, S; Ray, SK | 1 |
| Blinkenberg, M; Erdal, JL; Kopp, TI; Magyari, M; Petersen, T; Sørensen, PS | 1 |
| Hsieh, TY; Lin, JC; Lu, MC; Shih, YL | 1 |
| Bensimon, AG; Conway, D; Cox, GM; Herrera, V; Macheca, M; Peeples, M; Vieira, MC | 1 |
| Benhamou, M; Golan, M; Ibrahim, B; Karni, A; Kolb, H; Mausner-Fainberg, K; Regev, K; Wilf-Yarkoni, A | 1 |
| Barnett, MH; Beadnall, HN; Buckland, ME; Ebrahimkhani, S; Suter, CM; Vafaee, F; Wang, C | 1 |
| Ariño, H; Baños, N; Blanco, Y; Llufriu, S; Martinez-Hernandez, E; Martinez-Lapiscina, EH; Montejo, C; Pulido-Valdeolivas, I; Reyes, D; Saiz, A; Sepúlveda, M; Sola-Valls, N; Zubizarreta, I | 1 |
| Akashi, H; Ando, K; Furuya, D; Kawada, H; Kawai, H; Kawakami, S; Matsushita, H; Moriuchi, M; Nakamura, N; Ogawa, Y; Suzuki, R | 1 |
| Davletov, B; García-Martínez, V; Gimenez-Molina, Y; Gutiérrez, LM; Villanueva, J | 1 |
| Abusamra, E; Ceccarelli, A; Hussain, SI; Mifsud, V | 1 |
| Andabaka, M; Basile, MS; Cavalli, E; Drulovic, J; Fagone, P; Ivanovic, J; Kalfin, R; Mammana, S; Martinovic, V; Mazzon, E; Mesaros, S; Nicoletti, F; Pekmezovic, T; Pennisi, M; Petralia, MC | 1 |
| Chen, CY; Cui, YM; Li, M; Ma, LY; Tian, X; Wu, Y; Yang, T; Zhou, S; Zhou, Y | 1 |
| Andersen, CU; Hilt, C; Nørgaard, TL | 1 |
| Antel, J; Bar-Or, A; Barnett, MH; Evans, A; Ghadiri, M; Giacomini, PS; Li, R; Rezk, A | 1 |
| Arlauskienė, A; Laužikienė, D; Ramašauskaitė, D; Varytė, G; Zakarevičienė, J | 1 |
| Baumjohann, D; Chang, Y; Huber, JE; Kümpfel, T; Meinl, E; Meinl, I | 1 |
| Alping, P; Askling, J; Burman, J; Fink, K; Fogdell-Hahn, A; Frisell, T; Gunnarsson, M; Hillert, J; Langer-Gould, A; Lycke, J; Nilsson, P; Olsson, T; Piehl, F; Salzer, J; Svenningsson, A; Vrethem, M | 1 |
| Benedetti, MD; Calabria, F; Farina, G; Forgione, A; Forlivesi, S; Gajofatto, A; Marangi, A; Marchioretto, F; Rossi, F; Stenta, G; Vianello, M; Vicenzi, V | 1 |
| Cambron, B; Delrée, P; Gustin, T; Jacobs, S; London, F | 1 |
| Eshaghi, A | 1 |
| Arnold, DL; Banwell, B; Bar-Or, A; Brück, W; Chitnis, T; Gärtner, J; Ghezzi, A; Giovannoni, G; Greenberg, BM; Häring, DA; Krupp, L; Merschhemke, M; Pearce, GL; Rostásy, K; Stites, TE; Tardieu, M; Waubant, E; Wolinsky, JS | 1 |
| Carruthers, R; Kingwell, E; Marrie, RA; Ng, HS; Tremlett, H; Zhang, T; Zhu, F | 1 |
| Geissbühler, Y; Moore, A; Rezaallah, B | 1 |
| Boffa, G; Bruschi, N; Capello, E; Cellerino, M; Inglese, M; Lapucci, C; Novi, G; Sbragia, E; Uccelli, A | 1 |
| Annovazzi, P; Baroncini, D; Barone, S; Barrilà, C; Binello, E; Bonavita, S; Carmisciano, L; Cerqua, R; Clerico, M; Cocco, E; Cordioli, C; Di Sapio, A; Frau, J; Frigeni, B; Grasso, R; Gutierrez, LP; Ippolito, D; La Gioia, S; Landi, D; Lanzillo, R; Laroni, A; Lavorgna, L; Maniscalco, GT; Mataluni, G; Perini, P; Pontecorvo, S; Rasia, S; Repice, A; Russo, CV; Saccà, F; Sartori, A; Signori, A; Signoriello, E; Sormani, MP; Stromillo, ML; Torri Clerici, V; Turano, G; Zarbo, IR | 1 |
| Arsang-Jang, S; Branicki, W; Eftekharian, MM; Ghafouri-Fard, S; Komaki, A; Kordestani, H; Mazdeh, M; Taheri, M | 1 |
| Cuvillier, O; Hatzoglou, A; Talmont, F | 1 |
| Ara, JR; Barrero, F; Forero, L; Izquierdo, G; Mallada-Frechin, J; Martínez-Ginés, ML; Marzo, ME; Meca-Lallana, J; Meca-Lallana, V; Moreno, MJ; Oreja-Guevara, C; Sánchez-Vera, I | 1 |
| Robertson, NP; Willis, MD | 1 |
| Angelopoulou, E; Gnatkovsky, V; Othman, I; Paudel, YN; Piperi, C; Shaikh, MF | 1 |
| Bertolotto, A; Capobianco, M; Carotenuto, A; Colombo, D; Comi, G; Iaffaldano, P; Morra, VB; Nica, M; Pozzilli, C; Prosperini, L; Rizzoli, S; Sangalli, F; Trojano, M | 1 |
| Carbone, ML; De Giglio, L; Failla, CM; Lacal, PM; Mazzanti, C; Messinese, S; Pagnanelli, G; Persechino, S; Pozzilli, C | 1 |
| Barzegar, M; Khorvash, F; Maghzi, AH; Mirmosayyeb, O; Nehzat, N; Sarrafi, R; Shaygannejad, V | 1 |
| Kondo, T | 1 |
| Azimi, AR; Nourbakhsh, B; Safavi, F | 1 |
| Benkert, P; Décard, B; Derfuss, T; Hänni, P; Kappos, L; Kuhle, J; Lienert, C; Lorscheider, J; Moser, A; von Wyl, V; Yaldizli, Ö | 1 |
| Diaz, V; Guevara, C; Naves, R; Rosas, CS; Villa, E | 1 |
| Amor, S; Baker, D; Giovannoni, G; Kang, AS; Schmierer, K | 1 |
| Abdelshafy, AAA; Chu, X; Elsaid, KMK; Elshawwaf, M; Ghobrial, RM; Kloc, M; Uosef, A; Vaughn, N | 1 |
| Amato, MP; Comi, G; Edan, G; Ghezzi, A; Hartung, HP; Havrdová, EK; Kappos, L; Montalban, X; Pozzilli, C; Sorensen, PS; Trojano, M; Vermersch, P | 1 |
| Filippi, M; Preziosa, P; Rocca, MA | 1 |
| Hayashi, F; Isobe, N; Kawano, Y; Kira, JI; Matsushita, T; Nakamura, Y; Sakoda, A; Tanaka, M; Watanabe, M; Yamasaki, R | 1 |
| Angarano, G; Bavaro, DF; Bollo, L; Guerra, T; Iaffaldano, P; Monno, L; Paolicelli, D; Saracino, A; Trojano, M | 1 |
| Brinker, A; Croteau, D; Kortepeter, CM; Tobenkin, A | 1 |
| Chen, HH; Chen, PL; Huang, CC; Huang, WN; Lee, WJ; Lin, CC; Lin, TS; Lyu, RK; Ro, LS; Su, JJ; Tsai, CP; Tsai, NW; Yang, A; Yang, CC | 1 |
| Chiba, K | 2 |
| Bascuñana, P; Brackhan, M; Möhle, L; Pahnke, J | 1 |
| Bergamaschi, R; Fabbro, BD; Mallucci, G; Zito, A | 1 |
| Cárcamo, C; Ciampi, E; Pelayo, C; Reyes, A; Soler, B; Uribe-San-Martín, R; Vergara, E | 1 |
| Abdelhak, A; Hemmer, B; Kemmerer, CL; Kowarik, MC; Krumbholz, M; Pernpeintner, V; Ruschil, C; Scholl, M; Ziemann, U | 1 |
| Carletti, S; Cerqua, R; Danni, M; Lattanzi, S; Rocchi, C; Silvestrini, M; Taffi, R | 1 |
| Huhtala, H; Kuusisto, H; Rauma, I; Soilu-Hänninen, M | 1 |
| Ghobrial, RM; Kloc, M | 1 |
| Akgün, K; Moser, T; Proschmann, U; Sellner, J; Ziemssen, T | 1 |
| Derfuss, T; Kuhle, J; Nagy, S | 1 |
| Do, JL; Patel, VR | 1 |
| Chouette, I; Durand, B; Lamy, F; Meite, M; Mekies, C; Papeix, C; Rerat, K; Tourbah, A; Tourniaire, P | 1 |
| Gözübatık Çelik, RG; Köseoğlu, M; Kürtüncü, M | 1 |
| Aschmann, HE; Kesselring, J; Puhan, MA; Spanu, A | 1 |
| Engelhardt, B; Enzmann, G; Homann, T; Huwiler, A; Kleuser, B; Stark, H; Stepanovska, B; Tietz, S; Zivkovic, A | 1 |
| Ahmed, SF; Alroughani, R; Ibrahim Ismail, I; Salama, S | 1 |
| Davydovskaya, MV; Kurguzova, DO; Luchinina, EV; Serebrova, SY; Shelekhova, TV; Zhuravleva, MV | 1 |
| Bhattacharyya, PK; Fox, RJ; Li, H; Lin, J; Lowe, MJ; Sakaie, KE | 1 |
| Amiri, MRM; Baghbanian, SM | 1 |
| Benkert, P; Derfuss, T; Hänni, P; Kappos, L; Kuhle, J; Lienert, C; Lorscheider, J; Yaldizli, Ö | 1 |
| Clarelli, F; Colombo, B; Comi, G; Esposito, F; Ferrè, L; Filippi, M; Martinelli, V; Mogavero, A; Moiola, L; Sangalli, F | 1 |
| Ettle, B; Inojosa, H; Rauser, B; Ziemssen, T | 1 |
| Batista, S; Cerqueira, JJ; Correia de Sá, J; Correia, AS; Costa, A; Ferreira, J; Martins Silva, A; Mendonça, MT; Nunes, CC; Pinheiro, J; Salgado, V; Sequeira, J; Sousa, L | 1 |
| Byrne, SN; Grau, GE; Hawke, S; Holdaway, K; Juillard, PG; Zinger, A | 1 |
| Avasarala, J | 1 |
| Zhao, Y | 1 |
| Bisecco, A; Capuano, R; d'Ambrosio, A; Filippi, M; Gallo, A; Gesualdo, C; Lanza, M; Leocani, L; Maimone, D; Marino, C; Rodegher, M; Rossi, S; Simonelli, F; Tedeschi, G | 1 |
| Comi, G; Dalla Costa, G; Moiola, L | 1 |
| Adlard, N; Khurana, V; Mah, JK; Nakhaipour, HR; Pohl, D; Schecter, R; Sébire, G; Vudumula, U | 1 |
| Arnold, DL; Butzkueven, H; Campbell, N; Filippi, M; Geurts, JJ; Ho, PR; Jeffery, D; Licata, S; Santra, S | 1 |
| Berger, E; Bigaut, K; Brassat, D; Brochet, B; Bucciarelli, F; Cappé, C; Carra, C; Cohen, M; De Seze, J; Debouverie, M; Defer, G; Derache, N; Labauge, P; Laplaud, DA; Lebrun-Frenay, C; Mathey, G; Mondot, L; Pignolet, B; Ruet, A; Vermersch, P; Wiertlewski, S; Zephir, H | 1 |
| Chen, S; Chen, W; Ghobrial, RM; Kloc, M; Uosef, A | 1 |
| Filippi, M; Moiola, L; Pagani, E; Preziosa, P; Rocca, MA; Rodegher, M | 1 |
| Alcalá Vicente, C; Bastida Paz, G; Ladrón Abia, P; Martínez Delgado, S | 1 |
| Bryll, A; Drabik, L; Karcz, P; Kolasinska, J; Kolasinska, M; Marona, M; Popiela, T; Skladzien, J; Slowik, A; Szaleniec, J; Wnuk, M; Ziekiewicz, M | 1 |
| Astling, D; Bennett, JL; Hemmer, B; Kowarik, MC; Lepennetier, G; Owens, GP; Ritchie, A | 1 |
| Conway, DS; Nakamura, K; Oh, SH; Ontaneda, D; Planchon, SM; Sakaie, K; Thompson, NR | 1 |
| Chun, J; Giovannoni, G; Hunter, SF | 1 |
| Alonso, R; Balbuena, ME; Bizzo, AL; Carnero Contentti, E; Carrá, A; Cohen, L; Correale, J; Cristiano, E; Deri, N; Eizaguirre, MB; Garcea, O; Lazaro, L; Liguori, NF; Lopez, P; Man, F; Miguez, J; Pappolla, A; Patrucco, L; Pettinichi, JP; Pita, C; Rojas, JI; Silva, BA; Tkachuk, V | 1 |
| Coutinho, AM; de Andrade, DC; de Lima, LGCA; de Souza Godoy, LF; Pimentel, GA | 1 |
| Azami, S; Konoeda, F; Sato, H | 1 |
| Carruthers, R; Evans, C; Kingwell, E; Marrie, RA; Tremlett, H; Walld, R; Zhang, T; Zhu, F | 1 |
| Airas, L; Bezukladova, S; Matilainen, M; Rissanen, E; Saraste, M; Saunavaara, V; Sucksdorff, M | 1 |
| Abraham, MJ; Acevedo, JAG; Fang, X; Gogia, B; Rai, PK; Thottempudi, N; Villarreal, JV | 1 |
| Harrer, A; Moser, T; Pilz, G; Radlberger, RF; Sakic, I; Wipfler, P | 1 |
| Guidetti, D; Immovilli, P; Morelli, N; Rota, E | 1 |
| Battaglia, MA; Capobianco, M; Carmisciano, L; Comi, G; Cordioli, C; De Rossi, N; Immovilli, P; Moiola, L; Patti, F; Radaelli, M; Salvetti, M; Schiavetti, I; Sormani, MP; Tedeschi, G; Trojano, M; Zaratin, P | 1 |
| Ferilli, MAN; Papetti, L; Valeriani, M | 1 |
| Archer, RL; Baltz, BP; Chacko, JA; Chacko, JG; Stout, PW; Strati, P | 1 |
| Otero-Romero, S; Sánchez-Montalvá, A; Vidal-Jordana, A | 1 |
| Eadie, MJ; Goudarzi, MH; Hollingworth, SA | 1 |
| Baldanti, F; Bergamaschi, R; Fabbro, BD; Franciotta, D; Gastaldi, M; Mallucci, G; Zito, A | 1 |
| Capone, F; Di Lazzaro, V; Ferraro, E; Motolese, F | 1 |
| Assouad, R; Bodini, B; Chochon, F; De Paz, R; Heinzlef, O; Louapre, C; Lubetzki, C; Maillart, E; Mhanna, E; Nouchi, A; Papeix, C; Pourcher, V | 1 |
| Lanzillo, R; Petruzzo, M | 1 |
| Anwar-Hashim, Z; Aslanyan, A; Mihalova, T; Siripurapu, R | 1 |
| Aparasu, RR; Chen, H; Earla, JR; Hutton, GJ; Johnson, ML; Thornton, DJ | 1 |
| Karakosta, C; Kourentis, C | 1 |
| Caputo, F; Guerra, T; Iaffaldano, P; Orlando, B; Paolicelli, D; Trojano, M | 1 |
| Bertolotto, A; Capobianco, M; Malucchi, S | 1 |
| Amidei, A; Pasquali, L; Siciliano, G | 1 |
| Altincatal, A; Berdofe, A; Centonze, D; de Moor, C; Jung, E; Kim, M; Nagpal, A; Naylor, ML; Popescu, C; Radhakrishnan, M; Rajbhandari, R; Reder, AT; Sandrock, AW; Smirnakis, K | 1 |
| Borriello, G; Pozzilli, C | 1 |
| Dong, Y; Gu, ZC; Lv, Y; Ma, CL; Zhao, Z; Zhong, MK | 1 |
| Amato, MP; Derfuss, T; Fonderico, M; Hemmer, B; Portaccio, E; Selmaj, K; Stankoff, B; Tintorè, M | 1 |
| Cohen, JA; Cree, BA; Kappos, L; Laflamme, AK; Leppert, D; Piani Meier, D; Reder, AT; Ritter, S; Silva, D; Tomic, D | 1 |
| Alotaibi, AA; Freedman, MS; Roy, R | 1 |
| Beckmann, Y; Türe, S; Uzunköprü, C | 1 |
| Abulaban, A; Aggad, H; Al Bunyan, R; Al Jumah, M; Al Malik, Y; AlKhawajah, M; Almejally, M; Alnajashi, H; Alshamrani, F; Bohlega, S; Cupler, EJ; ElBoghdady, A; Makkawi, S; Qureshi, S; Shami, S | 1 |
| Jacobs, D; Pham Nguyen, TP; Thibault, D; Willis, AW | 1 |
| Filippi, M; Moiola, L; Zanetta, C | 1 |
| Ataei, S; Ghiasian, M; Mohammadi, Y; Nafisi, H; Ranjbar, A | 1 |
| Acar, P; Baba, C; Carmisciano, L; Demir, S; Efendi, H; Gumus, H; Gunduz, T; Gungor Dogan, I; Kale Icen, N; Karabudak, R; Koseoglu, M; Ozakbas, S; Petek Balci, B; Schiavetti, I; Sen, S; Siva, A; Sormani, MP; Terzi, M; Tuncer, A; Turan, OF; Tutuncu, M; Uygunoglu, U; Uzunkopru, C; Yetkin, MF | 1 |
| Zaffaroni, M | 1 |
| Berthelot, E; Bonnan, M; Cabre, P | 1 |
| Assouad, R; Boudot de la Motte, M; Depaz, R; Louapre, C; Lubetzki, C; Maillart, E; Papeix, C; Roux, T | 1 |
| Callegari, I; Derfuss, T; Galli, E | 1 |
| Barbano, L; Centonze, D; Falsini, B; Landi, D; Marfia, GA; Mataluni, G; Nicoletti, CG; Parisi, V; Quaranta, L; Ziccardi, L | 1 |
| Dubois, B; Goris, A; Humblet-Baron, S; Imbrechts, M; Liston, A; Mallants, K; Matthys, P; Mitera, T; Prezzemolo, T; Smets, I | 1 |
| Espinosa-Rosso, R; Gil-Bernal, R; Gómez-Gómez, C; González-Caballero, JL | 1 |
| Boffa, G; Cellerino, M; Cocco, E; Fenu, G; Frau, J; Fronza, M; Inglese, M; Landi, D; Mancuso, E; Marfia, GA; Nicoletti, CG; Ponzano, M; Ricchiuto, ME; Signori, A | 1 |
| Alkabie, S; Cuascut, FX; Hutton, GJ | 1 |
| Bigaut, K; Cohen, M; de Seze, J; Durand-Dubief, F; Lebrun-Frenay, C; Maillart, E; Planque, E; Zephir, H | 1 |
| Cohen, JA; McGinley, MP | 1 |
| A, N; C, Z; L, M; M, F; S, G; S, L | 1 |
| Baba, C; Ozakbas, S; Piri Cinar, B; Sagici, O; Yigit, P | 1 |
| Chapman, L | 1 |
| Bae, D; Baek, J; Ha, N; Kim, T; Ko, SM; Lee, JY; Lim, HS; Park, J; Som Jeong, D; Son, WC; Suh, D | 1 |
| Englund, S; Fang, F; Frisell, T; Longinetti, E; Piehl, F; Reutfors, J | 1 |
| de Chalus, A; Deiva, K; Taveira, M | 1 |
| Brescia Morra, V; Capobianco, M; Cavalla, P; Cellerino, M; Ferraro, D; Guerra, T; Iaffaldano, P; Inglese, M; Lus, G; Malucchi, S; Mirabella, M; Paolicelli, D; Patti, F; Pisano, E; Sola, P; Trojano, M; Vitetta, F; Zaffaroni, M | 1 |
| Arlauskienė, A; Ramašauskaitė, D; Varytė, G | 1 |
| Akcay, Hİ; Altunrende, B; Eraksoy, M; Gunduz, T; Karaaslan, Z; Kurtuncu, M; Turkoglu, R; Tüzün, E; Ulusoy, C; Yilmaz, V | 1 |
| Bonifácio, G; Correia, F; Costa, A; Ferro, D; Gonçalves, AI; Guerreiro, RP; Loureiro, JL; Pinheiro, J; Rocha, R; Rodrigues, R; Sá, MJ; Sabença, F; Vale, J | 1 |
| Adlard, N; Brennan, R; Cameron, C; Dahlke, F; Drudge, C; Haltner, A; Samjoo, IA; Spin, P; Worthington, E | 1 |
| Galetta, K; George, IC; Gillani, RL; Ham, AS; Hotan, GC; Hutto, SK; Kaplan, TB; Klawiter, EC; Mateen, FJ; Matiello, M; Rice, DR; Vogel, AC | 1 |
| Calabrese, P; Cutter, G; Dahlke, F; Häring, DA; Kappos, L; Langdon, DW; Penner, IK; Tomic, D | 1 |
| Colombo, E; Farina, C | 1 |
| Airas, L; Nuutinen, S; Paavilainen, T; Rinne, J; Rissanen, E; Rokka, J; Sucksdorff, M; Tuisku, J | 1 |
| Gusman, DH; Shoemake, C | 1 |
| de Paula Faria, D; de Vries, EFJ; Dierckx, RAJO; Doorduin, J; Vállez García, D | 1 |
| Bergamaschi, R; Boiocchi, C; Cuccia, M; Mallucci, G; Osera, C; Pascale, A; Pistono, C | 1 |
| Miller, A; Staun-Ram, E | 1 |
| Banik, NL; Dasgupta, S; Miller, LG; Purohit, S; Ray, SK; Wang, G; Young, JA | 1 |
| Alsop, J; Cornelissen, C; Medin, J; Vormfelde, SV; Ziemssen, T | 1 |
| Fragoso, YD | 1 |
| Cezairlioğlu, Ş; Horasanlı, B; Kal, A; Kal, Ö; Oğuz Ulusoy, M | 1 |
| Alassiri, A; Algahtani, H; Shirah, B | 1 |
| Blennow, K; Khademi, M; Kockum, I; Lycke, J; Olsson, T; Piehl, F; Zetterberg, H | 1 |
| Forci, B; Mariottini, A; Massacesi, L; Mechi, C; Repice, A | 1 |
| Giovannoni, G; Hawkes, C; Lublin, F; Waubant, E | 1 |
| Bennett, I; Jithoo, R; Pham, C | 1 |
| Hashimoto, Y; Kira, JI; Matsushita, T; Shinoda, K; Tanaka, E; Uehara, T; Yamasaki, R | 1 |
| Bal, M; Darios, FD; Davletov, B; Flašker, A; García-Martinez, V; Gutiérrez, LM; Jorgacevski, J; Kavalali, ET; Leese, C; Nosyreva, E; Villanueva, J; Zorec, R | 1 |
| Herrera, V; Johnson, KM; Ko, JJ; Lin, F; Zhou, H | 1 |
| Kinoshita, M; Tanaka, K; Tanaka, M | 1 |
| Graf, J; Hartung, HP; Warnke, C | 1 |
| Antel, J; Bar-Or, A; Fitz-Gerald, L; Ghadiri, M; Giacomini, PS; Haegert, D; Li, R; Nyirenda, M; Rezk, A | 1 |
| Hoogervorst, ELJ; Killestein, J; Leurs, CE; Mostert, JP; Uitdehaag, BMJ; van den Eertwegh, AJM; van Eijk, J | 1 |
| Chaudhry, BZ; Cohen, JA; Conway, DS | 1 |
| Carlini, G; Cerqua, R; Danni, M; Lattanzi, S; Provinciali, L; Pulcini, A; Silvestrini, M; Taffi, R | 1 |
| Halpern, R; Herrera, V; Johnson, K; Korrer, S; Park, Y; Trenz, HM; Williams, MJ | 1 |
| Brown, S; Chan, N; Grigoriadis, G; Yuen, HLA | 1 |
| Bakshi, R; Comi, G; Hartung, HP; Wiendl, H; Williams, IM | 1 |
| Brück, W; Ellenberger, D; Gärtner, J; Hummel, H; Huppke, B; Huppke, P; Rostasy, K; Stark, W | 1 |
| Bedri, SK; Fink, K; Glaser, A; Hillert, J; Kockum, I; Lundström, W; Manouchehrinia, A; Olsson, T | 1 |
| Bettelli, E; Buckner, JH; Duhen, R; Eken, A; Fry, M; Kita, M; Oukka, M; Singh, AK | 1 |
| Billings, SD; Cohen, JA; Hudgens, CW; Ko, JS; Mahajan, KR; Tetzlaff, MT | 1 |
| Akimoto, S; Amino, I; Doi, S; Fujiki, N; Fukazawa, T; Hisahara, S; Kikuchi, S; Minami, N; Miyazaki, Y; Mizuno, M; Nakamura, M; Nakano, F; Niino, M; Shimohama, S; Suzuki, M; Takahashi, E; Terayama, Y | 1 |
| McGee, JC; Minagar, A | 1 |
| AbuBaker, J; Al-Khairi, I; Al-Temaimi, R; Alroughani, R | 1 |
| Foroozan, R; Khimani, KS | 1 |
| Donahue, RR; Doolen, S; Grachen, CM; Iannitti, T; Shaw, BC; Taylor, BK | 1 |
| Diego Vélez, J; Enriquez-Marulanda, A; Luis Orozco, J; Maria Granados, A; Parrado, L; Quiñones, J; Valderrama-Chaparro, J | 1 |
| Bakshi, R; Chitnis, T; Chu, R; Dupuy, SL; Healy, BC; Khalid, F; Kim, G; Tauhid, S; Tummala, S; Weiner, HL; Yousuf, F | 1 |
| Carandini, T; Comi, G; Dalla Costa, G; Finardi, A; Furlan, R; Garzetti, L; Martinelli, V | 1 |
| Boes, CJ; Colgan, JP; Flanagan, EP; Howard, MT; Stitt, DW | 1 |
| Badihian, S; Manouchehri, N; Mirmosayyeb, O; Shaygannejad, V | 1 |
| Chataway, J; Doshi, A | 1 |
| Chadha, K; George, R; Hojnacki, D; Johnson, J; Kolb, C; Nir, A; Nir, R; Sternberg, Z; Yu, J | 1 |
| Cox, RJ; Eide, GE; Jul-Larsen, Å; Lartey, SL; Myhr, KM; Olberg, HK; Vedeler, CA | 1 |
| Altintas, A; Saip, S; Siva, A; Tutuncu, M; Uygunoglu, U | 1 |
| Berwick, A; David, OJ; Hara, H; Lang, M; Li, P; Pezous, N; Schmouder, R; Tiel-Wilck, K; Ziemssen, T | 1 |
| Albrecht, H; Cornelissen, C; Haas, J; Klotz, L; Lang, M; Lassek, C; Medin, J; Schmidt, S; Tackenberg, B; Ziemssen, T | 1 |
| Baharnoori, M; Chitnis, T; Chua, A; Diaz-Cruz, C; Gonzalez, CT; Healy, BC; Stankiewicz, J; Weiner, HL | 1 |
| Angerer, IC; Boxberger, N; Fitzner, B; Flechtner, K; Friess, J; Hecker, M; Koczan, D; Meister, S; Roch, L; Rüge, A; Schröder, I; Thiesen, HJ; Winkelmann, A; Zettl, UK | 1 |
| Bajrami, A; Calabrese, M; Camera, V; Magliozzi, R; Pitteri, M | 1 |
| Clarelli, F; Colombo, B; Comi, G; Esposito, F; Ferrè, L; Filippi, M; Martinelli Boneschi, F; Martinelli, V; Moiola, L; Radaelli, M; Rocca, MA; Sangalli, F; Sferruzza, G; Storelli, L | 1 |
| Hartikainen, JEK; Hartikainen, P; Laiho, A; Laitinen, TM; Laitinen, TP; Simula, S | 1 |
| Faissner, S; Gold, R | 1 |
| Rommer, PS; Zettl, UK | 1 |
| Aoyama, S; Kuwabara, S; Masuda, H; Mori, M; Ohtani, R; Uchida, T; Uzawa, A | 1 |
| Ciccarelli, O; Schoonheim, MM | 1 |
| Limmroth, V; Ziemssen, T | 1 |
| Arévalo Roa, HO; Díaz Rojas, JA; Guarín Téllez, NE; Moreno Calderón, JA; Muñoz-Galindo, IM | 1 |
| Calkwood, J; Khan, N; Kolodny, S; Korn, JR; Lathi, E; Medin, J; Silva, D; Silversteen, J; Weinstock-Guttman, B; Zivadinov, R | 1 |
| Brieva, L; Cano, A; Hervás-García, JV; Mansilla, MJ; Martínez-Cáceres, EM; Moral-Torres, E; Munteis, E; Navarro-Barriuso, J; Presas-Rodriguez, S; Quirant-Sánchez, B; Ramo-Tello, C; Teniente-Serra, A | 2 |
| Buc, M | 1 |
| Campos, MM; da Costa, JC; Gomez, MV; Greggio, S; Silva, RBM; Venturin, GT | 1 |
| Kalincik, T | 1 |
| Agan, K; Akbarzade, A; Bereket, A; Enver, EO; Gunal, DI; Guran, T; Haklar, G; Sunter, G; Turan, S; Vatansever, P | 1 |
| Banzi, R; Bertele', V; Garattini, S; Gerardi, C; Rossi, S | 1 |
| Giacomini, PS | 1 |
| Fukazawa, T; Kawashima, A; Miyazaki, Y; Niino, M; Sato, K; Yamada, M | 1 |
| Bieber, T; Froehlich, A; Landsberg, J; Schmidt, S; Wenzel, J | 1 |
| Alvarez, E; Bergsland, N; Chitnis, T; Cohan, S; Dwyer, MG; Hunter, SF; Khan, N; Kinkel, P; Korn, JR; Medin, J; Naismith, RT; Silva, D; Weinstock-Guttman, B; Zivadinov, R | 1 |
| Alvarez, E; Corboy, JR; Honce, JM; Nair, K; Sillau, S; Vollmer, B; Vollmer, T | 1 |
| Alroughani, R; Barnett, M; Boz, C; Brooks, JBB; Butzkueven, H; Fragoso, YD; Granella, F; Haartsen, J; Havrdova, E; Horakova, D; Lugaresi, A; Menoyo, JLS; Olascoaga, J; Pucci, E; Spelman, T; Terzi, M; Vucic, S | 1 |
| Briner, M; Chan, A; Engelhardt, B; Evangelopoulos, ME; Hoepner, R; Huwiler, A; Miclea, A; Salmen, A; Schrewe, L | 1 |
| Blizzard, L; Chen, J; Palmer, AJ; Simpson, S; Taylor, BV; van der Mei, IAF | 1 |
| Członkowska, A; Mirowska-Guzel, D | 1 |
| Oshima, Y; Tanimoto, T; Tojo, A; Yuji, K | 1 |
| Chen, W; Ghobrial, RM; Kloc, M; Li, XC | 1 |
| Amann, M; Andelova, M; Derfuss, T; Fischer-Barnicol, B; Kappos, L; Mehling, M; Naegelin, Y; Rasenack, M; Sprenger, T; Von Felten, S | 1 |
| Cascione, M; Cree, BAC; Meng, X; Schofield, L; Tenenbaum, N; Wendt, J | 1 |
| Ahn, SW; Cho, JY; Huh, SY; Hyun, JW; Kim, BJ; Kim, HJ; Kim, SH; Kim, W; Lee, SH; Park, MS | 1 |
| Hecker, M; Loebermann, M; Metze, C; Reisinger, EC; Schweiger, B; Winkelmann, A; Zettl, UK | 1 |
| Meca-Lallana, V; Sánchez, P; Vivancos, J | 1 |
| Mitsikostas, DD; Papadopoulos, D | 1 |
| Bernard-Valnet, R; Biotti, D; Bonneville, F; Brassat, D; Ciron, J; Dumas, H; Lafontan, JF; Pignolet, B | 1 |
| Alberro, A; Castillo-Triviño, T; Falcón-Pérez, JM; Fernandez-Mercado, M; Lopetegui, I; Muñoz-Culla, M; Olascoaga, J; Osorio-Querejeta, I; Otaegui, D; Prada, Á; Sáenz-Cuesta, M; Tainta, M | 1 |
| Abrams, K; Bujkiewicz, S; Dequen, P; Jenkins, D; Martina, R | 1 |
| Amoruso, A; Avolio, C; Blonda, M; D'Arrigo, G; Di Francescantonio, V; Grasso, R; Verderio, C | 1 |
| Ahlqvist, M; Erdeljac, N; Gilmour, R; Kehr, G; Knerr, L | 1 |
| Butzkueven, H; Hall, AJ; Lim, LL; Lo, TC; Pimentel, RS; Silva, DG | 1 |
| Alvarez, E; Bergsland, N; Carl, E; Chitnis, T; Dwyer, MG; Khan, N; Korn, JR; Medin, J; Naismith, RT; Silva, D; Weinstock-Guttman, B; Zivadinov, R | 1 |
| Babb, J; Carraro, M; Hou, Q; Jhaveri, M; Livingston, T; Mendoza, JP; Nicholas, J; Ontaneda, D; Riester, K; Zhou, J | 1 |
| Ando, Y; Ikeda, T; Kakuma, T; Watari, M | 1 |
| Camp, SM; Garcia, JGN; Marciniak, A; Polt, R | 1 |
| Carruthers, R; Evans, C; Kingwell, E; Marrie, RA; Setayeshgar, S; Tremlett, H; Zhang, T; Zhu, F | 1 |
| Akgün, K; Haase, R; Kaufmann, M; Proschmann, U; Ziemssen, T | 1 |
| Erdogmus, UA; Kamisli, O; Kamisli, S; Özcan, C; Tecellioglu, M | 1 |
| Bertolotto, A; Brescia, F; Caldano, M; Lo Re, M; Martire, S; Montarolo, F; Panzica, G; Perga, S | 1 |
| Chitnis, T; Choudhry, NK; Desai, RJ; Gagne, JJ; Hurley, E; Mahesri, M; Matlin, OS; Minden, S; Shrank, WH; Spettell, CM; Tong, A | 1 |
| Cheong, WL; Yoon, EL | 1 |
| Duquette, P; Freedman, MS; Grand'Maison, F; Haddad, P; Khurana, V; Lara, N; Lee, L; Nakhaipour, HR; Schecter, R; Vorobeychik, G | 1 |
| Blaho, VA; Chun, J; Jonnalagadda, D; Kihara, Y | 1 |
| Axelsson, M; Dubuisson, N; Giovannoni, G; Gnanapavan, S; Lycke, J; Malmeström, C; Novakova, L | 1 |
| Takahashi, K | 1 |
| Grigoriadis, N; Hadjigeorgiou, GM; Heliopoulos, I; Karapanayiotides, T; Katsanos, AH; Kilidireas, C; Palaiodimou, L; Papathanasopoulos, P; Tsivgoulis, G; Voumvourakis, K | 1 |
| Azizoglu, ZB; Cakir, M; Canatan, H; Dönmez Altuntaş, H; Eken, A; Erdem, S; Haliloglu, Y; Kara, I; Kilic, O; Kutuk, MS; Mirza, M; Okus, FZ; Oukka, M; Turkoglu, EM; Vural, A; Yetkin, MF | 1 |
| Alonso-Magdalena, L; Dangond, F; Galazka, A; Martinelli, V; Pfleger, C; Phillips, L; Rieckmann, P; Vermersch, P | 1 |
| Alvarez, E; Corboy, JR; Nair, KV; Sillau, S; Vollmer, BL; Vollmer, T | 1 |
| Arsang-Jang, S; Eftekharian, MM; Ghafouri-Fard, S; Komaki, A; Mazdeh, M; Taheri, M | 1 |
| Bastien, M; Cavalcanti, A; Chochon, F; Lubetzki, C; Robert, C; Routier, E; Thomas, M; Velter, C | 1 |
| Boraldi, F; Fernandez, O; Garcia-Fernandez, M; Hurtado-Guerrero, I; Lara, E; Martín-Montañez, E; Oliver, B; Pavia, J; Valverde, N | 1 |
| Ayzenberg, I; Deguchi, K; Gold, R; Kamada, M; Kufukihara, K; Kume, K; Nakahara, J; Schneider, R; Takata, T; Tomaske, L | 1 |
| Baroncini, D; Boffa, G; Callegari, I; Cellerino, M; Ghezzi, A; Inglese, M; Lapucci, C; Mancardi, GL; Novi, G; Pardini, M; Roccatagliata, L; Sormani, MP; Uccelli, A; Zaffaroni, M | 1 |
| Hu, F; Li, H; Li, K; Zhang, Y | 1 |
| Ayoglu, B; Bedri, SK; Fink, K; Glaser, A; Grönlund, H; Hamsten, C; Hillert, J; Månberg, A; Manouchehrinia, A; Nilsson, OB; Nilsson, P; Olsson, T | 1 |
| Adoni, T; Fragoso, YD; Gomes, S; Goncalves, MVM; Parolin, LF; Rosa, G; Ruocco, HH | 1 |
| Avendano, S; Cabre, P; de Roquemaurel, A; Galli, P; Landais, A | 1 |
| Bowen, JD | 1 |
| Baghbanian, SM; Cheraghmakani, H; Nasehi, MM | 1 |
| Nisar, MK | 1 |
| Akgün, K; Bucki, R; Proschmann, U; Sehr, T; Zendzian-Piotrowska, M; Ziemssen, T | 1 |
| Berenguer-Ruiz, L; Gimenez-Martinez, J; Palazón-Bru, A; Sempere, AP | 1 |
| Keserü, B; Waldvogel, D; Wiederkehr, M | 1 |
| Al Khedr, A; Barbin, L; Berger, E; Bourre, B; Brassat, D; Brochet, B; Cabre, P; Camdessanché, JP; Casey, R; Casez, O; Clavelou, P; De Sèze, J; Debouverie, M; Debroucker, T; Defer, G; Edan, G; Foucher, Y; Gout, O; Guennoc, AM; Heinzlef, O; Labauge, P; Labeyrie, C; Laplaud, DA; Lebrun-Frenay, C; Leray, E; Lubetzki, C; Magy, L; Maubeuge, N; Michel, L; Moreau, T; Nifle, C; Papeix, C; Patry, I; Pelletier, J; Rollot, F; Stankoff, B; Thouvenot, E; Tourbah, A; Vermersch, P; Vukusic, S; Wahab, A; Wiertlewski, S | 1 |
| Akatani, R; Chihara, N; Katanazaka, K; Matsumoto, R; Sekiguchi, K; Ueda, T | 1 |
| Ghasemi-Kasman, M; Javan, M; Yazdi, A | 1 |
| Bianchi, R; Grohmann, U; Macchiarulo, A; Orabona, C; Puccetti, P; Volpi, C | 1 |
| Itokazu, T; Takahashi, R; Yamashita, T | 1 |
| Abouzeid, N; Al-Jumah, M; Alroughani, R; Alsaadi, T; Alsharoqi, I; Bohlega, S; Dahdaleh, M; ElKallab, K; Hashem, S; Inshasi, J; Khoury, S; Tawfeek, T; Yamout, B; Zakaria, M | 1 |
| Chun, J; Groves, A; Kihara, Y | 1 |
| Andriukhina, OM; Iakushina, TI; Kotov, SV; Lizhdvoĭ, VIu; Vasilenko, IA | 1 |
| Eadie, M; Hollingworth, S; Page, A; Walker, K | 1 |
| Collins, W; Francis, G; Jager, RD; Jampol, LM; Reder, AT; Tang, D; Zarbin, MA; Zhang, X | 1 |
| Griffith, JW; Luster, AD | 1 |
| Derfuss, T; Fischer-Barnicol, B; Kappos, L; Kuhle, J; Lindberg, RL; Lorscheider, J; Mehta, SK; Paroz, C; Pierson, DL; Ricklin, ME; Sprenger, T; Waschbisch, A | 1 |
| Cohen, JA; Willis, MA | 1 |
| Benoilid, A; Blanc, F; Chanson, JB; Collongues, N; Courtois, S; de Seze, J; Fleury, M; Ongagna, JC; Zaenker, C | 1 |
| Benghiat, F; Lysandropoulos, AP | 1 |
| Cohen, JA; Collins, W; Francis, G; Kappos, L; Mercier, F; O'Connor, P; Tang, D | 1 |
| Airas, L; Malm, H; Ruuskanen, J | 1 |
| Agashivala, N; Balderston McGuiness, C; Bergvall, N; Capkun, G; Karkare, SU; Korn, JR; Lahoz, R; Makin, C; Petrilla, A; Pradhan, A | 1 |
| Abouzaid, S; Agashivala, N; Boulanger, L; Brandes, DW; Kim, E; Wu, N; Wu, Y | 1 |
| Bourdette, D; Paul, F | 1 |
| Fazekas, F; Harrer, A; Kraus, J; Oppermann, K; Pilz, G; Sellner, J; Trinka, E; Wipfler, P | 1 |
| Cong, ZX; Ji, XJ; Wang, HD; Zhang, L; Zhou, Y; Zhu, JH | 1 |
| Ahmad, I; Deshmukh, VA; Gage, FH; Green, CC; Kerman, B; Kim, HJ; Kondo, T; Lairson, LL; Lawson, BR; Lyssiotis, CA; Padmanabhan, K; Schultz, PG; Swoboda, JG; Tardif, V; Theofilopoulos, AN | 1 |
| Antel, J; Bar-Or, A; Galleguillos, L; Henault, D; Johnson, T; Moore, C | 1 |
| Tanaka, K; Tanaka, M | 1 |
| Al-Jaderi, Z; Maghazachi, AA | 1 |
| Freedman, MS | 1 |
| Asensio-Sánchez, VM; Ramoa-Osorio, R; Trujillo-Guzmán, L | 1 |
| Francis, CE | 1 |
| Alwan, S; Dahlgren, L; Lu, E; Sadovnick, AD; Synnes, A; Tremlett, H; Wang, BW | 1 |
| Fernández, Ó; Garcia-Garcia, M; Montalban, X; Oreja-Guevara, C; Rodríguez-Antigüedad, A | 1 |
| Anthony, DC; Leppert, D; Losey, P; Meier, DP; Sibson, NR | 1 |
| Langer-Gould, AM | 1 |
| Cohen, JA; Collins, W; Francis, G; Heining, P; Kappos, L; Karlsson, G; Koren, G; Zhang, X | 1 |
| Alroughani, R | 1 |
| Damoiseaux, J; Hupperts, R; Muris, AH; Rolf, L; van Daele, M | 1 |
| Araki, M; Aranami, T; Chihara, N; Lin, Y; Matsuoka, T; Miyake, S; Murata, M; Nakamura, M; Ogawa, M; Okamoto, T; Sato, W; Yamamura, T | 1 |
| Al Khedr, A; Anne, O; Berger, E; Bourre, B; Brassat, D; Brochet, B; Camdessanche, JP; Camu, W; Casez, O; Castelnovo, G; Clavelou, P; Cohen, M; Courtois, S; De Sèze, J; Debouverie, M; Defer, G; Fromont, A; Heinzlef, O; Le Page, E; Lebrun, C; Maillart, E; Papeix, C; Pelletier, J; Rico, A; Ruet, A; Stankoff, B; Tourbah, A; Vukusic, S; Wiertlewski, S; Zephir, H | 1 |
| Amino, I; Doi, S; Fujiki, N; Fukazawa, T; Kikuchi, S; Minami, N; Miyazaki, Y; Niino, M; Nonaka, T; Takahashi, E; Tashiro, J | 1 |
| Agius, M; Chin, P; Grinspan, A; Hashmonay, R; Meng, X | 1 |
| Brogi, D; Comi, G; Guidi, L; Laroni, A; Lugaresi, A; Mancardi, GL; Morra, VB; Pozzilli, C; Raimondi, D; Turrini, R; Uccelli, A | 1 |
| Chen, C; Cugati, S; Lee, A; Thoo, S | 1 |
| Bergvall, N; Korn, JR; Lahoz, R; Reynolds, T | 1 |
| di Nuzzo, L; Nasca, C; Nicoletti, F; Orlando, R | 1 |
| Goldman, MD; Jones, DE; Ward, MD | 1 |
| Corral, I; Costa-Frossard, L; Kawiorski, MM; Viedma-Guiard, E | 1 |
| Faßbender, K; Halmer, R; Walter, S | 1 |
| Lovera, J; Villemarette-Pittman, N | 1 |
| Fichman-Horn, S; Hellmann, MA; Inbar, E; Lev, N; Lotan, I; Luckman, J; Mosberg-Galili, R; Steiner, I; Yakimov, M | 1 |
| Agashivala, N; Bergvall, N; Capkun, G; Karkare, SU; Korn, JR; Lahoz, R; Makin, C; McGuiness, CB; Petrilla, AA; Pradhan, A | 1 |
| Capitolo, E; Chaabane, L; Colombo, E; Di Dario, M; Farina, C; Martino, G; Newcombe, J | 1 |
| Dillman, R; Franklin, MA; Happe, LE; Marshall, LZ | 1 |
| Lovett-Racke, AE; Racke, MK; Yang, Y | 1 |
| Callegaro, D; Sato, DK | 1 |
| Arruda, CC; Arruda, WO; Brooks, JB; Damasceno, A; Damasceno, CA; de Morais, MM; Finkelsztejn, A; Finkelsztejn, J; Fragoso, YD; Gama, PD; Giacomo, MC; Gomes, S; Goncalves, MV; Matta, AP; Oliveira, EM; Ribeiro, Y; Sato, HK; Tauil, CB | 1 |
| Bermel, RA; Cohen, JA; Hara-Cleaver, C; Hersh, CM; Ontaneda, D; Rudick, RA | 1 |
| Shoenfeld, Y; Steinman, L | 1 |
| Almulla, A; Alroughani, R; Lamdhade, S; Thussu, A | 1 |
| Dehmel, T; Hartung, HP; Holmen, C; Kieseier, BC; Leussink, VI; Nordin, N; Olsson, T; Ramanujam, R; Warnke, C; Wolfram, K | 1 |
| Moses, H | 1 |
| Dang, HA; Muls, N; Sindic, CJ; van Pesch, V | 1 |
| Artemiadis, AK; Kolokythopoulos, D; Nikolaou, G; Papanastasiou, I; Tegos, N; Terentiou, A; Triantafyllou, N | 1 |
| Bakshi, R; Brinkmann, V; Camm, J; Hla, T | 1 |
| Bencsik, K; Karácsony, M; Vécsei, L | 1 |
| Bankó, N; Bencsik, K; Csete, G; Faragó, P; Kincses, ZT; Király, A; Szabó, N; Tóth, E; Vécsei, L; Veréb, D | 1 |
| Tanaka, M | 2 |
| Brew, BJ; Calic, Z; Cappelen-Smith, C; Cuganesan, R; Hodgkinson, SJ; McDougall, A | 1 |
| Adinolfi, LE; Alfieri, G; Dalla Mora, L; Lus, G; Marrone, A; Rainone, I; Rinaldi, L; Signoriello, E | 1 |
| Airas, L; Anthony, DC; Dickens, AM; Elo, P; Eskola, O; Haaparanta-Solin, M; Johansson, J; Jones, PA; Marjamäki, P; Rinne, J; Solin, O; Trigg, W | 1 |
| Sellebjerg, F; Sørensen, PS | 1 |
| Fratta, M; Lus, G; Sagliocchi, A; Signoriello, E | 1 |
| Barkhof, F; Bright, JR; Cohen, JA; de Vera, A; Francis, G; Häring, DA; Kappos, L; Radue, EW; Sprenger, T; von Rosenstiel, P | 1 |
| Arroyo, R; Bijarnia, M; Curovic-Perisic, V; Izquierdo, G; Kappos, L; Keil, A; Mehling, M; Selmaj, K; Singh, A; von Rosenstiel, P | 1 |
| Goldman, MD; Naismith, RT | 1 |
| Alroughani, R; Butzkueven, H; Duquette, P; Fernandez-Bolaños, R; Girard, M; Grammond, P; Grand'Maison, F; Granella, F; Havrdova, E; He, A; Hodgkinson, S; Horakova, D; Hupperts, R; Iuliano, G; Izquierdo, G; Jokubaitis, V; Kalincik, T; Lechner-Scott, J; Lugaresi, A; Oreja-Guevara, C; Pucci, E; Rozsa, C; Sánchez-Menoyo, JL; Sola, P; Spelman, T; Spitaleri, D; Terzi, M; Trojano, M; Van Pesch, V; Verheul, F | 1 |
| Gündel, M; Hofmann-Apitius, M; Kotelnikova, E; Lozano-Rubi, R; Malhotra, A; Martinez-Lapiscina, EH; Martinez-Lapsicina, EH; Mevissen, HT; Mueller, B; Pastor, X; Rajput, AM; Saiz, A; Toldo, L; Villoslada, P; Zubizarreta, I | 1 |
| Angioni, C; Arlt, O; Huwiler, A; Pfeilschifter, JM; Radeke, HH; Schmidt, H; Schröder, M; Schwiebs, A | 1 |
| Bopp, T; Jolivel, V; Jonuleit, H; Klotz, L; Kraus, S; Lerch, S; Luessi, F; Paterka, M; Ploen, R; Poisa-Beiro, L; Roberg, T; Trinschek, B; Wiendl, H; Witsch, E; Zipp, F | 1 |
| Carreón-Guarnizo, E; Hernández-Clares, R; Meca-Lallana, JE | 1 |
| Li, S; Mei, X; Wang, JR; Zhu, B | 1 |
| Adoni, T; Fragoso, YD; Gomes, S; Goncalves, MV; Matta, AP; Mendes, MF; Siquineli, F | 1 |
| Abe, M; Kanda, T; Koga, M; Maeda, T; Nishihara, H; Sano, Y; Shimizu, F; Takeshita, Y | 1 |
| de Jong, B; Derfuss, T; Giovannoni, G; Izquierdo, G; Juliusson, G; Mazibrada, G; Molyneux, P; Nicholas, R; Overell, J; Ziemssen, T | 1 |
| Anderson, G; Rodriguez, M | 1 |
| Anstadt, EJ; Clark, RB; Fujiwara, M; Khanna, KM | 1 |
| Hla, T; Proia, RL | 1 |
| Alarcón-Duque, JA; Castillo-Trivino, T; Lopetegui, I; López de Munain, A; Olascoaga, J | 1 |
| Aloi, JJ; English, C | 1 |
| Barkley, A; Silber, E; Tully, T | 1 |
| Bagnato, F; Pawate, S | 1 |
| D'Onghia, M; Direnzo, V; Manni, A; Paolicelli, D; Tortorella, C; Trojano, M; Zoccolella, S | 1 |
| Kawano, Y; Kira, J; Masaki, K; Matsuse, D; Matsushita, T; Murai, H; Sato, S; Song, ZY; Yamasaki, R; Yoshimura, S | 1 |
| Alfredsson, L; Askling, J; Forsberg, L; Frisell, T; Hillert, J; Kiesel, C; Nordin, N; Olsson, T; Piehl, F | 1 |
| Cocco, E; Coghe, GC; Fenu, G; Frau, F; Lorefice, L; Marrosu, MG | 1 |
| Prager, B; Ransohoff, RM; Spampinato, SF | 1 |
| Alves-Leon, SV; Apostolos Pereira, SL; Barreira, AA; Brito Ferreira, ML; Callegaro, D; Cunha Matta, AP; Finkelsztejn, A; Fragoso, YD; Gomes, S; Magno Goncalves, MV; Marques, VD; Moraes Machado, MI; Papais-Alvarenga, RM; Tauil, CB | 1 |
| Boangher, S; Goffette, S; Mespouille, P; Van Pesch, V | 1 |
| Chihara, N; Endo, H; Kanda, F; Kowa, H; Sekiguchi M D, K; Toda, T | 1 |
| Hilz, MJ; Intravooth, T; Koehn, J; Lee, DH; Linker, RA; Moeller, S; Wang, R | 1 |
| Bandyopadhyay, M; Candido, K; Dasgupta, S; Soufi, H | 1 |
| Fernández Fournier, M; Gómez Fernández, C; González Ramos, J; Herranz Pinto, P; Mayor Ibarguren, A; Romero Gómez, MP; Tallón Barranco, A | 1 |
| Cotleur, A; Kanda, T; Love, A; Obermeier, B; Ransohoff, RM; Sano, Y; Spampinato, SF; Takeshita, Y | 1 |
| Gielen, J; Laton, J; Nagels, G; Van Schependom, J | 1 |
| Accoto, S; De Blasi, V; De Donno, A; De Masi, R; Idolo, A; Orlando, S; Pasca, S; Scarpello, R; Spagnolo, L | 1 |
| Bertolotto, A; Caldano, M; Lugaresi, A; Marnetto, F; Spadaro, M | 1 |
| Antel, JP; Healy, LM; Michell-Robinson, MA | 1 |
| Huang, D | 1 |
| Harirchian, MH; Siroos, B; Taalimi, A | 1 |
| Bläuer, C; Coslovsky, M; Derfuss, T; Kappos, L; Zimmer, A | 1 |
| Bramanti, P; Calabrò, RS; Guarneri, C; Mazzon, E; Russo, M; Sessa, E | 1 |
| Cavarretta, R; Di Rienzo, M; Ferratini, M; Racca, V; Rovaris, M; Toccafondi, A; Vaini, E | 1 |
| Bakshi, R; Häring, DA | 1 |
| Afazel, S; Harrer, A; Haschke-Becher, E; Kraus, J; Oppermann, K; Pilz, G; Sellner, J; Trinka, E; Wipfler, P | 1 |
| Harel, A; Lublin, F; Straus Farber, R | 1 |
| Antel, JP; Healy, LM | 1 |
| Blanc, CA; Grist, JJ; Lane, TE; Rosen, H; Sears-Kraxberger, I; Steward, O | 1 |
| Achtnichts, L; Conen, A; Fux, CA; Nedeltchev, K; Obreja, O | 1 |
| Matsui, M | 1 |
| Hashi, Y; Kondo, T | 1 |
| Kohriyama, T; Ochi, K | 1 |
| Saida, K; Ueda, N | 1 |
| Hartung, HP; Olsson, T; Warnke, C | 1 |
| Dhindsa, JS; Gill, GS; Grobelny, DW; Samuvel, DJ; Saxena, N; Singh, AK; Singh, I | 1 |
| Elovaara, I; Färkkilä, M; Kuusisto, H; Martola, J; Remes, AM; Soilu-Hänninen, M; Tienari, P | 1 |
| Khoury, SJ; Tamim, H; Yamout, BI; Zeineddine, MM | 1 |
| Cao, R; Guo, L; Hou, H; Liu, X; Miao, J; Song, X; Sun, Y | 1 |
| Delgado, A; Martínez-Cartro, M | 1 |
| Berkowitz, AL; Kaplan, TB; Samuels, MA | 1 |
| Grüner, S; Mayer, CA; Ottenlinger, F; Pfarr, K; Pfeilschifter, JM; Radeke, HH; Schwiebs, A; Wagner, A | 1 |
| Bittner, S; Fluri, F; Kleinschnitz, C; Meuth, SG; Schuhmann, MK | 1 |
| Aly, L; Chitnis, T; Gandhi, R; Glanz, B; Griffin, R; Gwanyalla, N; Hei, H; Kivisakk, P; Kumar, D; Mazzola, MA; Murugaiyan, G; Nejad, P; Patel, B; Pertel, T; Raheja, R; Rajabi, H; Regev, K; Weiner, HL | 1 |
| Andreadou, E; Evangelopoulos, DS; Evangelopoulos, ME; Kilidireas, C; Koutoulidis, V | 1 |
| Forrestel, AK; Longworth, S; Micheletti, RG; Modi, BG; Wilck, MB | 1 |
| Basuki, MA; Booth, DR; Burke, T; Fabis-Pedrini, MJ; Fewings, N; Gatt, PN; Goldinger, A; Kermode, AG; McKay, FC; Parnell, GP; Powell, JE; Schibeci, SD; Stewart, GJ; Vucic, S | 1 |
| Al-Khamis, FA | 1 |
| Al Khedr, A; Barbin, L; Berger, E; Bourre, B; Brassat, D; Brochet, B; Cabre, P; Camdessanché, JP; Casey, R; Clavelou, P; Créange, A; De Sèze, J; Debouverie, M; Debroucker, T; Defer, G; Edan, G; Foucher, Y; Gout, O; Heinzlef, O; Jousset, N; Labauge, P; Laplaud, DA; Lebrun-Frenay, C; Magy, L; Moreau, T; Papeix, C; Pelletier, J; Rousseau, C; Stankoff, B; Thouvenot, E; Tourbah, A; Vermersch, P; Vukusic, S; Wiertlewski, S | 1 |
| Barnett, MH; Byrne, S; Combes, V; Grau, GE; Hawke, S; Latham, SL; Zinger, A | 1 |
| Hartung, HP; Loebermann, M; Reisinger, EC; Winkelmann, A; Zettl, UK | 1 |
| Kretzschmar, B; Pellkofer, H; Weber, MS | 1 |
| Cristóbal, I; García-Foncillas, J; González-Alonso, P; Madoz-Gúrpide, J; Manso, R; Rojo, F | 1 |
| Anastasiadou, S; Knöll, B | 1 |
| Bonder, CS; Dimasi, DP; Grimbaldeston, MA; Heddle, R; Pitman, MR; Pitson, SM; Sun, WY; Zhuang, Y | 1 |
| Axelsson, M; Blennow, K; Khademi, M; Lycke, J; Malmeström, C; Novakova, L; Olsson, T; Piehl, F; Zetterberg, H | 1 |
| Achtnichts, L; Benkert, P; Derfuss, T; Disanto, G; Du Pasquier, R; Findling, O; Gobbi, C; Kamm, CP; Kappos, L; Kuhle, J; Lalive, PH; Lorscheider, J; Lotter, C; Louvion, JF; Mattle, HP; Mueller, S; Nedeltchev, K; Pot, C; Radue, EW; Ramseier, S; Schluep, M; Sprenger, T; Stippich, C; Vehoff, J; Yaldizli, Ö; Zecca, C | 1 |
| Antoniou, C; Economidi, A; Karampidou, K; Katsavos, S; Marinos, L; Matoula, T; Nasis, G; Nikolaou, V; Stratigos, A | 1 |
| Blumenfeld, S; Miller, A; Staun-Ram, E | 1 |
| Koch-Henriksen, N; Magyari, M; Sellebjerg, F; Soelberg Sørensen, P | 1 |
| Fernanda Mendes, M; Fragoso, YD; Gama, PDD; Gomes, S; Khouri, JMN; Matta, APDC; Stella, CRAV | 1 |
| Habibi, M; Kuttab, HM | 1 |
| Crabtree-Hartman, E; Graves, JS; Hatcher, SE; Nourbakhsh, B; Waubant, E | 1 |
| Carotenuto, A; Cerillo, I; Dubbioso, R; Iodice, R; Manganelli, F; Santoro, L | 1 |
| Gräfe, R; Hildebrandt, U; Papathemeli, D; Ulrich, J; Zettl, UK | 1 |
| Brescia Morra, V; Cittadini, A; De Angelis, G; de Rosa, A; Lanzillo, R; Marsili, A; Pane, C; Puorro, G; Russo, CV; Saccà, F | 1 |
| Zécri, FJ | 1 |
| Lazibat, I; Rotim, K; Šamija, RK | 1 |
| Arcona, S; Li, Y; Taber, C; Zhou, H | 1 |
| Agostini, S; Caputo, D; Clerici, M; La Rosa, F; Longhi, R; Marventano, I; Mendozzi, L; Piancone, F; Rovaris, M; Saresella, M; Zoppis, M | 1 |
| Beran, RG; Boyko, A; Chiquete, E; Correale, J; Frider, N; Milojevic, S; Strauch, JB | 1 |
| Canichella, F; Ferrucci, A; Francia, P; Fubelli, F; Giuliani, M; Musumeci, MB; Pozzilli, C; Presta, V; Timpano, J; Tocci, G; Volpe, M | 1 |
| Bartels, A; Barth, S; Greve, B; Herrmann, MM; Schumann, KM; Weissert, R | 1 |
| Weinshenker, BG; Wingerchuk, DM | 1 |
| du Pasquier, R; Durand-Dubief, F; Marignier, R; Vukusic, S | 1 |
| Alves-Leon, SV; Becker, J; Brooks, JB; Correa, EC; Damasceno, A; Fragoso, YD; Gama, PD; Gama, RA; Maciel, EP; Matta, AP; Winckler, TC | 1 |
| Akimoto, S; Amino, I; Doi, S; Fujiki, N; Fukazawa, T; Hisahara, S; Kanazawa, I; Kikuchi, S; Minami, N; Miyazaki, Y; Mizuno, M; Nakamura, M; Niino, M; Ochi, R; Shimohama, S; Suzuki, M; Takahashi, E; Terayama, Y | 1 |
| Angerer, IC; Fitzner, B; Flechtner, K; Friess, J; Hecker, M; Koczan, D; Meister, S; Roch, L; Schröder, I; Thiesen, HJ; Winkelmann, A; Zettl, UK | 1 |
| Chard, D; Chataway, J; Trip, A | 1 |
| Merschhemke, M; Putzki, N; Tomic, D | 1 |
| Andrade, C | 1 |
| Graves, JS; Hatcher, SE; Waubant, E | 1 |
| Garris, CS; Griffin, CW; Han, MH; Huang, Y; Moreno, MA; Tsai, HC | 1 |
| Chan, A; Edwards, MR; Fox, RJ; Levison, D; Lewin, JB; Marantz, JL; Xiao, J; Zhang, A | 1 |
| Hahn, JN; Kaushik, DK; Mishra, MK; Silva, C; Wang, J; Yong, VW | 1 |
| Lasek-Bal, A; Puz, P | 1 |
| Bianco, A; Brescia Morra, V; Buttari, F; Capra, R; Centonze, D; Cordioli, C; Cortese, A; Di Battista, G; Ferraro, E; Francia, A; Galgani, S; Gasperini, C; Haggiag, S; Millefiorini, E; Mirabella, M; Pontecorvo, S; Pozzilli, C; Prosperini, L; Ruggieri, S; Saccà, F | 1 |
| Schmidt, C | 1 |
| Akdemir, A; Dişli, A; Doyduk, D; Şen, A; Turgut, GÇ; Yavuz, S; Yıldırır, Y | 1 |
| Bergsland, N; Bonzani, I; Carl, E; Christoffersen, P; Dwyer, MG; Khan, N; Korn, JR; Medin, J; Price, J; Silva, D; Weinstock-Guttman, B; Zivadinov, R | 1 |
| Frank, B; Osmanovic, A; Pars, K; Pielen, A; Pul, R; Schmalstieg, H; Schwenkenbecher, P; Skripuletz, T; Stangel, M; Sühs, KW; Yildiz, Ö | 1 |
| Guo, M; Robinson, CL | 1 |
| Adamczyk-Sowa, M; Gąsior, M; Kluczewska, E; Mazur, B; Niedziela, JT; Niedziela, N; Sowa, P | 1 |
| Fujiwara, H; Fujiyoshi, K; Hata, J; Jinzaki, M; Momoshima, S; Nakahara, J; Nakamura, M; Okano, H; Suzuki, N; Suzuki, S; Takahashi, S; Tanikawa, M | 1 |
| Eraksoy, M; Gündüz, T; Kürtüncü, M | 1 |
| Afazel, S; de Vries, A; Harrer, A; Haschke-Becher, E; Hitzl, W; Kraus, J; McCoy, M; Oppermann, K; Pilz, G; Rispens, T; Sageder, M; Sellner, J; Stevanovic, V; Trinka, E; Wipfler, P | 1 |
| Tyor, WR; Vargas, DL | 1 |
| Memon, A; Miranda, J | 1 |
| Ciric, B; Gran, B; Li, X; Ma, CG; Rostami, A; Zhang, GX; Zhang, Y | 1 |
| Angerer, IC; Fitzner, B; Flechtner, K; Friess, J; Hecker, M; Koczan, D; Roch, L; Schröder, I; Thiesen, HJ; Winkelmann, A; Zettl, UK | 1 |
| Bornstein, PF; Carpenter, AF; Goodwin, SJ; Larson, AJ; Markus, CK | 1 |
| Airody, A; Gale, RP; Heath, G | 1 |
| Couto, CA; Medin, J; Mitchell, CR; Ziemssen, T | 1 |
| Haase, R; Proschmann, U; Rodriguez-Leal, FA; Sehr, T; Thomas, K; Ziemssen, T | 1 |
| Barnett, MH; De Stefano, N; Silva, DG | 1 |
| Milstien, S; Paugh, SW; Spiegel, S; Takabe, K | 1 |
| Garber, K | 1 |
| Benedetti, MD; Invernizzi, P; Monaco, S; Poli, S | 1 |
| Borriello, G; Cefaro, LA; Gasperini, C; Pozzilli, C; Prosperini, L; Tosto, G | 1 |
| Antel, J; Bar-Or, A; Brinkmann, V; Goebels, N; Kappos, L; Kristofic, C; Kuhle, J; Lindberg, RL; Mehling, M; Vedrine, C | 1 |
| Antel, J; Comi, G; de Vera, A; Kappos, L; Montalban, X; O'Connor, P; Pohlmann, H; Radue, EW | 1 |
| Eaton, R; Gonzalez, MI; Marshall, I; Papadopoulos, D; Patel, R; Philpott, KL; Reynolds, R; Richardson, JC; Rundle, J; Stretton, J | 1 |
| Yamamura, T | 1 |
| Hartung, HP; Kieseier, BC; Stüve, O; Wiendl, H | 1 |
| Eschenhagen, T; Friedrich, FW | 1 |
| Brinkmann, V | 2 |
| Gasperini, C; Ruggieri, S | 2 |
| Zéphir, H | 1 |
| Link, H; Martin, R | 1 |
| Martin, R | 1 |
| Gold, R; Haghikia, A | 1 |
| Antel, JP; Darlington, PJ; Jarjour, AA; Kennedy, TE; Ludwin, SK; Miron, VE; Soliven, B | 1 |
| Oberpichler-Schwenk, H | 1 |
| Hecht, B | 1 |
| Aktas, O; Hartung, HP; Kieseier, B; Küry, P | 1 |
| Nau, JY | 1 |
| Brinkmann, V; Hess, C; Kappos, L; Kuhle, J; Lindberg, R; Mehling, M; Raulf, F | 1 |
| Antel, J; Bar-Or, A; Haegert, DG; Johnson, TA; Keezer, M; Lapierre, Y; Shames, I | 1 |
| Slavin, AJ; Zamvil, SS | 1 |
| Alewijnse, AE; De Vries, HE; Dijkstra, CD; Lakeman, K; Peters, SL; Reijerkerk, A; Ronken, E; Van Der Valk, P; Van Doorn, R; Van Het Hof, B; Van Horssen, J; Verzijl, D; Witte, M | 1 |
| Banwell, B; Yiu, EM | 1 |
| Morrow, T | 1 |
| Fontoura, P; Garren, H | 1 |
| Aktas, O; Hartung, HP; Hohlfeld, R; Ingwersen, J; Kieseier, B; Küry, P | 1 |
| Fox, EJ | 1 |
| Kalinowska-Łyszczarz, A; Losy, J | 1 |
| Chun, J; Noguchi, K | 1 |
| Aradhye, S; Baumruker, T; Billich, A; Brinkmann, V; Burtin, P; Francis, G; Heining, P; Schmouder, R | 1 |
| Ratner, M | 1 |
| Gold, R | 1 |
| Antel, JP; Bar-Or, A; Johnson, TA; Lapierre, Y | 1 |
| Bonzano, L; De Stefano, N; Roccatagliata, L; Sormani, MP | 1 |
| Choi, JW; Chun, J; Gardell, SE; Herr, DR; Kennedy, G; Lee, CW; Lu, M; Noguchi, K; Rivera, R; Teo, ST; Yung, YC | 1 |
| Jadidi-Niaragh, F; Mirshafiey, A | 1 |
| Bolli, MH; Lescop, C; Nayler, O | 1 |
| Filippi, M | 1 |
| Brinkmann, V; Merkler, D; Pinschewer, DD | 1 |
| Barkhof, F; Hohlfeld, R; Polman, C | 1 |
| Antel, J; Bar-Or, A; Johnson, TA; Kappos, L; Mehling, M | 1 |
| Durovic, B; Eichin, D; Fritz, S; Gasser, O; Hess, C; Hilbert, P; Kappos, L; Klimkait, T; Kuhle, J; Lindberg, RL; Mehling, M | 1 |
| Carmona, O; Cocco, E; Drulovic, J; Duddy, M; Eggers, C; Gold, R; Haghikia, A; Zéphir, H | 1 |
| Oberlies, NH; Pearce, CJ; Strader, CR | 1 |
| Ishii, K; Kim, SU; Satoh, J; Sugiyama, S; Tabunoki, H; Yoshino, T | 1 |
| Chun, J; Cohen, JA | 1 |
| Kieseier, BC; Wiendl, H | 1 |
| Fujita, T; Kohno, T; Tsuji, T; Yoshida, Y | 1 |
| Berger, JR; Espinosa, PS | 1 |
| Arnason, B | 1 |
| Goodin, D | 1 |
| Willoughby, E | 1 |
| Csépány, T | 1 |
| Brinkman, V; Cojean, C; Li, L; Matsumoto, M; Pachner, AR; Seabrook, TJ | 1 |
| Bernardi, G; Centonze, D; De Chiara, V; Furlan, R; Lo Giudice, T; Martino, G; Martorana, A; Motta, C; Musella, A; Rossi, S; Studer, V | 1 |
| Hohlfeld, R | 1 |
| Agarwal, S; Franklin, M; Meyer, K; Miller, RM; O'Day, K | 1 |
| Derfuss, T; Kappos, L; Mehling, M | 1 |
| Hla, T; Obinata, H | 1 |
| Gillingwater, TH | 1 |
| Casanova, B; Díaz-Llopis, M; España-Gregori, E; Gallego-Pinazo, R; Pardo-López, D | 1 |
| Braun, R; Conzett, KB; Dummer, R; French, LE; Hofbauer, GF; Jelcic, I; Kamarachev, J; Kolm, I; Linnebank, M | 1 |
| Löbermann, M; Reisinger, EC; Winkelmann, A; Zettl, UK | 1 |
| Frohman, T; Hardeman, P; O'Donoghue, DL; Orchard, M | 1 |
| Constantinescu, CS; Gran, B; Sanvito, L | 1 |
| Popova, NF | 1 |
| Brinkmann, V; Chun, J | 1 |
| Cahalan, SM; Cameron, MD; Gonzalez-Cabrera, PJ; Kago, T; Leaf, NB; Nguyen, N; Rosen, H; Sarkisyan, G | 1 |
| Matsushita, T | 1 |
| David, OJ; Kovarik, JM; Schmouder, RL | 1 |
| Sørensen, PS | 1 |
| Hafler, DA; Pelletier, D | 1 |
| Chabwine, JN; Démonet, JF; du Pasquier, RA; Hirt, L; Kuntzer, T; Michel, P; Rossetti, AR; Schluep, M; Vingerhoets, FG | 1 |
| Wise, J | 1 |
| Amor, S; Kipp, M | 1 |
| Doxani, C; Hadjigeorgiou, GM; Mprotsis, T; Schmid, CH; Zintzaras, E | 1 |
| Hogan, EL; Krotkiewski, H; Podbielska, M | 1 |
| Eckert, BJ; Roskell, NS; Rycroft, CE; Tyas, DA; Zimovetz, EA | 1 |
| Jin, J; Tian, YL; Wang, XJ | 1 |
| Graham-Rowe, D | 1 |
| Cocco, G | 1 |
| Adachi, K; Chiba, K | 1 |
| Buttmann, M; Weise, G | 1 |
| Johnston, J; So, TY | 1 |
| Du Pasquier, R; Schluep, M | 1 |
| Danilycheva, IV; Kryzhanovskiĭ, SM; Shmyrev, VI | 1 |
| García-Merino, JA; Sánchez, AJ | 1 |
| Chiba, K; Yoshii, N | 1 |
| Faber, H; Fischer, HJ; Weber, F | 1 |
| Aguilera, C; Tintoré, M; Tur, C | 1 |
| Agoropoulou, C; Burtin, P; Calabresi, P; de Vera, A; Francis, G; Hohlfeld, R; Holdbrook, F; Kappos, L; Mueller-Lenke, N; O'Connor, P; Polman, CH; Radue, EW; Selmaj, K; Zhang-Auberson, L | 1 |
| Bourdette, D; Yadav, V | 1 |
| Ais-Larisgoitia, A; de Lorenzo-Pinto, A; Rodríguez-González, CG | 1 |
| Hopkins, CR | 1 |
| Katz, KD; King, AM; Menke, NB; Pizon, AF | 1 |
| Lassmann, H | 1 |
| de Vries, HE; Dekker, N; Dijkstra, C; Kooij, G; Lopes-Pinheiro, MA; Nijland, PG; Reijerkerk, A; van Doorn, R; van het Hof, B; van Horssen, J; van van der Valk, P; Witte, ME | 1 |
| Lopez, AF; Pitman, MR; Pitson, SM; Woodcock, JM | 1 |
| Furberg, CD; Moore, TJ | 1 |
| Bourdette, D; Gilden, D | 1 |
| Linssen, WH; Pouwels, PJ; van Oosten, BW; Visser, F; Wattjes, MP | 1 |
| Baumgartner, A; Gross, CM; Rauer, S; Stich, O | 1 |
| Huggins, A; Sergott, RC | 1 |
| Hemmer, B; Stüve, O | 1 |
| Hartung, HP; Jander, S; Kieseier, BC; Turowski, B | 1 |
| Tar, L; Vécsei, L | 1 |
| Annovazzi, P; Baroncini, D; Comi, G; Filippi, M; Ghezzi, A; Minonzio, G; Rocca, MA; Zaffaroni, M | 1 |
| Baum, K; Björnsson, ES; Chen, EY; Collins, W; Lee, WM; Löve, A; Merz, M; Olafsson, S | 1 |
| Haas, J; Hartung, HP; Linker, RA; Meergans, M; Ortler, S; Tracik, F | 1 |
| Niino, M | 1 |
| Dinkin, M; Paul, F | 1 |
| Gelfand, JM; Green, AJ; Nolan, R | 1 |
| Chenevier, F; Confavreux, C; Roggerone, S; Vukusic, S | 1 |
| Filippi, M; Rocca, MA | 1 |
| Eienbröker, C; Gold, R; Havla, J; Hellwig, K; Hohlfeld, R; Kleiter, I; Krumbholz, M; Kümpfel, T; Meinl, I; Seitz, F; Tackenberg, B | 1 |
| Merkely, B; Széplaki, G | 1 |
| Komoly, S | 1 |
| Bandichhor, R; Iqbal, J; Mulakayala, N; Oruganti, S; Rao, P | 1 |
| Fox, RJ | 1 |
| Afshar, AR; Fernandes, JK; Hariprasad, SM; Ksiazek, SM; Patel, RD; Reder, AT; Sheth, VS | 1 |
| Senior, K | 1 |
| Massberg, S; von Andrian, UH | 1 |
| Böhler, T; Budde, K; Glander, P; Liefeldt, L; Neumayer, HH; Peters, H; Schütz, M; Waiser, J | 1 |
| Weissert, R | 1 |
| Miller, D | 1 |
| Baumruker, T; Billich, A; Brinkmann, V | 1 |
| Böhler, T; Budde, K; Martini, S; Peters, H | 1 |
| Burton, JM; O'Connor, P | 1 |
| Gonsette, RE | 1 |
| Hartung, HP; Hohlfeld, R; Klatt, J | 1 |
| Balatoni, B; Beerli, C; Billich, A; Foster, CA; Hiestand, PC; Howard, LM; Persohn, E; Reuschel, R; Schwartz, M; Schweitzer, A | 1 |
| Brown, BA; Kantesaria, PP; McDevitt, LM | 1 |
| Bilbe, G; Dev, KK; Hoyer, D; Kuhn, RR; Mattes, H; Mir, A; Mullershausen, F | 1 |
| Foster, CA; Hiestand, PC; Meier, DP; Rausch, M | 1 |
| Chiba, K; Kataoka, H | 1 |
| Antel, JP; Miron, VE | 1 |
184 review(s) available for fingolimod hydrochloride and Multiple Sclerosis
| Article | Year |
|---|---|
[Siponimod: a new view at the therapy of secondary progressive multiple sclerosis].
Topics: Azetidines; Benzyl Compounds; Fingolimod Hydrochloride; Humans; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive | 2021 |
Acting centrally or peripherally: A renewed interest in the central nervous system penetration of disease-modifying drugs in multiple sclerosis.
Topics: Blood-Brain Barrier; Central Nervous System; Fingolimod Hydrochloride; Humans; Multiple Sclerosis; Pharmaceutical Preparations | 2021 |
Rituximab for people with multiple sclerosis.
Topics: Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Rituximab; Young Adult | 2021 |
Progressive multifocal leukoencephalopathy and sphingosine 1-phosphate receptor modulators used in multiple sclerosis: an updated review of literature.
Topics: Fingolimod Hydrochloride; Humans; Leukoencephalopathy, Progressive Multifocal; Multiple Sclerosis; Natalizumab; Sphingosine 1 Phosphate Receptor Modulators; Sphingosine-1-Phosphate Receptors | 2022 |
Multiple Sclerosis in Children: Differential Diagnosis, Prognosis, and Disease-Modifying Treatment.
Topics: Antibodies, Monoclonal; Child; Crotonates; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Immunosuppressive Agents; Multiple Sclerosis; Nitriles; Prognosis; Sphingosine 1 Phosphate Receptor Modulators; Toluidines | 2022 |
Risk for Cardiovascular Adverse Events Associated With Sphingosine-1-Phosphate Receptor Modulators in Patients With Multiple Sclerosis: Insights From a Pooled Analysis of 15 Randomised Controlled Trials.
Topics: Azetidines; Benzyl Compounds; Bradycardia; Drug-Related Side Effects and Adverse Reactions; Fingolimod Hydrochloride; Humans; Hypertension; Indans; Multiple Sclerosis; Oxadiazoles; Randomized Controlled Trials as Topic; Risk; Sphingosine 1 Phosphate Receptor Modulators; Sphingosine-1-Phosphate Receptors | 2021 |
Incidence of cancer in patients with multiple sclerosis (MS) who were treated with fingolimod: A systematic review and meta-analysis.
Topics: Fingolimod Hydrochloride; Humans; Immunologic Factors; Immunosuppressive Agents; Incidence; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Neoplasms | 2022 |
BASAL CELL CARCINOMA AND SQUAMOUS CELL CARCINOMA IN A PATIENT TREATED WITH FINGOLIMOD FOR MULTIPLE SCLEROSIS - A CASE REPORT AND LITERATURE REVIEW.
Topics: Aged; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Neoplasm Recurrence, Local; Skin Neoplasms | 2022 |
Sphingosine-1-Phosphate (S1P) and S1P Signaling Pathway Modulators, from Current Insights to Future Perspectives.
Topics: Autoimmune Diseases; Fingolimod Hydrochloride; Humans; Lysophospholipids; Multiple Sclerosis; Receptors, Lysosphingolipid; Signal Transduction; Sphingosine | 2022 |
Sphingosine-1-phosphate receptor modulators in stroke treatment.
Topics: Animals; Fingolimod Hydrochloride; Immunosuppressive Agents; Lysophospholipids; Multiple Sclerosis; Receptors, Lysosphingolipid; Sphingosine 1 Phosphate Receptor Modulators; Sphingosine-1-Phosphate Receptors; Stroke | 2022 |
Is there a role for off-label high-efficacy disease-modifying drugs in progressive multiple sclerosis? A network meta-analysis.
Topics: Azetidines; Benzyl Compounds; Fingolimod Hydrochloride; Humans; Immunologic Factors; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Network Meta-Analysis; Off-Label Use; Rituximab | 2022 |
Post marketing new adverse effects of oral therapies in multiple sclerosis: A systematic review.
Topics: Dimethyl Fumarate; Drug-Related Side Effects and Adverse Reactions; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting | 2022 |
[Progressive Multifocal Leukoencephalopathy: An Overview of Current Topics].
Topics: Antiviral Agents; Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; JC Virus; Leukoencephalopathy, Progressive Multifocal; Multiple Sclerosis; Natalizumab | 2022 |
Autoimmune hemolytic anemia after treatment with fingolimod in a patient with multiple sclerosis (MS): A case report and review of the literature.
Topics: Anemia, Hemolytic, Autoimmune; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting | 2022 |
Association of NEDA-4 With No Long-term Disability Progression in Multiple Sclerosis and Comparison With NEDA-3: A Systematic Review and Meta-analysis.
Topics: Disease Progression; Fingolimod Hydrochloride; Humans; Interferon-beta; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting | 2022 |
Current status and new developments in sphingosine-1-phosphate receptor antagonism: fingolimod and more.
Topics: Fingolimod Hydrochloride; Humans; Immunologic Factors; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Receptors, Lysosphingolipid; Sphingosine; Sphingosine-1-Phosphate Receptors | 2022 |
Rationale for Use of Sphingosine-1-Phosphate Receptor Modulators in COVID-19 Patients: Overview of Scientific Evidence.
Topics: COVID-19; Fingolimod Hydrochloride; Humans; Multiple Sclerosis; SARS-CoV-2; Sphingosine; Sphingosine 1 Phosphate Receptor Modulators; Sphingosine-1-Phosphate Receptors | 2023 |
The impact of sphingosine-1-phosphate receptor modulators on COVID-19 and SARS-CoV-2 vaccination.
Topics: COVID-19; COVID-19 Vaccines; Fingolimod Hydrochloride; Humans; Multiple Sclerosis; SARS-CoV-2; Sphingosine; Sphingosine 1 Phosphate Receptor Modulators; Sphingosine-1-Phosphate Receptors; Vaccination | 2023 |
Prognostic significance of neurofilament light in Fingolimod therapy for Multiple Sclerosis: A systemic review and meta-analysis based on randomized control trials.
Topics: Biomarkers; Fingolimod Hydrochloride; Humans; Intermediate Filaments; Multiple Sclerosis; Prognosis | 2023 |
S1PR1 modulators in multiple sclerosis: Efficacy, safety, comparison, and chemical structure insights.
Topics: Antibodies; Fingolimod Hydrochloride; Humans; Multiple Sclerosis; Receptors, Lysosphingolipid; Sphingosine-1-Phosphate Receptors; Structure-Activity Relationship | 2023 |
Disease-modifying therapy for multiple sclerosis: Implications for gut microbiota.
Topics: Dimethyl Fumarate; Fingolimod Hydrochloride; Gastrointestinal Microbiome; Glatiramer Acetate; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab | 2023 |
Repurposing drugs against Alzheimer's disease: can the anti-multiple sclerosis drug fingolimod (FTY720) effectively tackle inflammation processes in AD?
Topics: Aged; Alzheimer Disease; Animals; Drug Repositioning; Fingolimod Hydrochloride; Humans; Inflammation; Mice; Multiple Sclerosis; Sclerosis | 2023 |
Molecular and neuroimmune pharmacology of S1P receptor modulators and other disease-modifying therapies for multiple sclerosis.
Topics: Antibodies, Monoclonal; Fingolimod Hydrochloride; Humans; Multiple Sclerosis; Sphingosine 1 Phosphate Receptor Modulators; Sphingosine-1-Phosphate Receptors | 2023 |
The Benefits and Risks of Switching from Fingolimod to Siponimod for the Treatment of Relapsing-Remitting and Secondary Progressive Multiple Sclerosis.
Topics: Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Neurodegenerative Diseases; Recurrence; Risk Assessment | 2023 |
Learning CNS immunopathology from therapeutic interventions.
Topics: Central Nervous System; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Natalizumab | 2023 |
Adverse effects of immunotherapies for multiple sclerosis: a network meta-analysis.
Topics: Adolescent; Adult; Alemtuzumab; Azathioprine; Cladribine; Daclizumab; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunosuppressive Agents; Immunotherapy; Interferon beta-1a; Interferon beta-1b; Male; Multiple Sclerosis; Natalizumab; Network Meta-Analysis; Rituximab; Young Adult | 2023 |
Ceramide and Sphingosine Regulation of Myelinogenesis: Targeting Serine Palmitoyltransferase Using microRNA in Multiple Sclerosis.
Topics: Animals; Brain; Ceramides; Fingolimod Hydrochloride; Humans; MicroRNAs; Molecular Targeted Therapy; Multiple Sclerosis; Myelin Sheath; Rats; Serine C-Palmitoyltransferase; Sphingosine | 2019 |
Peripheral T-cell lymphomas as fingolimod-associated lymphoproliferative disorder for patients with multiple sclerosis - case report with literature review.
Topics: Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Lymphoma, T-Cell, Peripheral; Lymphoproliferative Disorders; Multiple Sclerosis | 2020 |
The efficacy and safety of fingolimod in patients with relapsing multiple sclerosis: A meta-analysis.
Topics: Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Quality of Life; Recurrence | 2020 |
Pregnancy and Multiple Sclerosis: An Update on the Disease Modifying Treatment Strategy and a Review of Pregnancy's Impact on Disease Activity.
Topics: Adult; Alemtuzumab; Antibodies, Monoclonal, Humanized; Crotonates; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Hydroxybutyrates; Interferon-beta; Multiple Sclerosis; Natalizumab; Nitriles; Pregnancy; Pregnancy Complications; Pregnancy Outcome; Prospective Studies; Rituximab; Toluidines | 2020 |
[Multiple sclerosis and immuno-modulators of sphingosine 1-phosphate receptors].
Topics: Animals; Drug Discovery; Fingolimod Hydrochloride; Humans; Immunomodulation; Immunosuppressive Agents; Multiple Sclerosis; Sphingosine-1-Phosphate Receptors | 2020 |
From the Molecular Mechanism to Pre-clinical Results: Anti-epileptic Effects of Fingolimod.
Topics: Animals; Anticonvulsants; Disease Models, Animal; Epilepsy; Fingolimod Hydrochloride; Humans; Multiple Sclerosis; Seizures; Sphingosine 1 Phosphate Receptor Modulators | 2020 |
Multiple Sclerosis Treatment and Melanoma Development.
Topics: Antirheumatic Agents; Biomarkers; Biopsy; Disease Susceptibility; Female; Fingolimod Hydrochloride; Humans; Immunohistochemistry; Immunosuppressive Agents; Melanoma; Melanoma, Cutaneous Malignant; Middle Aged; Multiple Sclerosis; Natalizumab; Skin Neoplasms; Vascular Endothelial Growth Factor A | 2020 |
The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic.
Topics: Alemtuzumab; Antibodies, Monoclonal, Humanized; Antibodies, Viral; Betacoronavirus; CD8-Positive T-Lymphocytes; Cladribine; Coronavirus Infections; COVID-19; Crotonates; Cytokine Release Syndrome; Deprescriptions; Dimethyl Fumarate; Fingolimod Hydrochloride; Glatiramer Acetate; Hematopoietic Stem Cell Transplantation; Humans; Hydroxybutyrates; Immune Evasion; Immunity, Innate; Immunologic Factors; Immunosuppressive Agents; Interferon-beta; Lymphopenia; Macrophages; Monocytes; Multiple Sclerosis; Natalizumab; Nitriles; Pandemics; Pneumonia, Viral; Respiratory Distress Syndrome; SARS-CoV-2; Toluidines | 2020 |
Discovery of fingolimod based on the chemical modification of a natural product from the fungus, Isaria sinclairii.
Topics: Animals; Drug Discovery; Fatty Acids, Monounsaturated; Fingolimod Hydrochloride; Humans; Hypocreales; Lymphocytes; Multiple Sclerosis; Structure-Activity Relationship | 2020 |
Fingolimod as a Treatment in Neurologic Disorders Beyond Multiple Sclerosis.
Topics: Alzheimer Disease; Animals; Anti-Inflammatory Agents, Non-Steroidal; Disease Models, Animal; Drug Evaluation, Preclinical; Epilepsy; Fingolimod Hydrochloride; Humans; Lymphocytes; Mice; Multiple Sclerosis; Nervous System Diseases; Neuroprotective Agents; Rats; Sphingosine 1 Phosphate Receptor Modulators | 2020 |
The role of TH17 cells in multiple sclerosis: Therapeutic implications.
Topics: Fingolimod Hydrochloride; Humans; Multiple Sclerosis; Natalizumab; Th1 Cells; Th17 Cells | 2020 |
[Comparison of the clinical benefits of second-line drugs modifying the course of multiple sclerosis].
Topics: Cladribine; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting | 2020 |
Newly approved agents for relapsing remitting multiple sclerosis: how real-world evidence compares with randomized clinical trials?
Topics: Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Randomized Controlled Trials as Topic | 2021 |
Sphingosine 1-phosphate Receptor Modulator Therapy for Multiple Sclerosis: Differential Downstream Receptor Signalling and Clinical Profile Effects.
Topics: Animals; Azetidines; Benzyl Compounds; Fingolimod Hydrochloride; Humans; Indans; Multiple Sclerosis; Oxadiazoles; Prodrugs; Signal Transduction; Sphingosine-1-Phosphate Receptors | 2021 |
Assessing and mitigating risk of infection in patients with multiple sclerosis on disease modifying treatment.
Topics: Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunosuppressive Agents; Multiple Sclerosis; Natalizumab | 2021 |
Fingolimod-associated macular edema: A case report of late onset.
Topics: Fingolimod Hydrochloride; Fluorescein Angiography; Humans; Macular Edema; Male; Middle Aged; Multiple Sclerosis; Tomography, Optical Coherence; Visual Acuity | 2022 |
Incidence and Risk of Infection Associated With Fingolimod in Patients With Multiple Sclerosis: A Systematic Review and Meta-Analysis of 8,448 Patients From 12 Randomized Controlled Trials.
Topics: Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Incidence; Infections; Multiple Sclerosis; Odds Ratio; Publication Bias; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors | 2021 |
Sphingosine 1-Phosphate Receptor Modulators for Multiple Sclerosis.
Topics: Central Nervous System Agents; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Sphingosine 1 Phosphate Receptor Modulators | 2021 |
Managing multiple sclerosis in the Covid19 era: a review of the literature and consensus report from a panel of experts in Saudi Arabia.
Topics: Consensus; COVID-19; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Pandemics; RNA, Viral; SARS-CoV-2; Saudi Arabia | 2021 |
Update on treatment in multiple sclerosis.
Topics: Abnormalities, Drug-Induced; Algorithms; Antibodies, Monoclonal, Humanized; Cladribine; Crotonates; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Hematopoietic Stem Cell Transplantation; Humans; Hydroxybutyrates; Immunologic Factors; Immunosuppressive Agents; Indans; Interferon-beta; Male; Mitoxantrone; Multiple Sclerosis; Natalizumab; Nitriles; Oxadiazoles; Pregnancy; Sphingosine 1 Phosphate Receptor Modulators; Sphingosine-1-Phosphate Receptors; Toluidines | 2021 |
Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions.
Topics: Animals; Azetidines; Benzyl Compounds; Clinical Trials as Topic; Fingolimod Hydrochloride; Humans; Immune System Diseases; Indans; Multiple Sclerosis; Nervous System Diseases; Oxadiazoles; Signal Transduction; Sphingosine 1 Phosphate Receptor Modulators; Sphingosine-1-Phosphate Receptors; Thiazoles | 2021 |
Pediatric onset multiple sclerosis: Future challenge for early diagnosis and treatment.
Topics: Adolescent; Age of Onset; Child; Child, Preschool; Cognition Disorders; Demyelinating Autoimmune Diseases, CNS; Diagnosis, Differential; Early Diagnosis; Female; Fingolimod Hydrochloride; Humans; Immunologic Factors; Infant; Magnetic Resonance Imaging; Male; Multiple Sclerosis; Natalizumab; Sphingosine 1 Phosphate Receptor Modulators; Symptom Assessment | 2021 |
Pregnancy and multiple sclerosis: an update.
Topics: Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Infant; Multiple Sclerosis; Natalizumab; Pregnancy | 2021 |
Lessons from S1P receptor targeting in multiple sclerosis.
Topics: Animals; Central Nervous System; Fingolimod Hydrochloride; Humans; Lymphocytes; Lysophospholipids; Multiple Sclerosis; Receptors, Lysosphingolipid; Sphingosine; Sphingosine-1-Phosphate Receptors | 2022 |
What's new about oral treatments in Multiple Sclerosis? Immunogenetics still under question.
Topics: Administration, Oral; Animals; Crotonates; Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Immunogenetics; Immunosuppressive Agents; Multiple Sclerosis; Nitriles; Toluidines | 2017 |
Effector and regulatory B cells in Multiple Sclerosis.
Topics: Alemtuzumab; Animals; B-Lymphocyte Subsets; B-Lymphocytes, Regulatory; Crotonates; Dimethyl Fumarate; Encephalomyelitis, Autoimmune, Experimental; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Hydroxybutyrates; Immunologic Factors; Immunosuppressive Agents; Interferon-beta; Multiple Sclerosis; Natalizumab; Nitriles; Rituximab; Toluidines | 2017 |
Multiple sclerosis treatment with fingolimod: profile of non-cardiologic adverse events.
Topics: Central Nervous System; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Lymphocytes; Magnetic Resonance Imaging; Multiple Sclerosis | 2017 |
Tumefactive demyelinating lesions: A comprehensive review.
Topics: Adrenal Cortex Hormones; Brain Neoplasms; Central Nervous System Neoplasms; Demyelinating Autoimmune Diseases, CNS; Deprescriptions; Diagnosis, Differential; Fingolimod Hydrochloride; Humans; Immunologic Factors; Immunosuppressive Agents; Magnetic Resonance Imaging; Multiple Sclerosis; Natalizumab; Plasma Exchange; Risk Factors | 2017 |
Sphingosine 1-Phosphate Receptor Modulators for the Treatment of Multiple Sclerosis.
Topics: Animals; Azetidines; Benzyl Compounds; Clinical Trials as Topic; Fingolimod Hydrochloride; Humans; Immunologic Factors; Indans; Indoles; Multiple Sclerosis; Naphthalenes; Oxadiazoles; Propanolamines; Receptors, Lysosphingolipid; Thiazoles; Treatment Outcome | 2017 |
Benefit-Risk Profile of Sphingosine-1-Phosphate Receptor Modulators in Relapsing and Secondary Progressive Multiple Sclerosis.
Topics: Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Natalizumab; Receptors, Lysosphingolipid; Risk Assessment | 2017 |
Multiple sclerosis, a treatable disease .
Topics: Adjuvants, Immunologic; Alemtuzumab; Crotonates; Demyelinating Diseases; Dimethyl Fumarate; Fingolimod Hydrochloride; Glatiramer Acetate; Glucocorticoids; Humans; Hydroxybutyrates; Immunologic Factors; Immunosuppressive Agents; Interferon beta-1a; Interferon beta-1b; Mitoxantrone; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Nitriles; Toluidines | 2017 |
Potential neuroprotective effect of Fingolimod in multiple sclerosis and its association with clinical variables.
Topics: Animals; Astrocytes; Clinical Trials as Topic; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Neurons; Neuroprotective Agents; Receptors, Lysosphingolipid | 2018 |
Oral Therapies for Multiple Sclerosis.
Topics: Administration, Oral; Cladribine; Clinical Trials as Topic; Crotonates; Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Immunosuppressive Agents; Multiple Sclerosis; Nitriles; Quinolones; Sphingosine 1 Phosphate Receptor Modulators; Toluidines | 2019 |
Managing the side effects of multiple sclerosis therapy: pharmacotherapy options for patients.
Topics: Alemtuzumab; Cladribine; Crotonates; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Hydroxybutyrates; Immunologic Factors; Immunosuppressive Agents; Interferon-beta; Multiple Sclerosis; Natalizumab; Neoplasms; Nitriles; Toluidines | 2018 |
New biological agents in the treatment of multiple sclerosis.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biological Products; Cladribine; Daclizumab; Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Immunoglobulin G; Immunologic Factors; Immunosuppressive Agents; Indans; Multiple Sclerosis; Natalizumab; Neuromyelitis Optica; Oxadiazoles; Rituximab | 2018 |
Preapproval and postapproval evidence on drugs for multiple sclerosis.
Topics: 4-Aminopyridine; Alemtuzumab; Clinical Trials as Topic; Crotonates; Daclizumab; Dimethyl Fumarate; Drug Development; European Union; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Immunosuppressive Agents; Interferon-beta; Multiple Sclerosis; Natalizumab; Nitriles; Polyethylene Glycols; Recurrence; Toluidines; Treatment Outcome | 2018 |
The inclusion of real world evidence in clinical development planning.
Topics: Bayes Theorem; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Computer Simulation; Evidence-Based Medicine; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Network Meta-Analysis; Randomized Controlled Trials as Topic; Research Design; Sample Size; Treatment Outcome | 2018 |
An update on sphingosine-1-phosphate receptor 1 modulators.
Topics: Autoimmune Diseases; Biological Availability; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Oxadiazoles; Receptors, Lysosphingolipid; Sphingolipids | 2018 |
Adherence to oral disease-modifying therapy in multiple sclerosis patients: A systematic review.
Topics: Crotonates; Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Immunosuppressive Agents; Medication Adherence; Multiple Sclerosis; Nitriles; Toluidines | 2019 |
Fingolimod: Lessons Learned and New Opportunities for Treating Multiple Sclerosis and Other Disorders.
Topics: Animals; Central Nervous System; Fingolimod Hydrochloride; Humans; Lysophospholipids; Multiple Sclerosis; Sphingosine-1-Phosphate Receptors | 2019 |
Comparative efficacy and acceptability of disease-modifying therapies in patients with relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis.
Topics: Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunosuppressive Agents; Interferon beta-1a; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Network Meta-Analysis | 2020 |
Severe Exacerbation of Multiple Sclerosis Following Withdrawal of Fingolimod.
Topics: Adult; Brazil; Disease Progression; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Male; Multiple Sclerosis; Retrospective Studies; Substance Withdrawal Syndrome | 2019 |
Highly Aggressive Multiple Sclerosis.
Topics: Adult; Age Factors; Alemtuzumab; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunosuppressive Agents; Male; Multiple Sclerosis; Natalizumab; Optic Neuritis; Sex Factors; Treatment Failure | 2019 |
Possible regenerative effects of fingolimod (FTY720) in multiple sclerosis disease: An overview on remyelination process.
Topics: Animals; Disease Models, Animal; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Oligodendroglia; Remyelination; Sphingosine-1-Phosphate Receptors | 2020 |
Preclinical discovery and development of fingolimod for the treatment of multiple sclerosis.
Topics: Administration, Oral; Animals; Drug Development; Drug Evaluation, Preclinical; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Sphingosine 1 Phosphate Receptor Modulators; Structure-Activity Relationship | 2019 |
Fingolimod: direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy.
Topics: Animals; Central Nervous System; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine | 2013 |
Targeting cells in motion: migrating toward improved therapies.
Topics: Antibodies, Monoclonal, Humanized; Cell Adhesion; Cell Migration Inhibition; Fingolimod Hydrochloride; Humans; Immunosuppression Therapy; Immunotherapy; Integrin alpha4; Molecular Targeted Therapy; Multiple Sclerosis; Natalizumab; Propylene Glycols; Signal Transduction; Sphingosine; T-Lymphocyte Subsets; T-Lymphocytes | 2013 |
Fingolimod therapy for multiple sclerosis.
Topics: Central Nervous System; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Lysophospholipids; Multiple Sclerosis; Propylene Glycols; Sphingosine; Treatment Outcome | 2013 |
[Multiple sclerosis and pregnancy].
Topics: Female; Fetus; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunosuppressive Agents; Interferon-beta; Maternal-Fetal Exchange; Multiple Sclerosis; Peptides; Pregnancy; Propylene Glycols; Recurrence; Sphingosine | 2013 |
Tumefactive MS lesions under fingolimod: a case report and literature review.
Topics: Adolescent; Brain; Female; Fingolimod Hydrochloride; Follow-Up Studies; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Multiple Sclerosis; Oligoclonal Bands; Plasma Exchange; Propylene Glycols; Sphingosine | 2013 |
FTY720 for cancer therapy (Review).
Topics: Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Neoplasms; Phosphorylation; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine; United States; United States Food and Drug Administration | 2013 |
[New and future treatments for neurological disorders--knowledge essential to daily clinics and future prospects. Topics: 9. Therapeutic progress in multiple sclerosis and neuromyelitis optica].
Topics: Antibodies, Monoclonal; Autoantibodies; Fingolimod Hydrochloride; Humans; Multiple Sclerosis; Neuromyelitis Optica; Propylene Glycols; Secondary Prevention; Sphingosine | 2013 |
Treatment options for patients with multiple sclerosis who have a suboptimal response to interferon-β therapy.
Topics: Antibodies, Monoclonal, Humanized; Databases, Bibliographic; Decision Making; Fingolimod Hydrochloride; Humans; Immunologic Factors; Interferon-beta; Multiple Sclerosis; Natalizumab; Propylene Glycols; Sphingosine | 2014 |
Visual issues in multiple sclerosis.
Topics: Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Macular Edema; Multiple Sclerosis; Neuromyelitis Optica; Nystagmus, Pathologic; Ocular Motility Disorders; Optic Neuritis; Prognosis; Propylene Glycols; Sphingosine; Uveitis | 2013 |
A review of safety-related pregnancy data surrounding the oral disease-modifying drugs for multiple sclerosis.
Topics: Abnormalities, Drug-Induced; Administration, Oral; Animals; Crotonates; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Immunologic Factors; Multiple Sclerosis; Nitriles; Pregnancy; Pregnancy Outcome; Prenatal Exposure Delayed Effects; Propylene Glycols; Sphingosine; Toluidines | 2014 |
Molecular pharmacodynamics of new oral drugs used in the treatment of multiple sclerosis.
Topics: Administration, Oral; Animals; Blood-Brain Barrier; Crotonates; Dimethyl Fumarate; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Immune System; Multiple Sclerosis; NF-E2-Related Factor 2; Nitriles; Propylene Glycols; Quinolones; Sphingosine; Toluidines | 2014 |
Overview and safety of fingolimod hydrochloride use in patients with multiple sclerosis.
Topics: Administration, Oral; Clinical Trials, Phase III as Topic; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Propylene Glycols; Sphingosine | 2014 |
Sphingolipids: important players in multiple sclerosis.
Topics: Ceramides; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Lysophospholipids; Multiple Sclerosis; Propylene Glycols; Sphingolipids; Sphingomyelin Phosphodiesterase; Sphingomyelins; Sphingosine | 2014 |
Is T-bet a potential therapeutic target in multiple sclerosis?
Topics: Animals; Antibodies, Monoclonal, Humanized; Dimethyl Fumarate; Drug Discovery; Encephalomyelitis, Autoimmune, Experimental; Fingolimod Hydrochloride; Fumarates; Humans; Immunotherapy; Molecular Targeted Therapy; Multiple Sclerosis; Natalizumab; Propylene Glycols; Sphingosine; T-Box Domain Proteins; Th17 Cells | 2014 |
Cardiac and vascular effects of fingolimod: mechanistic basis and clinical implications.
Topics: Atrioventricular Node; Cardiovascular System; Down-Regulation; Fingolimod Hydrochloride; Heart Rate; Humans; Immunosuppressive Agents; Multiple Sclerosis; Propylene Glycols; Receptors, Lysosphingolipid; Signal Transduction; Sphingosine | 2014 |
[[Natalizumab therapy, 2013].
Topics: Adult; Antibodies, Monoclonal, Humanized; Disease Progression; Fingolimod Hydrochloride; Humans; Immunocompromised Host; Immunosuppressive Agents; JC Virus; Leukoencephalopathy, Progressive Multifocal; Magnetic Resonance Imaging; Multiple Sclerosis; Natalizumab; Propylene Glycols; Sphingosine | 2014 |
Grey matter atrophy in patients suffering from multiple sclerosis.
Topics: Adjuvants, Immunologic; Antibodies, Monoclonal, Humanized; Atrophy; Fingolimod Hydrochloride; Glatiramer Acetate; Gray Matter; Humans; Immunosuppressive Agents; Interferon beta-1a; Interferon beta-1b; Interferon-beta; Multiple Sclerosis; Muscle, Skeletal; Natalizumab; Peptides; Predictive Value of Tests; Propylene Glycols; Sphingosine; Treatment Outcome | 2014 |
Therapeutic interference with leukocyte recirculation in multiple sclerosis.
Topics: Antibodies, Monoclonal, Humanized; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Natalizumab; Propylene Glycols; Sphingosine | 2015 |
[Oral treatments in multiple sclerosis].
Topics: Administration, Oral; Crotonates; Dimethyl Fumarate; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Nitriles; Propylene Glycols; Quinolones; Sphingosine; Toluidines | 2014 |
Multiple sclerosis: the role of melatonin and N-acetylserotonin.
Topics: Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunologic Factors; Immunosuppressive Agents; Interferon-beta; Lithium Compounds; Melatonin; Multiple Sclerosis; Nootropic Agents; Serotonin; Valproic Acid | 2015 |
Emerging biology of sphingosine-1-phosphate: its role in pathogenesis and therapy.
Topics: Acute Lung Injury; Anemia, Sickle Cell; Animals; Autoimmune Diseases; Cardiovascular Diseases; Cell Physiological Phenomena; Disease Models, Animal; Fingolimod Hydrochloride; Hematopoietic Stem Cell Mobilization; Humans; Influenza, Human; Lysophospholipids; Membrane Lipids; Mice; Multiple Sclerosis; Neoplasms; Neovascularization, Physiologic; Neurogenesis; Propylene Glycols; Receptors, Lysosphingolipid; Sphingolipids; Sphingosine | 2015 |
New FDA-Approved Disease-Modifying Therapies for Multiple Sclerosis.
Topics: Alemtuzumab; Antibodies, Monoclonal, Humanized; Crotonates; Dimethyl Fumarate; Drug Approval; Drug Costs; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Hydroxybutyrates; Immunosuppressive Agents; Interferon-beta; Multiple Sclerosis; Nitriles; Polyethylene Glycols; Toluidines; United States; United States Food and Drug Administration | 2015 |
Newer agents in the treatment of multiple sclerosis.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD20; Clinical Trials as Topic; Crotonates; Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Multiple Sclerosis; Nitriles; Toluidines; Treatment Outcome | 2015 |
Induction and escalation therapies in multiple sclerosis.
Topics: Animals; Crotonates; Dimethyl Fumarate; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Hydroxybutyrates; Induction Chemotherapy; Interferon-beta; Maintenance Chemotherapy; Mitoxantrone; Multiple Sclerosis; Natalizumab; Nitriles; Randomized Controlled Trials as Topic; Toluidines; Treatment Outcome | 2015 |
Therapeutic Impact of Sphingosine 1-phosphate Receptor Signaling in Multiple Sclerosis.
Topics: Animals; Fingolimod Hydrochloride; Humans; Multiple Sclerosis; Receptors, Lysosphingolipid; Signal Transduction | 2016 |
Regulation of human glia by multiple sclerosis disease modifying therapies.
Topics: Antibodies, Monoclonal; Astrocytes; Blood-Brain Barrier; Central Nervous System; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Interferon-beta; Microglia; Multiple Sclerosis; Oligodendroglia | 2015 |
Novel Agents for Relapsing Forms of Multiple Sclerosis.
Topics: Adjuvants, Immunologic; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD20; Crotonates; Daclizumab; Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Immunoglobulin G; Immunologic Factors; Immunosuppressive Agents; Multiple Sclerosis; Natalizumab; Nitriles; Recurrence; Toluidines | 2016 |
Sphingosine-1-Phosphate Receptors in the Central Nervous and Immune Systems.
Topics: Animals; Central Nervous System; Clinical Trials as Topic; Fingolimod Hydrochloride; Humans; Immune System; Multiple Sclerosis; Receptors, Lysosphingolipid; Signal Transduction | 2016 |
[Magnetic resonance imaging of the brain in the monitoring of immune therapy of multiple sclerosis].
Topics: Alemtuzumab; Antibodies, Monoclonal, Humanized; Contrast Media; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Immunotherapy; Magnetic Resonance Imaging; Multiple Sclerosis; Natalizumab | 2015 |
Cardiovascular Dysfunction in Multiple Sclerosis.
Topics: Animals; Autonomic Nervous System; Blood Pressure; Cardiovascular Abnormalities; Fingolimod Hydrochloride; Heart Rate; Humans; Mitoxantrone; Multiple Sclerosis | 2015 |
The use of immune modulating drugs for the treatment of multiple sclerosis.
Topics: Alemtuzumab; Antibodies, Monoclonal, Humanized; Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Immunologic Factors; Immunosuppressive Agents; Molecular Targeted Therapy; Multiple Sclerosis; Natalizumab | 2016 |
Disease-modifying therapies and infectious risks in multiple sclerosis.
Topics: Animals; Antibodies, Monoclonal, Humanized; Communicable Diseases; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Risk Factors | 2016 |
The Use of Oral Disease-Modifying Therapies in Multiple Sclerosis.
Topics: Animals; Clinical Trials as Topic; Crotonates; Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Immunosuppressive Agents; Multiple Sclerosis; Nitriles; Quinolones; Toluidines | 2016 |
Potential anti-tumor effects of FTY720 associated with PP2A activation: a brief review.
Topics: Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Neoplasms; Protein Phosphatase 2 | 2016 |
Management of multiple sclerosis and the integration of related specialty pharmacy programs within health systems.
Topics: Academic Medical Centers; Crotonates; Disease Management; Fingolimod Hydrochloride; Health Systems Plans; Humans; Hydroxybutyrates; Immunosuppressive Agents; Multiple Sclerosis; Nitriles; Pharmacy Service, Hospital; Toluidines | 2016 |
From Natural Product to the First Oral Treatment for Multiple Sclerosis: The Discovery of FTY720 (Gilenya™)?
Topics: Administration, Oral; Animals; Biological Products; Fingolimod Hydrochloride; Humans; Multiple Sclerosis | 2016 |
INNOVATIVE THERAPIES REDEFINE TREATMENT GOALS IN MULTIPLE SCLEROSIS.
Topics: Alemtuzumab; Antibodies, Monoclonal, Humanized; Disease Progression; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Multiple Sclerosis; Natalizumab; Patient Care Planning | 2016 |
Clinical implications for substandard, nonproprietary medicines in multiple sclerosis: focus on fingolimod.
Topics: Drugs, Generic; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Pharmaceutical Preparations; United States; World Health Organization | 2016 |
Disease modifying therapies for relapsing multiple sclerosis.
Topics: Administration, Intravenous; Administration, Oral; Alemtuzumab; Antibodies, Monoclonal, Humanized; Crotonates; Daclizumab; Dimethyl Fumarate; Drug Substitution; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Hydroxybutyrates; Immunoglobulin G; Immunologic Factors; Injections; Interferon-beta; Magnetic Resonance Imaging; Mitoxantrone; Multiple Sclerosis; Natalizumab; Nitriles; Toluidines | 2016 |
Comparative effectiveness using a matching-adjusted indirect comparison between delayed-release dimethyl fumarate and fingolimod for the treatment of multiple sclerosis.
Topics: Administration, Oral; Adult; Dimethyl Fumarate; Disease Progression; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Randomized Controlled Trials as Topic; Recurrence; Treatment Outcome | 2017 |
Update on disease-modifying therapies for multiple sclerosis.
Topics: Administration, Oral; Alemtuzumab; Antibodies, Monoclonal, Humanized; Crotonates; Daclizumab; Dimethyl Fumarate; Drug Approval; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Hydroxybutyrates; Immunoglobulin G; Immunologic Factors; Infusions, Intravenous; JC Virus; Leukoencephalopathy, Progressive Multifocal; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Nitriles; Polyomavirus Infections; Recurrence; Toluidines; Treatment Outcome; Tumor Virus Infections; United States; United States Food and Drug Administration | 2017 |
The Ocular Manifestations of Drugs Used to Treat Multiple Sclerosis.
Topics: Alemtuzumab; Antibodies, Monoclonal, Humanized; Eye Diseases; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Interferons; Mitoxantrone; Multiple Sclerosis; Natalizumab | 2017 |
Multiple sclerosis in the real world: A systematic review of fingolimod as a case study.
Topics: Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis | 2017 |
Effect of Fingolimod on Brain Volume Loss in Patients with Multiple Sclerosis.
Topics: Brain; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Interferon beta-1a; Magnetic Resonance Imaging; Multiple Sclerosis; Randomized Controlled Trials as Topic; Treatment Outcome | 2017 |
"Inside-out" signaling of sphingosine-1-phosphate: therapeutic targets.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; Enzyme Activation; Fingolimod Hydrochloride; Humans; Hypersensitivity; Immunosuppressive Agents; Lysophospholipids; Multiple Sclerosis; Neoplasms; Phosphotransferases (Alcohol Group Acceptor); Propylene Glycols; Receptors, Lysosphingolipid; Signal Transduction; Sphingosine; Sulfhydryl Compounds | 2008 |
Azathioprine in multiple sclerosis.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Azathioprine; Chemistry, Pharmaceutical; Cyclophosphamide; Drug Design; Fingolimod Hydrochloride; Humans; Immunologic Factors; Immunosuppressive Agents; Methotrexate; Methyltransferases; Mitoxantrone; Models, Chemical; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Propylene Glycols; Sphingosine | 2008 |
Emerging oral drugs for multiple sclerosis.
Topics: Administration, Oral; Cladribine; Crotonates; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Immunosuppressive Agents; Multiple Sclerosis; Nitriles; Propylene Glycols; Quinolones; Sphingosine; Toluidines | 2008 |
[New therapeutic approach for autoimmune diseases by the sphingosine 1-phosphate receptor modulator, fingolimod (FTY720)].
Topics: Animals; Autoimmune Diseases; Clinical Trials as Topic; Encephalomyelitis; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine | 2009 |
[Molecular target drug development for curing multiple sclerosis].
Topics: Abatacept; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Autoimmunity; Clinical Trials as Topic; Daclizumab; Drug Discovery; Fingolimod Hydrochloride; Humans; Immunoconjugates; Immunoglobulin G; Integrin alpha4beta1; JC Virus; Leukoencephalopathy, Progressive Multifocal; Ligands; Lysophospholipids; Multiple Sclerosis; Natalizumab; Opportunistic Infections; Propylene Glycols; Receptors, Antigen, T-Cell; Sphingosine; Ustekinumab | 2009 |
[Fingolimod - a new immunomodulator].
Topics: Biological Availability; Fingolimod Hydrochloride; Graft Rejection; Humans; Immunosuppressive Agents; Kidney Transplantation; Multiple Sclerosis; Propylene Glycols; Sphingosine | 2009 |
FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system.
Topics: Animals; Astrocytes; Brain; Encephalomyelitis, Autoimmune, Experimental; Fingolimod Hydrochloride; Gap Junctions; Humans; Immune System; Inflammation; Lymph Nodes; Lysophospholipids; Multiple Sclerosis; Phosphorylation; Phosphotransferases (Alcohol Group Acceptor); Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine; T-Lymphocytes | 2009 |
New oral drugs for multiple sclerosis.
Topics: Cladribine; Clinical Trials, Phase III as Topic; Crotonates; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Immunosuppressive Agents; Multiple Sclerosis; Nitriles; Propylene Glycols; Quinolones; Sphingosine; Toluidines | 2009 |
[Development of oral therapies for multiple sclerosis--fingolimod, cladribine and other drugs].
Topics: Cladribine; Clinical Trials as Topic; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Propylene Glycols; Sphingosine | 2010 |
Fingolimod is a potential novel therapy for multiple sclerosis.
Topics: Animals; Cell Movement; Clinical Trials as Topic; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Lymphocytes; Mice; Multiple Sclerosis; Nerve Regeneration; Propylene Glycols; Rats; Receptors, Lysosphingolipid; Sphingosine | 2010 |
Multiple sclerosis therapies: molecular mechanisms and future.
Topics: Alemtuzumab; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Cladribine; Crotonates; Daclizumab; Dimethyl Fumarate; Encephalomyelitis, Autoimmune, Experimental; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Immunoglobulin G; Immunosuppressive Agents; Immunotherapy; Mice; Multiple Sclerosis; Myelin Basic Protein; Nitriles; Peptide Fragments; Propylene Glycols; Quinolones; Rituximab; Sphingosine; Toluidines; Vaccines, DNA | 2010 |
[Oral fingolimod in multiple sclerosis: therapeutic modulation of the sphingosine-1-phosphate system].
Topics: Administration, Oral; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Prevalence; Propylene Glycols; Receptors, Lysosphingolipid; Risk Assessment; Risk Factors; Sphingosine; Treatment Outcome | 2011 |
Emerging oral agents for multiple sclerosis.
Topics: 4-Aminopyridine; Cladribine; Clinical Trials as Topic; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Propylene Glycols; Quinolones; Sphingosine | 2010 |
Emerging disease-modifying oral therapies for multiple sclerosis.
Topics: Administration, Oral; Animals; Clinical Trials as Topic; Drug Discovery; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Propylene Glycols; Sphingosine | 2011 |
Roles for lysophospholipid S1P receptors in multiple sclerosis.
Topics: Animals; Central Nervous System; Encephalomyelitis, Autoimmune, Experimental; Fingolimod Hydrochloride; Humans; Inflammation; Lymphocytes; Lysophospholipids; Multiple Sclerosis; Phosphorylation; Propylene Glycols; Receptors, Lysophospholipid; Signal Transduction; Sphingosine | 2011 |
Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis.
Topics: Administration, Oral; Animals; Drug Discovery; Fingolimod Hydrochloride; Humans; Inflammation Mediators; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Research; Sphingosine | 2010 |
Oral therapies for multiple sclerosis: a review of agents in phase III development or recently approved.
Topics: Administration, Oral; Cladribine; Clinical Trials, Phase III as Topic; Crotonates; Dimethyl Fumarate; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Multiple Sclerosis; Nitriles; Propylene Glycols; Quinolones; Sphingosine; Toluidines | 2011 |
Magnetic resonance imaging as surrogate for clinical endpoints in multiple sclerosis: data on novel oral drugs.
Topics: Administration, Oral; Brain; Cladribine; Disability Evaluation; Disease Progression; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Multiple Sclerosis; Predictive Value of Tests; Propylene Glycols; Recurrence; Regression Analysis; Reproducibility of Results; Sphingosine; Time Factors; Treatment Outcome | 2011 |
Therapeutic approach to multiple sclerosis by novel oral drug.
Topics: Administration, Oral; Cladribine; Crotonates; Diterpenes; Epoxy Compounds; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Multiple Sclerosis; Nitriles; Patents as Topic; Phenanthrenes; Propylene Glycols; Quinolones; Sphingosine; Toluidines | 2011 |
Synthetic sphingosine 1-phosphate receptor modulators--opportunities and potential pitfalls.
Topics: Animals; Fingolimod Hydrochloride; Humans; Lysophospholipids; Multiple Sclerosis; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine; Structure-Activity Relationship | 2011 |
Multiple sclerosis in 2010: Advances in monitoring and treatment of multiple sclerosis.
Topics: Biomarkers; Cladribine; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Multiple Sclerosis; Propylene Glycols; Randomized Controlled Trials as Topic; Sphingosine | 2011 |
Impact of sphingosine 1-phosphate modulation on immune outcomes.
Topics: Animals; Fingolimod Hydrochloride; Gene Expression Regulation; Humans; Immune System; Immunosuppressive Agents; Lymphocytes; Lysophospholipids; Multiple Sclerosis; Propylene Glycols; Receptors, Lysosphingolipid; Signal Transduction; Sphingosine; Virus Diseases | 2011 |
Future clinical challenges in multiple sclerosis: Relevance to sphingosine 1-phosphate receptor modulator therapy.
Topics: Animals; Clinical Trials as Topic; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine | 2011 |
Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis.
Topics: Fingolimod Hydrochloride; Humans; Immune System; Immunosuppressive Agents; Lymphocytes; Lysophospholipids; Multiple Sclerosis; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine | 2011 |
Oral fingolimod (gilenya) for multiple sclerosis.
Topics: Administration, Oral; Animals; Fingolimod Hydrochloride; Headache; Humans; Immunosuppressive Agents; Multiple Sclerosis; Propylene Glycols; Randomized Controlled Trials as Topic; Sphingosine | 2010 |
Managing MS in a changing treatment landscape.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cladribine; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Interferon-beta; Mitoxantrone; Multiple Sclerosis; Natalizumab; Propylene Glycols; Sphingosine | 2011 |
Fingolimod (FTY720): a recently approved multiple sclerosis drug based on a fungal secondary metabolite.
Topics: Fatty Acids, Monounsaturated; Fingolimod Hydrochloride; Hypocreales; Immunosuppressive Agents; Multiple Sclerosis; Propylene Glycols; Sphingosine; Structure-Activity Relationship; United States; United States Food and Drug Administration | 2011 |
Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis.
Topics: Animals; Central Nervous System; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Disease Models, Animal; Fingolimod Hydrochloride; Heart Diseases; Humans; Immunosuppressive Agents; Infections; Liver Diseases; Lymphocytes; Lysophospholipids; Multiple Sclerosis; Propylene Glycols; Receptors, Lysosphingolipid; Respiration Disorders; Sphingosine | 2011 |
[Current treatment of multiple sclerosis].
Topics: Administration, Oral; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cladribine; Dimethyl Fumarate; Drug Administration Schedule; Fingolimod Hydrochloride; Fumarates; Glatiramer Acetate; Humans; Immunosuppressive Agents; Interferon-beta; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Peptides; Propylene Glycols; Quinolones; Sphingosine; Treatment Outcome | 2011 |
Fingolimod for multiple sclerosis: mechanism of action, clinical outcomes, and future directions.
Topics: Central Nervous System; Clinical Trials as Topic; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Propylene Glycols; Sphingosine; Treatment Outcome | 2011 |
Sphingosine 1-phosphate in coagulation and inflammation.
Topics: Animals; Atherosclerosis; Blood Coagulation; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Inflammation; Lymph Nodes; Lymphocytes; Lysophospholipids; Multiple Sclerosis; Neoplasm Metastasis; Neoplasms; Neovascularization, Pathologic; Propylene Glycols; Receptors, Lysosphingolipid; Signal Transduction; Sphingosine; Tumor Necrosis Factor-alpha | 2012 |
Novel therapeutic approaches to autoimmune demyelinating disorders.
Topics: Administration, Oral; Animals; Antibodies, Monoclonal; Drug Design; Fingolimod Hydrochloride; Humans; Immunologic Factors; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine | 2011 |
A mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya).
Topics: Administration, Oral; Animals; Drug Discovery; Fingolimod Hydrochloride; Humans; Immunologic Factors; Multiple Sclerosis; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine | 2011 |
[Multiple sclerosis: current therapies and future perspectives].
Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunosuppressive Agents; Interferon-beta; Molecular Targeted Therapy; Multiple Sclerosis; Natalizumab; Peptides; Propylene Glycols; Sphingosine | 2011 |
Clinical pharmacokinetics of fingolimod.
Topics: Animals; Blood Proteins; Drug Interactions; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Kidney Diseases; Liver Diseases; Multiple Sclerosis; Propylene Glycols; Protein Binding; Sphingosine | 2012 |
Fingolimod for multiple sclerosis.
Topics: Adult; Algorithms; Central Nervous System; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Multiple Sclerosis; Propylene Glycols; Sphingosine | 2012 |
FTY720 on the way from the base camp to the summit of the mountain: relevance for remyelination.
Topics: Animals; Astrocytes; Axons; Central Nervous System; Disease Models, Animal; Fingolimod Hydrochloride; Humans; Lysophospholipids; Mice; Microglia; Multiple Sclerosis; Myelin Sheath; Neurons; Oligodendroglia; Propylene Glycols; Rats; Receptors, Lysosphingolipid; Sphingosine | 2012 |
Network analysis of randomized controlled trials in multiple sclerosis.
Topics: Disease Progression; Fingolimod Hydrochloride; Humans; Interferon beta-1a; Interferon-beta; Magnetic Resonance Imaging; Multiple Sclerosis; Placebos; Propylene Glycols; Randomized Controlled Trials as Topic; Sphingosine | 2012 |
Signaling and regulatory functions of bioactive sphingolipids as therapeutic targets in multiple sclerosis.
Topics: Apoptosis; Ceramides; Fatty Acids, Monounsaturated; Fingolimod Hydrochloride; Humans; Lysophospholipids; Metabolic Networks and Pathways; Multiple Sclerosis; Myelin Sheath; Propylene Glycols; Receptors, G-Protein-Coupled; Serine C-Palmitoyltransferase; Signal Transduction; Sphingolipids; Sphingosine | 2012 |
Annualized relapse rate of first-line treatments for multiple sclerosis: a meta-analysis, including indirect comparisons versus fingolimod.
Topics: Adult; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Interferon beta-1a; Interferon beta-1b; Interferon-beta; Male; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Peptides; Poisson Distribution; Propylene Glycols; Recurrence; Sphingosine; Time Factors | 2012 |
[Research progress of the selective sphingosine-1-phosphate receptor 1 agonists].
Topics: Animals; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Lysophospholipids; Multiple Sclerosis; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine; Structure-Activity Relationship | 2012 |
Discovery of fingolimod, the sphingosine 1-phosphate receptor modulator and its application for the therapy of multiple sclerosis.
Topics: Animals; Drug Discovery; Encephalomyelitis, Autoimmune, Experimental; Fatty Acids, Monounsaturated; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Kidney Transplantation; Lymphocytes; Multiple Sclerosis; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine | 2012 |
[New disease-modifying and symptomatic therapies for multiple sclerosis].
Topics: 4-Aminopyridine; Cannabinoids; Cooperative Behavior; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Interdisciplinary Communication; Multiple Sclerosis; Propylene Glycols; Sphingosine | 2012 |
First-line disease-modifying therapies in paediatric multiple sclerosis: a comprehensive overview.
Topics: Adolescent; Child; Child, Preschool; Dose-Response Relationship, Drug; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunologic Factors; Immunosuppressive Agents; Infant; Injections, Intramuscular; Injections, Subcutaneous; Interferon beta-1a; Interferon beta-1b; Interferon-beta; Multiple Sclerosis; Peptides; Propylene Glycols; Randomized Controlled Trials as Topic; Sphingosine; Time Factors | 2012 |
[Multiple sclerosis: beyong first line therapies].
Topics: Adjuvants, Immunologic; Antibodies, Monoclonal, Humanized; Choice Behavior; Combined Modality Therapy; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Immunotherapy; Multiple Sclerosis; Natalizumab; Patient Education as Topic; Propylene Glycols; Sphingosine; Therapies, Investigational | 2012 |
[Sphingosine-1-phosphate signaling system and the innovative mechanism of action of fingolimod in treatment of multiple sclerosis: review of foreign literature].
Topics: Animals; Disease Models, Animal; Fingolimod Hydrochloride; Humans; Immune System; Immunosuppressive Agents; Lysophospholipids; Multiple Sclerosis; Propylene Glycols; Receptors, Lysosphingolipid; Signal Transduction; Sphingosine | 2012 |
[Pharmacological properties and clinical efficacy of fingolimod hydrochloride (Imusera®/Gilenya®) for the treatment of multiple sclerosis].
Topics: Administration, Oral; Animals; Clinical Trials, Phase I as Topic; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Fingolimod Hydrochloride; Humans; Lymphocytes; Lysophospholipids; Multiple Sclerosis; Propylene Glycols; Receptors, Lysosphingolipid; Secondary Prevention; Sphingosine; Th17 Cells | 2012 |
[Emerging therapies for multiple sclerosis].
Topics: 4-Aminopyridine; Administration, Oral; Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Cladribine; Clinical Trials as Topic; Crotonates; Daclizumab; Dimethyl Fumarate; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Immunoglobulin G; Immunosuppressive Agents; Middle Aged; Multicenter Studies as Topic; Multiple Sclerosis; Nitriles; Propylene Glycols; Quinolones; Rituximab; Sphingosine; Toluidines; Young Adult | 2013 |
ACS chemical neuroscience molecule spotlight on gilenya (fingolimod; FTY720).
Topics: Animals; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Neurosciences; Propylene Glycols; Randomized Controlled Trials as Topic; Societies, Scientific; Sphingosine | 2011 |
4-aminopyridine toxicity: a case report and review of the literature.
Topics: 4-Aminopyridine; Adult; Benzodiazepines; Drug Overdose; Fingolimod Hydrochloride; Humans; Male; Multiple Sclerosis; Paroxetine; Propylene Glycols; Sphingosine | 2012 |
Molecular targets of FTY720 (fingolimod).
Topics: Antineoplastic Agents; Apoptosis; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Lymphopenia; Lysophospholipids; Multiple Sclerosis; Neoplasms; Phosphorylation; Phosphotransferases (Alcohol Group Acceptor); Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine | 2012 |
Development of oral agent in the treatment of multiple sclerosis: how the first available oral therapy, fingolimod will change therapeutic paradigm approach.
Topics: Administration, Oral; Animals; Drug Design; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Interferon beta-1a; Interferon-beta; Multiple Sclerosis; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine | 2012 |
[Fingolimod therapy in multiple sclerosis--the issue of the pathomechanism].
Topics: Administration, Oral; Animals; Blood-Brain Barrier; Cardiovascular System; Central Nervous System; Dendritic Cells; Encephalomyelitis, Autoimmune, Experimental; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Lymphocyte Count; Lysophospholipids; Multiple Sclerosis; Organophosphates; Propylene Glycols; Sphingosine; Th17 Cells; Treatment Outcome | 2012 |
[An update on the treatment options for multiple sclerosis].
Topics: Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Interferons; Japan; Multiple Sclerosis; Propylene Glycols; Sphingosine; Treatment Outcome | 2012 |
Multiple sclerosis: new measures to monitor the disease.
Topics: Brain; Fingolimod Hydrochloride; Humans; Magnetic Resonance Imaging; Multiple Sclerosis; Neuromyelitis Optica; Propylene Glycols; Sphingosine | 2013 |
[Clinical significance of the cardiovascular effects of fingolimod treatment in multiple sclerosis].
Topics: Atrioventricular Block; Bradycardia; Cardiovascular System; Clinical Trials as Topic; Drug Administration Schedule; Fingolimod Hydrochloride; Heart Conduction System; Humans; Hypertension; Immunosuppressive Agents; Interferon beta-1a; Interferon-beta; Multiple Sclerosis; Propylene Glycols; Receptors, Lysosphingolipid; Secondary Prevention; Sphingosine; Treatment Outcome | 2012 |
Synthesis of novel therapeutic agents for the treatment of multiple sclerosis: a brief overview.
Topics: Cladribine; Crotonates; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Molecular Structure; Multiple Sclerosis; Nitriles; Propylene Glycols; Quinolones; Small Molecule Libraries; Sphingosine; Toluidines | 2013 |
FTY720 (fingolimod) in renal transplantation.
Topics: Clinical Trials as Topic; Fingolimod Hydrochloride; Graft Survival; Humans; Immunosuppressive Agents; Kidney Transplantation; Multiple Sclerosis; Propylene Glycols; Sphingosine | 2006 |
FTY720, an immunomodulatory sphingolipid mimetic: translation of a novel mechanism into clinical benefit in multiple sclerosis.
Topics: Animals; Central Nervous System; Clinical Trials as Topic; Encephalomyelitis, Autoimmune, Experimental; Endothelium, Lymphatic; Fingolimod Hydrochloride; Humans; Immunologic Factors; Lymphocytes; Lysophospholipids; Multiple Sclerosis; Propylene Glycols; Receptors, Lysosphingolipid; Sphingolipids; Sphingosine | 2007 |
Current perspectives on FTY720.
Topics: Animals; Fingolimod Hydrochloride; Graft Rejection; Humans; Immunosuppressive Agents; Multiple Sclerosis; Propylene Glycols; Sphingosine | 2007 |
Novel oral agents for multiple sclerosis.
Topics: Administration, Oral; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Cladribine; Clinical Trials as Topic; Dimethyl Fumarate; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Interferon beta-1b; Interferon-beta; Isoxazoles; Leflunomide; Minocycline; Multiple Sclerosis; Mycophenolic Acid; Propylene Glycols; Pyridones; Quinolones; Sphingosine | 2007 |
Compared benefit of approved and experimental immunosuppressive therapeutic approaches in multiple sclerosis.
Topics: Antibodies, Monoclonal; Cladribine; Cyclophosphamide; Drug Delivery Systems; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Isoxazoles; Ligands; Mitoxantrone; Multiple Sclerosis; Propylene Glycols; Sphingosine | 2007 |
Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology.
Topics: Animals; Disease; Fingolimod Hydrochloride; Gene Deletion; Graft Rejection; Health; Humans; Immunosuppressive Agents; Multiple Sclerosis; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine | 2007 |
[FTY720 (Fingolimod) as a new therapeutic option for multiple sclerosis].
Topics: Administration, Oral; Animals; Clinical Trials, Phase III as Topic; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Propylene Glycols; Sphingosine | 2007 |
Fingolimod: a novel immunosuppressant for multiple sclerosis.
Topics: Animals; Drugs, Investigational; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Propylene Glycols; Sphingosine | 2007 |
Brain sphingosine-1-phosphate receptors: implication for FTY720 in the treatment of multiple sclerosis.
Topics: Animals; Brain; Drug Delivery Systems; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine | 2008 |
Ascomycete derivative to MS therapeutic: S1P receptor modulator FTY720.
Topics: Administration, Oral; Animals; Ascomycota; Biological Products; Disease Models, Animal; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Molecular Structure; Multiple Sclerosis; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine; Treatment Outcome | 2008 |
[Therapeutic effect of S1P receptor modifying drugs for autoimmune diseases].
Topics: Animals; Autoimmune Diseases; Clinical Trials, Phase II as Topic; Disease Models, Animal; Drug Design; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine | 2008 |
Central nervous system effects of current and emerging multiple sclerosis-directed immuno-therapies.
Topics: Animals; Antineoplastic Agents; Central Nervous System; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Interferon Type I; Multiple Sclerosis; Peptides; Propylene Glycols; Recombinant Proteins; Sphingosine | 2008 |
28 trial(s) available for fingolimod hydrochloride and Multiple Sclerosis
| Article | Year |
|---|---|
Immune response to the third COVID-19 vaccine dose is related to lymphocyte count in multiple sclerosis patients treated with fingolimod.
Topics: Antibodies, Viral; BNT162 Vaccine; COVID-19; COVID-19 Vaccines; Fingolimod Hydrochloride; Humans; Immunity; Immunoglobulin G; Lymphocyte Count; Multiple Sclerosis; Prospective Studies; SARS-CoV-2 | 2022 |
Baseline retinal nerve fiber layer thickness as a predictor of multiple sclerosis progression: New insights from the FREEDOMS II study.
Topics: Disease Progression; Fingolimod Hydrochloride; Humans; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Nerve Fibers; Retina; Tomography, Optical Coherence | 2023 |
Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: causal inference to emulate a multiarm randomised trial.
Topics: Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunosuppressive Agents; Interferon-beta; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Pregnancy; Recurrence | 2023 |
Consistent control of disease activity with fingolimod versus IFN β-1a in paediatric-onset multiple sclerosis: further insights from PARADIG
Topics: Adolescent; Age Factors; Age of Onset; Child; Disability Evaluation; Disease Progression; Double-Blind Method; Endpoint Determination; Female; Fingolimod Hydrochloride; Humans; Interferon beta-1a; Kaplan-Meier Estimate; Male; Multiple Sclerosis; Risk Reduction Behavior; Sphingosine 1 Phosphate Receptor Modulators; Treatment Outcome | 2020 |
Pre-treatment T-cell subsets associate with fingolimod treatment responsiveness in multiple sclerosis.
Topics: Adolescent; Adult; Aged; Cohort Studies; Female; Fingolimod Hydrochloride; Flow Cytometry; Humans; Immunologic Memory; Immunophenotyping; Immunosuppressive Agents; Lymphocyte Count; Male; Membrane Glycoproteins; Middle Aged; Multiple Sclerosis; Prospective Studies; T-Lymphocyte Subsets; Young Adult | 2020 |
Effect of fingolimod on MRI outcomes in patients with paediatric-onset multiple sclerosis: results from the phase 3 PARADIG
Topics: Adolescent; Brain; Child; Disease Progression; Female; Fingolimod Hydrochloride; Humans; Interferon beta-1a; Magnetic Resonance Imaging; Male; Multiple Sclerosis; Neuroimaging; Sphingosine 1 Phosphate Receptor Modulators | 2020 |
The introduction of new medications in pediatric multiple sclerosis: Open issues and challenges.
Topics: Adult; Child; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis | 2021 |
Benefit-harm balance of fingolimod in patients with MS: A modelling study based on FREEDOMS.
Topics: Fingolimod Hydrochloride; Freedom; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting | 2020 |
Natalizumab versus fingolimod for patients with active relapsing-remitting multiple sclerosis: results from REVEAL, a prospective, randomised head-to-head study.
Topics: Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Prospective Studies; Treatment Outcome | 2020 |
Disability improvement as a clinically relevant outcome in clinical trials of relapsing forms of multiple sclerosis.
Topics: Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Interferon-beta; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting | 2021 |
Antioxidative effects of silymarin on the reduction of liver complications of fingolimod in patients with relapsing-remitting multiple sclerosis: A clinical trial study.
Topics: Adult; Antioxidants; Chemical and Drug Induced Liver Injury; Double-Blind Method; Female; Fingolimod Hydrochloride; Humans; Liver; Male; Middle Aged; Multiple Sclerosis; Recurrence; Silymarin | 2021 |
Electronic pill bottles to monitor and promote medication adherence for people with multiple sclerosis: A randomized, virtual clinical trial.
Topics: Adult; Dimethyl Fumarate; Electronics; Female; Fingolimod Hydrochloride; Humans; Medication Adherence; Middle Aged; Multiple Sclerosis | 2021 |
Determination of Seminal Concentration of Fingolimod and Fingolimod-Phosphate in Multiple Sclerosis Patients Receiving Chronic Treatment With Fingolimod.
Topics: Adult; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis; Phosphates; Semen | 2018 |
Treatment retention on fingolimod compared with injectable multiple sclerosis therapies in African-American patients: A subgroup analysis of a randomized phase 4 study.
Topics: Adolescent; Adult; Aged; Aggression; Black or African American; Disability Evaluation; Disease Progression; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunosuppressive Agents; Interferon-beta; Male; Middle Aged; Multiple Sclerosis; Patient Satisfaction; Young Adult | 2018 |
Uveitis in Patients with Multiple Sclerosis in Clinical Trials of Fingolimod: Incidence, Prevalence, and Impact on Disease Course.
Topics: Adult; Disease Progression; Double-Blind Method; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Incidence; Male; Middle Aged; Multiple Sclerosis; Prevalence; Recurrence; Treatment Outcome; Uveitis | 2019 |
Ophthalmic evaluations in clinical studies of fingolimod (FTY720) in multiple sclerosis.
Topics: Adolescent; Adult; Double-Blind Method; Female; Fingolimod Hydrochloride; Fluorescein Angiography; Humans; Immunosuppressive Agents; Macular Edema; Male; Middle Aged; Multiple Sclerosis; Ophthalmoscopy; Propylene Glycols; Sphingosine; Tomography, Optical Coherence; Treatment Outcome; Uveitis; Visual Acuity; Young Adult | 2013 |
Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy.
Topics: Adolescent; Adult; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Infections; Lymphocyte Count; Lymphocytes; Male; Middle Aged; Multiple Sclerosis; Propylene Glycols; Sphingosine; Young Adult | 2014 |
Switching from natalizumab to fingolimod in multiple sclerosis: a French prospective study.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Cohort Studies; Drug Substitution; Female; Fingolimod Hydrochloride; France; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis; Natalizumab; Propylene Glycols; Prospective Studies; Risk Factors; Sphingosine; Tertiary Care Centers; Young Adult | 2014 |
Fingolimod therapy in early multiple sclerosis: an efficacy analysis of the TRANSFORMS and FREEDOMS studies by time since first symptom.
Topics: Adult; Disease Progression; Female; Fingolimod Hydrochloride; Gadolinium; Humans; Immunologic Factors; Immunosuppressive Agents; Interferon beta-1a; Interferon-beta; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Multiple Sclerosis; Propylene Glycols; Secondary Prevention; Sphingosine; Time Factors; Treatment Outcome | 2014 |
Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial.
Topics: Adolescent; Adult; Atrioventricular Block; Drug Therapy, Combination; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis; Propylene Glycols; Sphingosine; Young Adult | 2014 |
Initial lymphocyte count and low BMI may affect fingolimod-induced lymphopenia.
Topics: Adult; Aged; Body Mass Index; Cohort Studies; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Lymphocyte Count; Lymphopenia; Middle Aged; Multiple Sclerosis; Propylene Glycols; Sphingosine | 2014 |
Correlation between brain volume loss and clinical and MRI outcomes in multiple sclerosis.
Topics: Brain; Double-Blind Method; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Longitudinal Studies; Magnetic Resonance Imaging; Male; Multiple Sclerosis; Organ Size; Propylene Glycols; Sphingosine; Treatment Outcome | 2015 |
Randomized trial of vaccination in fingolimod-treated patients with multiple sclerosis.
Topics: Adolescent; Adult; Double-Blind Method; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Influenza Vaccines; Male; Middle Aged; Multiple Sclerosis; Propylene Glycols; Sphingosine; Treatment Outcome; Vaccination; Young Adult | 2015 |
Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study.
Topics: Administration, Oral; Adolescent; Adult; Disability Evaluation; Double-Blind Method; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Incidence; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis; Propylene Glycols; Respiratory Function Tests; Severity of Illness Index; Sphingosine; Time Factors; Young Adult | 2009 |
Reconstitution of circulating lymphocyte counts in FTY720-treated MS patients.
Topics: Adult; CD8-Positive T-Lymphocytes; Chemical and Drug Induced Liver Injury; Female; Fingolimod Hydrochloride; Follow-Up Studies; Humans; Immunosuppressive Agents; Lymph Nodes; Lymphocyte Count; Lymphocytes; Lymphopenia; Mediastinum; Middle Aged; Multiple Sclerosis; Patient Dropouts; Propylene Glycols; Receptors, CCR7; Sphingosine; Withholding Treatment | 2010 |
Distinct properties of circulating CD8+ T cells in FTY720-treated patients with multiple sclerosis.
Topics: CD8-Positive T-Lymphocytes; Cell Count; Cell Movement; Chemokine CCL2; Chemokine CXCL12; Cytokines; Fingolimod Hydrochloride; Flow Cytometry; Humans; Immunosuppressive Agents; Interferon-gamma; Multiple Sclerosis; Propylene Glycols; Receptors, CCR2; Sphingosine; Tumor Necrosis Factor-alpha | 2010 |
Antigen-specific adaptive immune responses in fingolimod-treated multiple sclerosis patients.
Topics: Adaptive Immunity; Adult; Enzyme-Linked Immunospot Assay; Female; Fingolimod Hydrochloride; Flow Cytometry; Humans; Immunosuppressive Agents; Influenza Vaccines; Male; Middle Aged; Multiple Sclerosis; Propylene Glycols; Prospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Sphingosine; T-Lymphocytes | 2011 |
Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis.
Topics: Administration, Oral; Adolescent; Adult; Brain; Disability Evaluation; Dose-Response Relationship, Drug; Double-Blind Method; Encephalitis; Female; Fingolimod Hydrochloride; Gadolinium; Humans; Immunosuppressive Agents; International Cooperation; Longitudinal Studies; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis; Outcome Assessment, Health Care; Propylene Glycols; Sphingosine; Time Factors; Young Adult | 2012 |
577 other study(ies) available for fingolimod hydrochloride and Multiple Sclerosis
| Article | Year |
|---|---|
Disease Reactivation after Fingolimod Discontinuation in Pregnant Multiple Sclerosis Patients.
Topics: Adult; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Pregnancy; Recurrence; Retrospective Studies | 2021 |
Skin care advice to patients with multiple sclerosis on Fingolimod treatment at increased risk of skin malignancy-room for improvement?
Topics: Adult; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Skin Care; Skin Neoplasms | 2022 |
ST-2191, an Anellated Bismorpholino Derivative of Oxy-Fingolimod, Shows Selective S1P
Topics: Animals; CHO Cells; Cricetulus; Fingolimod Hydrochloride; Humans; Lymphocyte Count; Lysophospholipids; Mice; Mice, Inbred C57BL; Multiple Sclerosis; Phosphotransferases (Alcohol Group Acceptor); Receptors, Lysosphingolipid; Signal Transduction; Sphingosine; T-Lymphocytes | 2021 |
Comparative effectiveness of dimethyl fumarate in multiple sclerosis.
Topics: Cohort Studies; Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Immunologic Factors; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Treatment Outcome | 2022 |
Proinflammatory CD20
Topics: Antigens, CD20; Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Multiple Sclerosis; Natalizumab; T-Lymphocyte Subsets | 2021 |
Differential Effects of Fingolimod and Natalizumab on Magnetic Resonance Imaging Measures in Relapsing-Remitting Multiple Sclerosis.
Topics: Fingolimod Hydrochloride; Humans; Immunologic Factors; Immunosuppressive Agents; Magnetic Resonance Imaging; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Retrospective Studies | 2021 |
Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies.
Topics: 2019-nCoV Vaccine mRNA-1273; Adult; Antibodies, Monoclonal, Humanized; Antibody Formation; BNT162 Vaccine; Cladribine; COVID-19; COVID-19 Vaccines; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Italy; Male; Middle Aged; Multiple Sclerosis; Prospective Studies; Rituximab; Treatment Outcome | 2021 |
Fingolimod as a first- or second-line treatment in a mini-series of young Hellenic patients with adolescent-onset multiple sclerosis: focus on immunological data.
Topics: Adolescent; Adult; Child; Fingolimod Hydrochloride; HLA-DRB1 Chains; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab | 2022 |
Prediction of multiple sclerosis outcomes when switching to ocrelizumab.
Topics: Antibodies, Monoclonal, Humanized; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Recurrence | 2022 |
Current international trends in the treatment of multiple sclerosis in children-Impact of the COVID-19 pandemic.
Topics: Adult; Child; COVID-19; Fingolimod Hydrochloride; Humans; Multiple Sclerosis; Pandemics; SARS-CoV-2 | 2021 |
Four-year safety and effectiveness data from patients with multiple sclerosis treated with fingolimod: The Spanish GILENYA registry.
Topics: Adult; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Lymphopenia; Male; Middle Aged; Multiple Sclerosis; Recurrence; Registries; Retrospective Studies; Spain; Treatment Outcome | 2021 |
Humoral immunity to SARS-CoV-2 mRNA vaccination in multiple sclerosis: the relevance of time since last rituximab infusion and first experience from sporadic revaccinations.
Topics: Antibodies, Viral; COVID-19; COVID-19 Vaccines; Fingolimod Hydrochloride; Humans; Immunity, Humoral; Immunization, Secondary; Immunoglobulin G; Multiple Sclerosis; Pandemics; Rituximab; RNA, Messenger; SARS-CoV-2; Vaccination | 2023 |
Comparison of Dimethyl Fumarate vs Fingolimod and Rituximab vs Natalizumab for Treatment of Multiple Sclerosis.
Topics: Adult; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Rituximab | 2021 |
Progressive Functional and Neuroretinal Affectation in Patients With Multiple Sclerosis Treated With Fingolimod.
Topics: Fingolimod Hydrochloride; Humans; Multiple Sclerosis; Retina; Tomography, Optical Coherence; Visual Acuity | 2021 |
COVID-19 Infection in Fingolimod- or Siponimod-Treated Patients: Case Series.
Topics: Adolescent; Adult; Aged; Azetidines; Benzyl Compounds; Child; Clinical Trials as Topic; Comorbidity; COVID-19; Female; Fingolimod Hydrochloride; Follow-Up Studies; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis; Product Surveillance, Postmarketing; Retrospective Studies; Severity of Illness Index; Young Adult | 2021 |
Immunogenicity and safety of mRNA COVID-19 vaccines in people with multiple sclerosis treated with different disease-modifying therapies.
Topics: Antibodies, Monoclonal, Humanized; Antibodies, Viral; COVID-19; COVID-19 Vaccines; Fingolimod Hydrochloride; Humans; Immunity, Humoral; Immunogenicity, Vaccine; Immunoglobulin G; Multiple Sclerosis; SARS-CoV-2 | 2022 |
Multiple Sclerosis-associated Bacterial Ligand 654.
Topics: Cytokines; Fingolimod Hydrochloride; Humans; Interferon-beta; Ligands; Lipids; Microglia; Multiple Sclerosis | 2022 |
Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom.
Topics: Cost-Benefit Analysis; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab | 2022 |
Post-vaccine COVID-19 in patients with multiple sclerosis or neuromyelitis optica.
Topics: BNT162 Vaccine; COVID-19; Fingolimod Hydrochloride; Humans; Multiple Sclerosis; Neuromyelitis Optica; SARS-CoV-2 | 2022 |
Structural basis of sphingosine-1-phosphate receptor 1 activation and biased agonism.
Topics: beta-Arrestins; Cryoelectron Microscopy; Fingolimod Hydrochloride; Humans; Multiple Sclerosis; Sphingosine-1-Phosphate Receptors | 2022 |
Disease-modifying drugs for multiple sclerosis and subsequent health service use.
Topics: Aged; Canada; Female; Fingolimod Hydrochloride; Hospitalization; Humans; Male; Multiple Sclerosis; Patient Acceptance of Health Care | 2022 |
Ocrelizumab versus fingolimod after natalizumab cessation in multiple sclerosis: an observational study.
Topics: Antibodies, Monoclonal, Humanized; Fingolimod Hydrochloride; Humans; Immunologic Factors; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Recurrence | 2022 |
Long-term real-world effectiveness and safety of fingolimod over 5 years in Germany.
Topics: Fingolimod Hydrochloride; Germany; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Recurrence | 2022 |
Neurological update: treatment escalation in multiple sclerosis patients refractory to fingolimod-potentials and risks of subsequent highly active agents.
Topics: Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Recurrence | 2022 |
Acute Varicella-Zoster Virus meningitis in a multiple sclerosis patient treated with fingolimod.
Topics: Fingolimod Hydrochloride; Herpesvirus 3, Human; Humans; Meningitis; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting | 2022 |
The effects of dimethyl fumarate and fingolimod on T-cell lymphocyte proliferation in patients with multiple sclerosis.
Topics: CD28 Antigens; Cell Proliferation; Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Lymphocytes; Multiple Sclerosis; Pilot Projects; Treatment Outcome | 2022 |
Fingolimod impairs inactivated vaccine (CoronaVac)-induced antibody response to SARS-CoV-2 spike protein in persons with multiple sclerosis.
Topics: Antibodies, Viral; Antibody Formation; COVID-19; Fingolimod Hydrochloride; Humans; Multiple Sclerosis; SARS-CoV-2; Spike Glycoprotein, Coronavirus; Vaccination; Vaccines, Inactivated | 2022 |
Risk of Getting COVID-19 in People With Multiple Sclerosis: A Case-Control Study.
Topics: Adult; Age Factors; Case-Control Studies; COVID-19; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunosuppressive Agents; Interferon-beta; Italy; Male; Middle Aged; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Odds Ratio; Risk Factors; SARS-CoV-2; Severity of Illness Index; Sex Factors; Time Factors | 2022 |
Trends in the use of disease-modifying therapies among reproductive-aged women with multiple sclerosis in the United States from 2010 to 2019.
Topics: Adolescent; Adult; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunosuppressive Agents; Interferon-beta; Multiple Sclerosis; United States; Young Adult | 2022 |
Epidemiology of Pharmacological Treatment of Multiple Sclerosis in Croatia.
Topics: Croatia; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting | 2021 |
Rebound activity after fingolimod cessation: A case - control study.
Topics: Case-Control Studies; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Prospective Studies; Retrospective Studies | 2022 |
Cytotoxic B Cells in Relapsing-Remitting Multiple Sclerosis Patients.
Topics: Adult; Antigens, CD19; Antigens, CD20; B-Lymphocytes; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Interferon-beta; Lymphocyte Count; Male; Middle Aged; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Peptides; T-Lymphocytes | 2022 |
Comparative Effectiveness of Natalizumab Versus Anti-CD20 in Highly Active Relapsing-Remitting Multiple Sclerosis After Fingolimod Withdrawal.
Topics: Antigens, CD20; Fingolimod Hydrochloride; Humans; Immunologic Factors; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Recurrence | 2022 |
Is pregnancy in MS patients safe and what is its impact on MS course? Real World evidence of 1533 pregnancies in Czech Republic.
Topics: Czech Republic; Female; Fingolimod Hydrochloride; Humans; Multiple Sclerosis; Natalizumab; Pregnancy; Retrospective Studies | 2022 |
Six-month humoral response to mRNA SARS-CoV-2 vaccination in patients with multiple sclerosis treated with ocrelizumab and fingolimod.
Topics: Antibodies, Monoclonal, Humanized; Antibodies, Viral; BNT162 Vaccine; COVID-19; COVID-19 Vaccines; Fingolimod Hydrochloride; Humans; Immunoglobulin G; mRNA Vaccines; Multiple Sclerosis; RNA, Messenger; SARS-CoV-2; Vaccination; Vaccines, Synthetic | 2022 |
Influence of Previous Disease-Modifying Drug Exposure on T-Lymphocyte Dynamic in Patients With Multiple Sclerosis Treated With Ocrelizumab.
Topics: Antibodies, Monoclonal, Humanized; Fingolimod Hydrochloride; Humans; Lymphopenia; Multiple Sclerosis; Retrospective Studies | 2022 |
FACTORS ASSOCIATED WITH SWITCHING FROM INJECTABLE TO ORAL DISEASE MODIFYING AGENTS AMONG PATIENTS WITH MULTIPLE SCLEROSIS.
Topics: Adolescent; Adult; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis; Retrospective Studies | 2022 |
Multiple Sclerosis Relapses Following Cessation of Fingolimod.
Topics: Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Recurrence | 2022 |
The CLARION study design and status update: a long-term, registry-based study evaluating adverse events of special interest in patients with relapsing multiple sclerosis newly started on cladribine tablets.
Topics: Cladribine; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Registries; Tablets | 2022 |
Blood Neurofilament Light in Progressive Multiple Sclerosis: Post Hoc Analysis of 2 Randomized Controlled Trials.
Topics: Acute Disease; Atrophy; Biomarkers; Disease Progression; Fingolimod Hydrochloride; Humans; Intermediate Filaments; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Randomized Controlled Trials as Topic | 2022 |
Real-world effectiveness and safety of fingolimod in patients with multiple sclerosis in the Czech Republic: results from core and extension parts of the GOLEMS study up to 48 months.
Topics: Czech Republic; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Treatment Outcome | 2022 |
Humoral and Cellular Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients with Multiple Sclerosis: An Israeli Multi-Center Experience Following 3 Vaccine Doses.
Topics: BNT162 Vaccine; COVID-19; COVID-19 Vaccines; Fingolimod Hydrochloride; Humans; Immunity, Cellular; Immunoglobulin G; Israel; mRNA Vaccines; Multiple Sclerosis; RNA, Messenger; SARS-CoV-2; Vaccination; Vaccines, Synthetic | 2022 |
Risk of fingolimod rebound after switching to cladribine or rituximab in multiple sclerosis.
Topics: Cladribine; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Retrospective Studies; Rituximab | 2022 |
Anti-SARS-CoV-2 monoclonal antibodies for the treatment of active COVID-19 in multiple sclerosis: An observational study.
Topics: Antibodies, Viral; COVID-19; Fingolimod Hydrochloride; Humans; Middle Aged; Multiple Sclerosis; SARS-CoV-2 | 2022 |
Finnish multiple sclerosis patients treated with cladribine tablets: a nationwide registry study.
Topics: Adult; Cladribine; Cohort Studies; Fingolimod Hydrochloride; Finland; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Registries; Tablets | 2022 |
Longitudinal T-Cell Responses After a Third SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis on Ocrelizumab or Fingolimod.
Topics: Antibodies, Monoclonal, Humanized; COVID-19; COVID-19 Vaccines; Fingolimod Hydrochloride; Humans; Immunity, Cellular; Immunization, Secondary; Interferon-gamma; Multiple Sclerosis; Prospective Studies; SARS-CoV-2; T-Lymphocytes; Vaccination | 2022 |
The influence of disease-modifying therapy on hidden disability burden in people with newly diagnosed relapsing-remitting multiple sclerosis.
Topics: Adult; Cladribine; Cohort Studies; Disabled Persons; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Middle Aged; Motor Disorders; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting | 2022 |
Transitioning From S1P Receptor Modulators to B Cell-Depleting Therapies in Multiple Sclerosis: Clinical, Radiographic, and Laboratory Data.
Topics: Adult; Antigens, CD20; Female; Fingolimod Hydrochloride; Humans; Male; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Sphingosine-1-Phosphate Receptors | 2022 |
Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosis.
Topics: Fingolimod Hydrochloride; Humans; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Treatment Outcome | 2022 |
Novel multiple sclerosis agents-associated cardiotoxicity: A real-world pharmacovigilance study.
Topics: Fingolimod Hydrochloride; Humans; Immunologic Factors; Multiple Sclerosis; Pharmacovigilance; Sphingosine-1-Phosphate Receptors; United States; United States Food and Drug Administration | 2022 |
Immunomodulatory effects of cyclotides isolated from Viola odorata in an experimental autoimmune encephalomyelitis animal model of multiple sclerosis.
Topics: Amino Acid Sequence; Animals; Cyclotides; Encephalomyelitis, Autoimmune, Experimental; Female; Fingolimod Hydrochloride; Inflammation; Mice; Mice, Inbred C57BL; Multiple Sclerosis; Viola; Water | 2022 |
Breakthrough SARS-CoV-2 infections in MS patients on disease-modifying therapies.
Topics: COVID-19; COVID-19 Vaccines; Fingolimod Hydrochloride; Humans; Multiple Sclerosis; Retrospective Studies; SARS-CoV-2 | 2022 |
Early use of fingolimod is associated with better clinical outcomes in relapsing-remitting multiple sclerosis patients.
Topics: Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Severity of Illness Index | 2022 |
Newer disease modifying treatments in pediatric onset multiple sclerosis: Experience from a single center.
Topics: Child; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunosuppressive Agents; Male; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Retrospective Studies | 2022 |
Impact of disease-modifying therapies on evolving tissue damage in iron rim multiple sclerosis lesions.
Topics: Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Iron; Magnetic Resonance Imaging; Multiple Sclerosis | 2022 |
SARS-CoV-2 mRNA vaccinations fail to elicit humoral and cellular immune responses in patients with multiple sclerosis receiving fingolimod.
Topics: Antibodies, Viral; COVID-19; COVID-19 Vaccines; Fingolimod Hydrochloride; Humans; Immunity, Cellular; mRNA Vaccines; Multiple Sclerosis; Prospective Studies; RNA, Messenger; SARS-CoV-2; Vaccination; Vaccines, Synthetic | 2022 |
Fingolimod effects on the brain are mediated through biochemical modulation of bioenergetics, autophagy, and neuroinflammatory networks.
Topics: Animals; Autophagy; Brain; Endocannabinoids; Energy Metabolism; Fingolimod Hydrochloride; Interleukin-12; Mice; Multiple Sclerosis; Proteome | 2022 |
Humoral response and safety of the third booster dose of BNT162b2 mRNA COVID-19 vaccine in patients with multiple sclerosis treated with ocrelizumab or fingolimod.
Topics: Antibodies, Viral; BNT162 Vaccine; COVID-19; COVID-19 Vaccines; Fingolimod Hydrochloride; Humans; Immunoglobulin G; mRNA Vaccines; Multiple Sclerosis; RNA, Messenger; SARS-CoV-2 | 2022 |
Prediction of relapse activity when switching to cladribine for multiple sclerosis.
Topics: Chronic Disease; Cladribine; Fingolimod Hydrochloride; Humans; Immunologic Factors; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Recurrence | 2023 |
Disease reactivation after fingolimod cessation in Multiple Sclerosis patients with pregnancy desire: A retrospective study.
Topics: Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Pregnancy; Recurrence; Retrospective Studies | 2022 |
[Comments on the GLIMPSE study on evaluating the efficacy of the drug cladribine in tablets in routine clinical practice in comparison with other tablet drugs for the pathogenetic treatment of multiple sclerosis].
Topics: Cladribine; Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Tablets | 2022 |
Neurometabolic changes in multiple sclerosis: Fingolimod versus beta interferon or glatiramer acetate therapy.
Topics: Fatigue; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunosuppressive Agents; Interferon-beta; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting | 2022 |
Persistence, adherence, healthcare resource utilization and costs for ocrelizumab in the real-world of the Campania Region of Italy.
Topics: Adult; Antibodies, Monoclonal, Humanized; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Humans; Medication Adherence; Middle Aged; Multiple Sclerosis | 2022 |
How to choose initial treatment in multiple sclerosis patients: a case-based approach.
Topics: Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting | 2022 |
Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis.
Topics: Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Recurrence; Retrospective Studies | 2022 |
Treatment-refractory warts associated with fingolimod.
Topics: Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Warts | 2022 |
The effect of Zingiber Officinale Extract on Preventing Demyelination of Corpus Callosum in a Rat Model of Multiple Sclerosis
Topics: Animals; Anti-Inflammatory Agents; Corpus Callosum; Cuprizone; Demyelinating Diseases; Disease Models, Animal; Fingolimod Hydrochloride; Male; Mice; Mice, Inbred C57BL; Multiple Sclerosis; Myelin Sheath; Rats; Rats, Wistar; Zingiber officinale | 2022 |
Primary central nervous system lymphoma in a patient with multiple sclerosis using fingolimod.
Topics: Central Nervous System; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Lymphoma; Multiple Sclerosis | 2023 |
Three doses of COVID-19 vaccines in multiple sclerosis patients treated with disease-modifying therapies.
Topics: Antibodies, Viral; COVID-19; COVID-19 Vaccines; Female; Fingolimod Hydrochloride; Humans; Multiple Sclerosis; RNA, Messenger; Vaccines, Inactivated | 2022 |
Disease modifying therapies and disease activity during pregnancy and postpartum in a contemporary cohort of relapsing Multiple Sclerosis patients.
Topics: Female; Fingolimod Hydrochloride; Humans; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Postpartum Period; Pregnancy; Recurrence | 2022 |
The Patient and Clinician Assessment of Gastrointestinal (GI) Related Adverse Events Associated with Oral Disease-Modifying Therapies in Multiple Sclerosis: A Qualitative Study.
Topics: Cross-Sectional Studies; Crotonates; Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Nitriles; Qualitative Research; Recurrence; Toluidines | 2022 |
Cross-sectional analysis of the humoral response after SARS-CoV-2 vaccination in Sardinian multiple sclerosis patients, a follow-up study.
Topics: BNT162 Vaccine; COVID-19; COVID-19 Vaccines; Cross-Sectional Studies; Fingolimod Hydrochloride; Follow-Up Studies; Humans; Multiple Sclerosis; SARS-CoV-2; Vaccination | 2022 |
Periprosthetic joint infection due to Mycoplasma hominis in a multiple sclerosis patient treated with fingolimod.
Topics: Anti-Infective Agents; Arthritis, Infectious; Fingolimod Hydrochloride; Humans; Male; Middle Aged; Multiple Sclerosis; Mycoplasma hominis; Mycoplasma Infections; Prosthesis-Related Infections; Sepsis; Sphingosine-1-Phosphate Receptors | 2022 |
Leptomeningeal enhancement under different MS immunotherapies: A monocentric retrospective cohort study of 214 patients.
Topics: Fingolimod Hydrochloride; Humans; Immunotherapy; Magnetic Resonance Imaging; Meninges; Multiple Sclerosis; Retrospective Studies | 2023 |
Discontinuation of second- versus first-line disease-modifying treatment in middle-aged patients with multiple sclerosis.
Topics: Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Middle Aged; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Recurrence; Retrospective Studies | 2023 |
Forskolin, an Adenylcyclase/cAMP/CREB Signaling Activator Restoring Myelin-Associated Oligodendrocyte Destruction in Experimental Ethidium Bromide Model of Multiple Sclerosis.
Topics: Adenylyl Cyclases; Animals; Colforsin; Cytokines; Demyelinating Diseases; Donepezil; Ethidium; Fingolimod Hydrochloride; Gliotoxin; Memantine; Multiple Sclerosis; Myelin Basic Protein; Myelin Sheath; Nerve Growth Factors; Neurodegenerative Diseases; Oligodendroglia; Rats; Rats, Wistar; Simvastatin | 2022 |
Fingolimod, teriflunomide and cladribine for the treatment of multiple sclerosis in women of childbearing age: description of drug utilization and exposed pregnancies in Germany.
Topics: Child; Cladribine; Cross-Sectional Studies; Drug Utilization; Female; Fingolimod Hydrochloride; Germany; Humans; Immunosuppressive Agents; Infant, Newborn; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Pregnancy | 2022 |
What are the trends in the treatment of multiple sclerosis in recent studies? - A bibliometric analysis with global productivity during 1980-2021.
Topics: Alemtuzumab; COVID-19; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Quality of Life; Recurrence | 2022 |
Electronic Health Diary Campaigns to Complement Longitudinal Assessments in Persons With Multiple Sclerosis: Nested Observational Study.
Topics: Adult; Crotonates; Electronics; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Hydroxybutyrates; Interferon beta-1a; Male; Medical Records; Middle Aged; Multiple Sclerosis; Nitriles; Quality of Life; Toluidines | 2022 |
Brain volume loss and physical and cognitive impairment in naive multiple sclerosis patients treated with fingolimod: prospective cohort study in Buenos Aires, Argentina.
Topics: Adult; Argentina; Biomarkers; Brain; Cognitive Dysfunction; Disability Evaluation; Disease Progression; Fingolimod Hydrochloride; Humans; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Prospective Studies | 2022 |
Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis.
Topics: Cladribine; Cohort Studies; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Recurrence; Treatment Outcome; Withholding Treatment | 2022 |
Serum 3-phenyllactic acid level is reduced in benign multiple sclerosis and is associated with effector B cell ratios.
Topics: B-Lymphocyte Subsets; Fingolimod Hydrochloride; Humans; Interleukin-4; Multiple Sclerosis | 2022 |
Immune cells transcriptome-based drug repositioning for multiple sclerosis.
Topics: Drug Repositioning; Fingolimod Hydrochloride; Gene Expression Profiling; Humans; Leukocytes, Mononuclear; Multiple Sclerosis; Phosphatidylinositol 3-Kinases; Transcriptome | 2022 |
Stability of longitudinal DTI metrics in MS with treatment of injectables, fingolimod and dimethyl fumarate.
Topics: Benchmarking; Brain; Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; White Matter | 2023 |
Peripheral myeloid-derived suppressor cells are good biomarkers of the efficacy of fingolimod in multiple sclerosis.
Topics: Animals; Biomarkers; Encephalomyelitis, Autoimmune, Experimental; Fingolimod Hydrochloride; Humans; Leukocytes, Mononuclear; Mice; Multiple Sclerosis; Myeloid-Derived Suppressor Cells | 2022 |
Serum Levels of CXCL13 Are Associated With Teriflunomide Response in Patients With Multiple Sclerosis.
Topics: Chemokine CXCL13; Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting | 2023 |
Using an animal model to predict the effective human dose for oral multiple sclerosis drugs.
Topics: Animals; Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Mice; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Rats | 2023 |
Impact of Siponimod on Enteric and Central Nervous System Pathology in Late-Stage Experimental Autoimmune Encephalomyelitis.
Topics: Animals; Benzyl Compounds; Central Nervous System; Encephalomyelitis, Autoimmune, Experimental; Fingolimod Hydrochloride; Mice; Multiple Sclerosis | 2022 |
Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry.
Topics: Cladribine; Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Registries; Retrospective Studies; Tablets | 2023 |
Management approach including pembrolizumab for fingolimod-associated progressive multifocal leukoencephalopathy in a patient with relapsing-remitting multiple sclerosis.
Topics: Fingolimod Hydrochloride; Humans; JC Virus; Leukoencephalopathy, Progressive Multifocal; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab | 2023 |
Effect of fingolimod therapy on quantitative macular changes among patients with relapsing-remitting multiple sclerosis: a four-year follow-up study from Oman.
Topics: Fingolimod Hydrochloride; Follow-Up Studies; Humans; Immunosuppressive Agents; Longitudinal Studies; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Oman; Retrospective Studies | 2022 |
Serology results after COVID vaccine in multiple sclerosis patients treated with fingolimod.
Topics: COVID-19; COVID-19 Vaccines; Fingolimod Hydrochloride; Humans; Multiple Sclerosis; Vaccination; Vaccines | 2023 |
Effect of multiple sclerosis disease-modifying therapies on the real-world effectiveness of two doses of BBIBP-CorV (Sinopharm) vaccine.
Topics: Cohort Studies; COVID-19; COVID-19 Drug Treatment; COVID-19 Vaccines; Fingolimod Hydrochloride; Humans; Multiple Sclerosis; SARS-CoV-2; Vaccination; Vaccines | 2023 |
Longitudinal characterisation of B and T-cell immune responses after the booster dose of COVID-19 mRNA-vaccine in people with multiple sclerosis using different disease-modifying therapies.
Topics: Antibodies, Viral; COVID-19; COVID-19 Vaccines; Cytokines; Fingolimod Hydrochloride; Humans; Immunoglobulin G; Multiple Sclerosis; RNA, Messenger; T-Lymphocytes | 2023 |
Complicated Monkeypox Infection in a Patient With Multiple Sclerosis and Fingolimod Treatment.
Topics: Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Mpox (monkeypox); Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting | 2023 |
Hematopoietic Stem Cell Transplantation in People With Active Secondary Progressive Multiple Sclerosis.
Topics: Fingolimod Hydrochloride; Glatiramer Acetate; Hematopoietic Stem Cell Transplantation; Humans; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting | 2023 |
[A case of multiple sclerosis with a tumefactive lesion during long-term treatment with fingolimod, leading to decompressive craniotomy].
Topics: Contrast Media; Decompressive Craniectomy; Fingolimod Hydrochloride; Gadolinium; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis | 2023 |
Neurocognitive impairment in multiple sclerosis and its association with thiol-disulfide homeostasis and ischemia-modified albumin.
Topics: Biomarkers; Disulfides; Fingolimod Hydrochloride; Homeostasis; Humans; Multiple Sclerosis; Neuropsychological Tests; Serum Albumin; Sulfhydryl Compounds | 2023 |
CD19+ B cell values predict the increase of anti-SARS CoV2 antibodies in fingolimod-treated and COVID-19-vaccinated patients with multiple sclerosis.
Topics: Adaptor Proteins, Signal Transducing; Adult; Antibodies, Viral; B-Lymphocytes; COVID-19; COVID-19 Vaccines; Fingolimod Hydrochloride; Humans; Multiple Sclerosis; Prospective Studies; SARS-CoV-2; Vaccination | 2023 |
A case of psoriasis and multiple sclerosis succesfully treated with concomitant fingolimod and secukinumab.
Topics: Antibodies, Monoclonal, Humanized; Fingolimod Hydrochloride; Humans; Multiple Sclerosis; Psoriasis; Severity of Illness Index; Treatment Outcome | 2023 |
The comparative effectiveness of fingolimod, natalizumab, and ocrelizumab in relapsing-remitting multiple sclerosis.
Topics: Fingolimod Hydrochloride; Humans; Immunologic Factors; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Recurrence; Treatment Outcome | 2023 |
Effect of smoking on disease activity in multiple sclerosis patients treated with dimethyl fumarate or fingolimod.
Topics: Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Retrospective Studies; Smoking | 2023 |
Progression of Mycosis Fungoides After Fingolimod Treatment for Multiple Sclerosis and Targeted Next-Generation Sequencing Demonstrating Potential Links Between the Two Diseases.
Topics: Fingolimod Hydrochloride; High-Throughput Nucleotide Sequencing; Humans; Multiple Sclerosis; Mycosis Fungoides; Skin Neoplasms | 2023 |
Switching to natalizumab or fingolimod in multiple sclerosis: Comparative effectiveness and effect of pre-switch disease activity.
Topics: Adult; Comparative Effectiveness Research; Fingolimod Hydrochloride; Humans; Immunologic Factors; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Recurrence; Treatment Outcome | 2023 |
Comparative effectiveness in multiple sclerosis: A methodological comparison.
Topics: Fingolimod Hydrochloride; Humans; Immunologic Factors; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Propensity Score; Recurrence; Treatment Outcome | 2023 |
A decade of fingolimod in multiple sclerosis: Insights from a large real-world cohort study.
Topics: Cohort Studies; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Recurrence | 2023 |
Effects of horizontal versus vertical switching of disease-modifying treatment after platform drugs on disease activity in patients with relapsing-remitting multiple sclerosis in Austria.
Topics: Austria; Fingolimod Hydrochloride; Humans; Immunologic Factors; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Treatment Outcome | 2023 |
Effectiveness and safety of switching from fingolimod and natalizumab to rituximab in patients with relapsing remitting multiple sclerosis.
Topics: Fingolimod Hydrochloride; Humans; Immunologic Factors; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Recurrence; Retrospective Studies; Rituximab; Treatment Outcome | 2023 |
Third COVID-19 vaccine dose for people with multiple sclerosis who did not seroconvert following two doses of BBIBP-CorV (Sinopharm) inactivated vaccine: A pilot study on safety and immunogenicity.
Topics: Antibodies, Viral; COVID-19; COVID-19 Vaccines; Fingolimod Hydrochloride; Humans; Immunoglobulin G; Multiple Sclerosis; Pilot Projects; Vaccines, Inactivated | 2023 |
A Prospective, Observational Study Assessing Effectiveness, Safety, and QoL of Greek Patients with Multiple Sclerosis Under Treatment with Fingolimod.
Topics: Adult; Female; Fingolimod Hydrochloride; Greece; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Prospective Studies; Quality of Life; Recurrence; Treatment Outcome | 2023 |
A prospective study of cellular immune response to booster COVID-19 vaccination in multiple sclerosis patients treated with a broad spectrum of disease-modifying therapies.
Topics: Antibodies, Viral; Cladribine; COVID-19; COVID-19 Vaccines; Fingolimod Hydrochloride; Humans; Immunity, Cellular; Multiple Sclerosis; Natalizumab; Prospective Studies; SARS-CoV-2; Vaccination | 2023 |
Retrospective analysis of effectiveness of fingolimod in real life setting in Turkey (REFINE).
Topics: Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunosuppressive Agents; Interferon-beta; Multiple Sclerosis; Recurrence; Retrospective Studies; Turkey | 2023 |
Increased NLRP3 Inflammasome Activation and Pyroptosis in Patients With Multiple Sclerosis With Fingolimod Treatment Failure.
Topics: Fingolimod Hydrochloride; Galectin 3; Humans; Inflammasomes; Leukocytes, Mononuclear; Multiple Sclerosis; NLR Family, Pyrin Domain-Containing 3 Protein; Pyroptosis; Tumor Necrosis Factor-alpha | 2023 |
Previous disease-modifying treatments influence T lymphocyte kinetics in people with multiple sclerosis switching to ocrelizumab.
Topics: Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Kinetics; Multiple Sclerosis; Natalizumab; Retrospective Studies | 2023 |
Generalized pustular psoriasis occurring in a patient with multiple sclerosis during treatment with fingolimod.
Topics: Chronic Disease; Etretinate; Fingolimod Hydrochloride; Humans; Multiple Sclerosis; Psoriasis; Skin Diseases, Vesiculobullous | 2023 |
Assessment of Functional Capacity of Immune System in Patients with Multiple Sclerosis using QuantiFERON Monitor.
Topics: Enzyme-Linked Immunosorbent Assay; Fingolimod Hydrochloride; Humans; Immune System; Interferon-gamma; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting | 2023 |
Fertility, pregnancy and childbirth in women with multiple sclerosis: a population-based study from 2018 to 2020.
Topics: Dimethyl Fumarate; Female; Fertility; Fingolimod Hydrochloride; Humans; Multiple Sclerosis; Natalizumab; Pregnancy | 2023 |
Very-long-chain fatty acids induce glial-derived sphingosine-1-phosphate synthesis, secretion, and neuroinflammation.
Topics: Animals; Bezafibrate; Encephalomyelitis, Autoimmune, Experimental; Fatty Acids; Fingolimod Hydrochloride; Immunosuppressive Agents; Mice; Multiple Sclerosis; Neuroglia; Neuroinflammatory Diseases; Propylene Glycols | 2023 |
Case Report: Severe rebound after withdrawal of fingolimod in a patient with neuromyelitis optica spectrum disorder.
Topics: Female; Fingolimod Hydrochloride; Humans; Immunologic Factors; Middle Aged; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Neuromyelitis Optica | 2023 |
Antibody response elicited by the SARS-CoV-2 vaccine booster in patients with multiple sclerosis: Who gains from it?
Topics: Antibodies, Viral; Antibody Formation; COVID-19; COVID-19 Vaccines; Fingolimod Hydrochloride; Humans; Multiple Sclerosis; Prospective Studies; Rituximab; SARS-CoV-2; Vaccination | 2023 |
Comparative adherence trajectories of oral disease-modifying agents in multiple sclerosis.
Topics: Adult; Crotonates; Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Medication Adherence; Multiple Sclerosis; Retrospective Studies | 2023 |
T cell responses to SARS-CoV-2 vaccination differ by disease-modifying therapy for multiple sclerosis.
Topics: COVID-19; COVID-19 Vaccines; Fingolimod Hydrochloride; Humans; Multiple Sclerosis; Pandemics; Rituximab; SARS-CoV-2; Vaccination | 2023 |
Symptomatic COVID-19 course and outcomes after three mRNA vaccine doses in multiple sclerosis patients treated with high-efficacy DMTs.
Topics: COVID-19; COVID-19 Vaccines; Fingolimod Hydrochloride; Humans; mRNA Vaccines; Multiple Sclerosis; Natalizumab; RNA, Messenger; SARS-CoV-2 | 2023 |
Targeting L-Selectin Lymphocytes to Deliver Immunosuppressive Drug in Lymph Nodes for Durable Multiple Sclerosis Treatment.
Topics: Animals; Encephalomyelitis, Autoimmune, Experimental; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; L-Selectin; Lymph Nodes; Lymphocytes; Mice; Multiple Sclerosis; Pharmaceutical Preparations; Sphingosine | 2023 |
Fingolimod-related atrioventricular block in paediatric age group with multiple sclerosis: two case reports.
Topics: Adolescent; Atrioventricular Block; Child; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Young Adult | 2023 |
Trends in the Epidemiology and Treatment of Pediatric-Onset Multiple Sclerosis in Alberta, Canada.
Topics: Adult; Alberta; Child; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Retrospective Studies; Young Adult | 2023 |
Multiple Sclerosis Disease Activity and Disability Following Cessation of Fingolimod for Pregnancy.
Topics: Adult; Female; Fingolimod Hydrochloride; Humans; Multiple Sclerosis; Postpartum Period; Pregnancy; Recurrence; Registries | 2023 |
mRNA versus inactivated virus COVID-19 vaccines in multiple sclerosis: Humoral responses and protectivity-Does it matter?
Topics: Antibodies, Viral; Cladribine; COVID-19; COVID-19 Vaccines; Cross-Sectional Studies; Female; Fingolimod Hydrochloride; Humans; Male; Multiple Sclerosis; Prospective Studies; RNA, Messenger; SARS-CoV-2; Vaccination | 2023 |
miRNA 548a-3p as biomarker of NEDA-3 at 2 years in multiple sclerosis patients treated with fingolimod.
Topics: Adolescent; Autoimmune Diseases; Biomarkers; Fingolimod Hydrochloride; Humans; MicroRNAs; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting | 2023 |
Comparison of multiple sclerosis patients with or without rebound activity after fingolimod cessation: Five-year clinical outcomes.
Topics: Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Recurrence | 2023 |
Current and future trends in multiple sclerosis management: Near East perspective.
Topics: COVID-19; Cross-Sectional Studies; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunosuppressive Agents; Interferon beta-1a; Lebanon; Male; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting | 2023 |
Three to four mRNA COVID-19 vaccines in multiple sclerosis patients on immunosuppressive drugs: Seroconversion and variant neutralization.
Topics: Antibodies, Neutralizing; Antibodies, Viral; BNT162 Vaccine; COVID-19; COVID-19 Vaccines; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Longitudinal Studies; Multiple Sclerosis; Prospective Studies; RNA, Messenger; SARS-CoV-2; Seroconversion; Vaccination | 2023 |
Index of cardiac-electrophysiological balance in relapsing-remitting multiple sclerosis patients treated with fingolimod.
Topics: Arrhythmias, Cardiac; Electrocardiography; Fingolimod Hydrochloride; Heart; Heart Rate; Humans; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting | 2023 |
Obstetric and Gynecologic Disorders and the Nervous System.
Topics: Breast Feeding; Female; Fingolimod Hydrochloride; Humans; Hypertension; Multiple Sclerosis; Pregnancy | 2023 |
Comparative effectiveness of cladribine tablets versus fingolimod in the treatment of highly active multiple sclerosis: A real-world study.
Topics: Cladribine; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Retrospective Studies; Tablets | 2023 |
Demographic Features and Clinical Course of Patients With Pediatric-Onset Multiple Sclerosis on Newer Disease-Modifying Treatments.
Topics: Adolescent; Adult; Child; Demography; Disease Progression; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Recurrence | 2023 |
Antibody response to SARS-CoV-2 vaccination or infection in a prospective cohort of children with neuroinflammatory diseases.
Topics: Adolescent; Adult; Antibodies, Monoclonal; Antibodies, Viral; Antibody Formation; Child; COVID-19; COVID-19 Vaccines; Fingolimod Hydrochloride; Humans; Multiple Sclerosis; Neuroinflammatory Diseases; Prospective Studies; SARS-CoV-2; Vaccination | 2023 |
Effects of disease-modifying therapies on lipid parameters in patients with multiple sclerosis.
Topics: Adult; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting | 2023 |
Initiation Patterns of Disease-Modifying Therapies for Multiple Sclerosis Among US Adults and Children, 2001 Through 2020.
Topics: Adolescent; Adult; Child; Cross-Sectional Studies; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Interferon-beta; Middle Aged; Multiple Sclerosis | 2023 |
Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis.
Topics: Adult; Female; Fingolimod Hydrochloride; Hematopoietic Stem Cell Transplantation; Humans; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab | 2023 |
The association between fingolimod and mental health outcomes in a cohort of Multiple Sclerosis patients with stress.
Topics: Anxiety; Fingolimod Hydrochloride; Humans; Multiple Sclerosis; Outcome Assessment, Health Care; Sleep Initiation and Maintenance Disorders | 2023 |
Use of follow-on fingolimod for multiple sclerosis: Analysis of effectiveness and patient reported outcomes in a real-world clinical setting.
Topics: Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Patient Reported Outcome Measures; Retrospective Studies | 2023 |
Real-life outcomes for oral disease-modifying treatments of relapsing-remitting multiple sclerosis patients: Adherence and adverse event profiles from Marmara University.
Topics: Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Retrospective Studies; Universities | 2023 |
Exploration of Tetrahydroisoquinoline- and Benzo[
Topics: Bradycardia; Fingolimod Hydrochloride; Humans; Multiple Sclerosis; Receptors, Lysosphingolipid; Sphingosine; Sphingosine-1-Phosphate Receptors; Tetrahydroisoquinolines | 2023 |
The impact of hybrid immunity on immune responses after SARS-CoV-2 vaccination in persons with multiple sclerosis treated with disease-modifying therapies.
Topics: Adaptive Immunity; Alemtuzumab; Antibodies; Antibodies, Viral; Cladribine; COVID-19; COVID-19 Vaccines; Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Interferon-gamma; Multiple Sclerosis; Natalizumab; SARS-CoV-2; Vaccination | 2023 |
Early use of high efficacy therapies in pediatric forms of relapsing-remitting multiple sclerosis: A real-life observational study.
Topics: Adolescent; Child; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunosuppressive Agents; Interferon beta-1a; Male; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Recurrence | 2023 |
A short washout period from fingolimod to anti-CD20 therapy is safe and decreases the risk of reactivation.
Topics: Cohort Studies; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Retrospective Studies | 2023 |
Restless legs syndrome in multiple sclerosis patients: Prevalence, impact, and association with disease-modifying therapies in a Saudi Arabian pilot study.
Topics: Cross-Sectional Studies; Fingolimod Hydrochloride; Humans; Multiple Sclerosis; Pilot Projects; Prevalence; Restless Legs Syndrome; Saudi Arabia; Severity of Illness Index; Sleepiness | 2023 |
Corticosteroid-induced low immunoglobulin levels in multiple sclerosis - A confounding factor.
Topics: Adrenal Cortex Hormones; Fingolimod Hydrochloride; Humans; Immunoglobulin G; Immunosuppressive Agents; Multiple Sclerosis; Retrospective Studies | 2023 |
Multiple Sclerosis, Disease-Modifying Therapies, and Infections.
Topics: Adult; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis; Natalizumab; Retrospective Studies; Rituximab | 2023 |
The effect of glatiramer acetate, IFNβ-1a, fingolimod, and dimethyl fumarate on the expression of T-bet, IFN-γ, and MEG3 in PBMC of RRMS patients.
Topics: Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Interferon-gamma; Leukocytes, Mononuclear; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Neurodegenerative Diseases | 2023 |
Real-world effectiveness of fingolimod in patients with multiple sclerosis in Bulgaria.
Topics: Adult; Bulgaria; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Middle Aged; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Prospective Studies; Quality of Life | 2023 |
Fingolimod (FTY720) improves the functional recovery and myelin preservation of the optic pathway in focal demyelination model of rat optic chiasm.
Topics: Animals; Demyelinating Diseases; Disease Models, Animal; Fingolimod Hydrochloride; Histone Deacetylase 1; Lysophosphatidylcholines; Male; Multiple Sclerosis; Myelin Sheath; Oligodendroglia; Optic Chiasm; Rats; Rats, Wistar; Recovery of Function; Remyelination; Sphingosine-1-Phosphate Receptors; Valproic Acid | 2019 |
Skin warts during fingolimod treatment in patients with multiple sclerosis.
Topics: Adult; Female; Fingolimod Hydrochloride; Humans; Immunologic Factors; Male; Multiple Sclerosis; Papillomavirus Infections; Warts; Young Adult | 2019 |
Clinical characteristics and use of disease modifying therapy in the nationwide Danish cohort of paediatric onset multiple sclerosis.
Topics: Adolescent; Cohort Studies; Female; Fingolimod Hydrochloride; Humans; Immunologic Factors; Immunosuppressive Agents; Male; Multiple Sclerosis; Natalizumab; Young Adult | 2020 |
Flare of hepatitis B virus after fingolimod treatment for relapsing and remitting multiple sclerosis.
Topics: Cost-Benefit Analysis; Fingolimod Hydrochloride; Hepatitis B virus; Humans; Immunosuppressive Agents; Lymphoma; Multiple Sclerosis; Neoplasm Recurrence, Local | 2020 |
Time to treatment failure following initiation of fingolimod versus teriflunomide for multiple sclerosis: a retrospective US claims study.
Topics: Adolescent; Adult; Crotonates; Female; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Male; Middle Aged; Multiple Sclerosis; Nitriles; Recurrence; Retrospective Studies; Time-to-Treatment; Toluidines; Treatment Failure; United States; Young Adult | 2020 |
Fingolimod Increases Brain-Derived Neurotrophic Factor Level Secretion from Circulating T Cells of Patients with Multiple Sclerosis.
Topics: Adult; Brain; Brain-Derived Neurotrophic Factor; Female; Fingolimod Hydrochloride; Humans; Male; Middle Aged; Multiple Sclerosis; Nerve Growth Factors; Neuroglia; Neuroprotective Agents; T-Lymphocytes; Young Adult | 2019 |
Serum Exosome MicroRNAs Predict Multiple Sclerosis Disease Activity after Fingolimod Treatment.
Topics: Adult; Biomarkers; Exosomes; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Male; MicroRNAs; Middle Aged; Multiple Sclerosis | 2020 |
Rebound of multiple sclerosis activity after fingolimod withdrawal due to planning pregnancy: Analysis of predisposing factors.
Topics: Adult; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Live Birth; Lymphocytes; Magnetic Resonance Imaging; Multiple Sclerosis; Pregnancy; Pregnancy Complications; Reproductive Behavior; Retrospective Studies; Severity of Illness Index; Symptom Flare Up; Time Factors | 2020 |
Multiple sclerosis drug FTY-720 toxicity is mediated by the heterotypic fusion of organelles in neuroendocrine cells.
Topics: Animals; Cattle; Cells, Cultured; Chromaffin Granules; Fingolimod Hydrochloride; Humans; Microscopy, Electron, Transmission; Mitochondria; Mitochondrial Dynamics; Multiple Sclerosis; Neuroendocrine Cells; Primary Cell Culture; Synaptosomal-Associated Protein 25; Toxicity Tests | 2019 |
Short term real-world Fingolimod efficacy and safety in Emirati patients with multiple sclerosis.
Topics: Adult; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis; Recurrence; Retrospective Studies; Treatment Outcome; United Arab Emirates | 2020 |
In Silico and In Vivo Analysis of IL37 in Multiple Sclerosis Reveals Its Probable Homeostatic Role on the Clinical Activity, Disability, and Treatment with Fingolimod.
Topics: Adult; Case-Control Studies; CD4-Positive T-Lymphocytes; Computer Simulation; Disease Progression; Diseases in Twins; Female; Fingolimod Hydrochloride; Gene Expression Regulation; Humans; Interleukin-1; Male; Middle Aged; Multiple Sclerosis; Recurrence; Twins, Monozygotic; Up-Regulation | 2019 |
Macular oedema and changes in macular thickness in multiple sclerosis patients treated with fingolimod.
Topics: Adult; Female; Fingolimod Hydrochloride; Humans; Macula Lutea; Macular Edema; Male; Multiple Sclerosis; Retina; Tomography, Optical Coherence; Visual Acuity | 2020 |
Fingolimod Profoundly Reduces Frequencies and Alters Subset Composition of Circulating T Follicular Helper Cells in Multiple Sclerosis Patients.
Topics: B-Lymphocytes; CD8-Positive T-Lymphocytes; Female; Fingolimod Hydrochloride; Humans; Immunologic Memory; Male; Multiple Sclerosis; Receptors, CXCR5; T-Lymphocytes, Helper-Inducer | 2020 |
Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients.
Topics: Adult; Cohort Studies; Female; Fingolimod Hydrochloride; Humans; Immunologic Factors; Incidence; Male; Middle Aged; Multiple Sclerosis; Natalizumab; Neoplasms; Rituximab; Sweden | 2020 |
Changing therapeutic strategies and persistence to disease-modifying treatments in a population of multiple sclerosis patients from Veneto region, Italy.
Topics: Adult; Azathioprine; Dimethyl Fumarate; Drug Prescriptions; Drug Utilization; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunologic Factors; Italy; Male; Medication Adherence; Middle Aged; Multiple Sclerosis; Time Factors | 2020 |
Glioblastoma in a fingolimod-treated multiple sclerosis patient: Causal or coincidental association?
Topics: Brain; Brain Neoplasms; Female; Fingolimod Hydrochloride; Glioblastoma; Humans; Middle Aged; Multiple Sclerosis; Sphingosine 1 Phosphate Receptor Modulators | 2020 |
First approved treatment in children with multiple sclerosis slows brain atrophy.
Topics: Atrophy; Brain; Child; Fingolimod Hydrochloride; Humans; Magnetic Resonance Imaging; Multiple Sclerosis | 2020 |
Adherence to laboratory monitoring among people taking oral drugs for multiple sclerosis: A Canadian population-based study.
Topics: British Columbia; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Laboratories; Male; Multiple Sclerosis; Pharmaceutical Preparations | 2021 |
An alternative to product-specific pregnancy registries? PRIM; PRegnancy outcomes Intensive Monitoring.
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Drug Industry; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Maternal-Fetal Exchange; Middle Aged; Multiple Sclerosis; Pharmacovigilance; Pregnancy; Pregnancy Outcome; Registries; Young Adult | 2020 |
Fingolimod and Dimethyl-Fumarate-Derived Lymphopenia is not Associated with Short-Term Treatment Response and Risk of Infections in a Real-Life MS Population.
Topics: Adult; Dimethyl Fumarate; Disease Progression; Female; Fingolimod Hydrochloride; Humans; Infections; Lymphocyte Count; Lymphocytes; Lymphopenia; Male; Multiple Sclerosis; Recurrence; Retrospective Studies; Risk | 2020 |
First therapy choice in newly diagnosed Multiple Sclerosis patients: A multicenter Italian study.
Topics: Aged; Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Italy; Male; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting | 2020 |
Assessment of expression profile of microRNAs in multiple sclerosis patients treated with fingolimod.
Topics: Adult; Biomarkers; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; MicroRNAs; Middle Aged; Multiple Sclerosis; Treatment Outcome | 2020 |
Spanish real-world experience with fingolimod in relapsing-remitting multiple sclerosis patients: MS NEXT study.
Topics: Adult; Aged; Disabled Persons; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Recurrence; Retrospective Studies; Spain | 2020 |
Multiple sclerosis and the risk of infection: considerations in the threat of the novel coronavirus, COVID-19/SARS-CoV-2.
Topics: Betacoronavirus; Coronavirus; Coronavirus Infections; COVID-19; Fingolimod Hydrochloride; Humans; Multiple Sclerosis; Natalizumab; Pandemics; Pneumonia, Viral; Rituximab; SARS-CoV-2; Severe acute respiratory syndrome-related coronavirus | 2020 |
Effectiveness of fingolimod in real-world relapsing-remitting multiple sclerosis Italian patients: the GENIUS study.
Topics: Adult; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Italy; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Retrospective Studies | 2020 |
COVID-19 infection in a patient with multiple sclerosis treated with fingolimod.
Topics: Adult; Betacoronavirus; Coronavirus Infections; COVID-19; Female; Fingolimod Hydrochloride; Humans; Multiple Sclerosis; Pandemics; Pneumonia, Viral; SARS-CoV-2 | 2020 |
[New Arrival of Disease Modifying Drugs Initiates New Era in Multiple Sclerosis Treatment in Japan].
Topics: Antibodies, Monoclonal, Humanized; Azetidines; Benzyl Compounds; Clinical Trials as Topic; Dimethyl Fumarate; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Interferons; Japan; Multiple Sclerosis; Natalizumab | 2020 |
B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran.
Topics: Adult; Antibodies, Monoclonal, Humanized; B-Lymphocytes; Betacoronavirus; Coronavirus Infections; Cough; COVID-19; Cross-Sectional Studies; Crotonates; Dimethyl Fumarate; Disease Susceptibility; Dyspnea; Epidemics; Female; Fever; Fingolimod Hydrochloride; Glatiramer Acetate; Hospitalization; Humans; Hydroxybutyrates; Immunocompromised Host; Immunologic Factors; Intensive Care Units; Interferons; Iran; Lung; Lymphocyte Depletion; Male; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Nitriles; Pandemics; Pneumonia, Viral; Rituximab; SARS-CoV-2; Severity of Illness Index; Toluidines; Tomography, X-Ray Computed | 2020 |
Disability progression
Topics: Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunosuppressive Agents; Interferon-beta; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Recurrence | 2021 |
Treating patients with multiple sclerosis during the COVID-19 pandemic: Assessing the expert recommendations.
Topics: Adult; Alemtuzumab; Antibodies, Monoclonal, Humanized; Betacoronavirus; Chile; Coronavirus Infections; COVID-19; Decision Making; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Guideline Adherence; Guidelines as Topic; Health Behavior; Humans; Immunologic Factors; Interferons; Lymphocyte Count; Male; Middle Aged; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Pandemics; Pneumonia, Viral; Quarantine; SARS-CoV-2; World Health Organization; Young Adult | 2020 |
Siponimod (Mayzent) Downregulates RhoA and Cell Surface Expression of the S1P1 and CX3CR1 Receptors in Mouse RAW 264.7 Macrophages.
Topics: Actin Cytoskeleton; Animals; Azetidines; Benzyl Compounds; Cell Membrane; Chemokine CCL2; Down-Regulation; Fingolimod Hydrochloride; Graft Rejection; Humans; Lysophospholipids; Macrophages; Membrane Proteins; Mice; Multiple Sclerosis; Organ Transplantation; Phosphoric Monoester Hydrolases; RAW 264.7 Cells; Receptors, Interleukin-8A; rhoA GTP-Binding Protein; Signal Transduction; Sphingosine; United States; United States Food and Drug Administration | 2020 |
COVID-19 will change MS care forever - No.
Topics: Alemtuzumab; Antibodies, Monoclonal, Humanized; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Vaccines; Dimethyl Fumarate; Disease Management; Drug Substitution; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunologic Factors; Interferon-beta; Multiple Sclerosis; Pandemics; Pneumonia, Viral; Rituximab; SARS-CoV-2; Telemedicine; Viral Vaccines | 2020 |
Two susceptible HLA-DRB1 alleles for multiple sclerosis differentially regulate anti-JC virus antibody serostatus along with fingolimod.
Topics: Adult; Aged; Alleles; Biomarkers; Female; Fingolimod Hydrochloride; Genetic Predisposition to Disease; HLA-DRB1 Chains; Humans; Immunosuppressive Agents; JC Virus; Male; Middle Aged; Multiple Sclerosis | 2020 |
Seroconversion and indolent course of COVID-19 in patients with multiple sclerosis treated with fingolimod and teriflunomide.
Topics: Adult; COVID-19; Crotonates; Disease Progression; Female; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Immunosuppressive Agents; Middle Aged; Multiple Sclerosis; Nitriles; SARS-CoV-2; Seroconversion; Toluidines | 2020 |
Tumefactive multiple sclerosis in association with fingolimod initiation and discontinuation.
Topics: Cognition; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Recurrence | 2021 |
Real-world evidence on the safety and effectiveness of fingolimod in patients with multiple sclerosis from Taiwan.
Topics: Adult; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Middle Aged; Multiple Sclerosis; Neoplasm Recurrence, Local; Retrospective Studies; Taiwan | 2021 |
Asymptomatic SARS-CoV-2 infection in two patients with multiple sclerosis treated with fingolimod.
Topics: Adult; Asymptomatic Diseases; Betacoronavirus; Coronavirus Infections; COVID-19; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Middle Aged; Multiple Sclerosis; Pandemics; Pneumonia, Viral; SARS-CoV-2; Treatment Outcome | 2020 |
Multiple sclerosis and related disorders: Short report peripheral vascular events in a real-world cohort of multiple sclerosis patients using Fingolimod.
Topics: Cohort Studies; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Prospective Studies | 2020 |
Differential effects of disease modifying drugs on peripheral blood B cell subsets: A cross sectional study in multiple sclerosis patients treated with interferon-β, glatiramer acetate, dimethyl fumarate, fingolimod or natalizumab.
Topics: Adult; Aged; Aged, 80 and over; Antigens, CD; Antigens, CD19; B-Lymphocyte Subsets; B-Lymphocytes; Cross-Sectional Studies; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Flow Cytometry; Glatiramer Acetate; Humans; Immunologic Memory; Immunophenotyping; Immunosuppressive Agents; Interferon-beta; Male; Middle Aged; Multiple Sclerosis; Natalizumab; Young Adult | 2020 |
Long-term outcome in multiple sclerosis patients treated with fingolimod.
Topics: Adult; Female; Fingolimod Hydrochloride; Humans; Longitudinal Studies; Male; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Treatment Outcome | 2020 |
Lipid Profile Alterations during Fingolimod Treatment in Multiple Sclerosis Patients.
Topics: Adult; Cholesterol; Cholesterol, HDL; Female; Fingolimod Hydrochloride; Follow-Up Studies; Humans; Immunosuppressive Agents; Lipids; Male; Middle Aged; Multiple Sclerosis; Retrospective Studies; Sphingosine 1 Phosphate Receptor Modulators; Treatment Outcome | 2020 |
The multiple sclerosis (MS) drugs as a potential treatment of ARDS in COVID-19 patients.
Topics: Azetidines; Benzyl Compounds; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Enzyme Inhibitors; Fingolimod Hydrochloride; Humans; Multiple Sclerosis; Pandemics; Pneumonia, Viral; Respiratory Distress Syndrome; rhoA GTP-Binding Protein; SARS-CoV-2 | 2020 |
Lymphocyte recovery after fingolimod discontinuation in patients with MS.
Topics: Adult; Female; Fingolimod Hydrochloride; Follow-Up Studies; Humans; Immune Reconstitution; Immunosuppressive Agents; Lymphocyte Count; Lymphopenia; Male; Middle Aged; Multiple Sclerosis | 2020 |
Branch retinal vein occlusion associated with fingolimod treatment for multiple sclerosis.
Topics: Fingolimod Hydrochloride; Fluorescein Angiography; Humans; Multiple Sclerosis; Retinal Vein; Retinal Vein Occlusion | 2021 |
Reasons for switching to fingolimod in patients relapsing-remitting multiple sclerosis in France: the ESGILE study.
Topics: Fingolimod Hydrochloride; France; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting | 2020 |
A case report with tuberculous meningitis during fingolimod treatment.
Topics: Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Interferon beta-1b; Multiple Sclerosis; Tuberculosis, Meningeal | 2020 |
Morpholino Analogues of Fingolimod as Novel and Selective S1P
Topics: Animals; Central Nervous System; CHO Cells; Cricetulus; Disease Models, Animal; Encephalomyelitis; Encephalomyelitis, Autoimmune, Experimental; Fingolimod Hydrochloride; Immunosuppressive Agents; Ligands; Lymphopenia; Lysophospholipids; Mice; Morpholinos; Multiple Sclerosis; Receptors, Lysosphingolipid; Sphingosine; Sphingosine-1-Phosphate Receptors; Spinal Cord; T-Lymphocytes | 2020 |
Impact of coronavirus disease (COVID-19) pandemic on multiple sclerosis care.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Alemtuzumab; Antibodies, Monoclonal, Humanized; Betacoronavirus; Child; Coronavirus Infections; COVID-19; Crotonates; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Immunologic Factors; Interferon-beta; Kuwait; Male; Middle Aged; Multiple Sclerosis; Natalizumab; Nitriles; Pandemics; Pneumonia, Viral; Recurrence; Rituximab; SARS-CoV-2; Surveys and Questionnaires; Telephone; Toluidines; Young Adult | 2020 |
Changes in structural and functional connectivity during two years of fingolimod therapy for multiple sclerosis.
Topics: Adult; Brain; Diffusion Tensor Imaging; Disease Progression; Female; Fingolimod Hydrochloride; Humans; Male; Middle Aged; Multiple Sclerosis | 2020 |
Cryptococcal meningoencephalitis in a multiple sclerosis patient after fingolimod discontinuation-a case report.
Topics: Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Meningoencephalitis; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting | 2021 |
Comparative analysis of dimethyl fumarate and fingolimod in relapsing-remitting multiple sclerosis.
Topics: Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting | 2021 |
Early evidence of disease activity during fingolimod predicts medium-term inefficacy in relapsing-remitting multiple sclerosis.
Topics: Cohort Studies; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab | 2021 |
The transitional phase of multiple sclerosis: The concept of PANGAEA 2.0 evolution study.
Topics: Fingolimod Hydrochloride; Humans; Multiple Sclerosis | 2020 |
REALMS study: real-world effectiveness and safety of fingolimod in patients with relapsing-remitting multiple sclerosis in Portugal.
Topics: Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Portugal; Retrospective Studies; Treatment Outcome | 2021 |
Selective modulation of trans-endothelial migration of lymphocyte subsets in multiple sclerosis patients under fingolimod treatment.
Topics: Cell Movement; Cells, Cultured; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Lymphocyte Subsets; Male; Multiple Sclerosis; Transendothelial and Transepithelial Migration; Treatment Outcome | 2020 |
Discordant disability data in multiple sclerosis phase 3 studies among sphingosine-1- receptor modulator drugs.
Topics: Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Pharmaceutical Preparations; Sphingosine | 2020 |
Effect of Fingolimod and Interferon β-1α in Children With Multiple Sclerosis.
Topics: Child; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Interferon beta-1a; Interferon-beta; Multiple Sclerosis | 2020 |
Two-year macular volume assessment in multiple sclerosis patients treated with fingolimod.
Topics: Fingolimod Hydrochloride; Humans; Macular Edema; Multiple Sclerosis; Tomography, Optical Coherence; Visual Acuity | 2021 |
Cost-effectiveness of fingolimod versus interferon-β1a for the treatment of pediatric-onset multiple sclerosis in Canada.
Topics: Canada; Child; Cost-Benefit Analysis; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Interferon beta-1a; Interferons; Markov Chains; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Quality of Life; Quality-Adjusted Life Years | 2020 |
BEST-MS: A prospective head-to-head comparative study of natalizumab and fingolimod in active relapsing MS.
Topics: Fingolimod Hydrochloride; Humans; Multiple Sclerosis; Natalizumab; Neoplasm Recurrence, Local; Prospective Studies | 2021 |
Fingolimod (FTY720) prevents chronic rejection of rodent cardiac allografts through inhibition of the RhoA pathway.
Topics: Allografts; Animals; Fingolimod Hydrochloride; Graft vs Host Disease; Immunosuppressive Agents; Mice; Multiple Sclerosis; Propylene Glycols; Rats; Rodentia; Sphingosine | 2021 |
Occurrence and microstructural features of slowly expanding lesions on fingolimod or natalizumab treatment in multiple sclerosis.
Topics: Fingolimod Hydrochloride; Humans; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Treatment Outcome | 2021 |
Fingolimod-induced remission in a patient with ulcerative colitis and multiple sclerosis.
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal; Colitis, Ulcerative; Drug Therapy, Combination; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; JC Virus; Leukapheresis; Leukoencephalopathy, Progressive Multifocal; Methylprednisolone; Middle Aged; Multiple Sclerosis; Remission Induction; Sphingosine-1-Phosphate Receptors; Tumor Necrosis Factor-alpha; Virus Activation | 2021 |
Olfactory Dysfunction in Patients With Relapsing-Remitting Multiple Sclerosis Treated With Disease-Modifying Therapies.
Topics: Anosmia; Dimethyl Fumarate; Fatigue; Fingolimod Hydrochloride; Humans; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Recurrence | 2022 |
Differential Effects of Fingolimod and Natalizumab on B Cell Repertoires in Multiple Sclerosis Patients.
Topics: Adolescent; Adult; Aged; B-Lymphocytes; Cell Lineage; Fingolimod Hydrochloride; Gene Expression Profiling; High-Throughput Nucleotide Sequencing; Humans; Memory B Cells; Middle Aged; Multiple Sclerosis; Natalizumab; Tumor Necrosis Factor Receptor Superfamily, Member 7; Young Adult | 2021 |
Measures of Thalamic Integrity are Associated with Cognitive Functioning in Fingolimod-treated Multiple Sclerosis Patients.
Topics: Cognition; Cognitive Dysfunction; Fingolimod Hydrochloride; Humans; Magnetic Resonance Imaging; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Neuropsychological Tests; Thalamus | 2021 |
Usage trend of oral drugs for multiple sclerosis patients in Argentina.
Topics: Argentina; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Pharmaceutical Preparations; Retrospective Studies | 2021 |
Intense Hypermetabolic Tumefactive Demyelination on 18F-FDG PET and MRI Related to Multiple Sclerosis Relapse After Fingolimod Suspension.
Topics: Biopsy; Female; Fingolimod Hydrochloride; Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Middle Aged; Multimodal Imaging; Multiple Sclerosis; Myelin Sheath; Positron-Emission Tomography; Recurrence; Withholding Treatment | 2021 |
[A patient with relapsing-remitting multiple sclerosis who relapsed frequently and developed primary biliary cholangitis after pregnancy and discontinuation of fingolimod].
Topics: Adult; Autoantibodies; Biomarkers; Diagnosis, Differential; Female; Fingolimod Hydrochloride; Humans; Liver Cirrhosis, Biliary; Magnetic Resonance Imaging; Mitochondria; Multiple Sclerosis; Pregnancy; Pregnancy Complications; Recurrence; Withholding Treatment | 2021 |
Short-term laboratory and related safety outcomes for the multiple sclerosis oral disease-modifying therapies: an observational study.
Topics: Administration, Oral; Adult; Crotonates; Databases, Factual; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Follow-Up Studies; Humans; Hydroxybutyrates; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis; Nitriles; Prospective Studies; Toluidines | 2021 |
Fingolimod treatment reverses signs of diffuse white matter damage in multiple sclerosis: A pilot study.
Topics: Brain; Diffusion Tensor Imaging; Fingolimod Hydrochloride; Humans; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Pilot Projects; White Matter | 2021 |
Tumefactive multiple sclerosis (TMS): A case series of this challenging variant of MS.
Topics: Adult; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Male; Middle Aged; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Retrospective Studies; Young Adult | 2021 |
Immune phenotyping study revealing caveats regarding a switch from fingolimod to cladribine.
Topics: Cladribine; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting | 2021 |
Two-year follow-up during fingolimod treatment in a pediatric multiple sclerosis patient still active on first-line treatment.
Topics: Adolescent; Child; Fingolimod Hydrochloride; Follow-Up Studies; Humans; Immunosuppressive Agents; Interferon beta-1a; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Prospective Studies; Retrospective Studies | 2021 |
Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; COVID-19; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Hospitalization; Humans; Immunologic Factors; Immunosuppressive Agents; Intensive Care Units; Interferons; Male; Middle Aged; Mortality; Multiple Sclerosis; Natalizumab; SARS-CoV-2; Severity of Illness Index; Young Adult | 2021 |
Fingolimod in pediatric multiple sclerosis: three case reports.
Topics: Adolescent; Child; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab | 2021 |
Primary mediastinal large B-cell lymphoma in a patient on Fingolimod for relapsing-remitting multiple sclerosis.
Topics: Adult; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Lymphoma, B-Cell; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting | 2021 |
Disease modifying therapies for relapsing-remitting multiple sclerosis: Use and costs in Australia (1996-2019).
Topics: Aged; Australia; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; National Health Programs; Tasmania | 2021 |
Safety of disease-modifying treatments in SARS-CoV-2 antibody-positive multiple sclerosis patients.
Topics: Adult; Antibodies, Viral; Asymptomatic Infections; COVID-19; Female; Fingolimod Hydrochloride; Humans; Male; Middle Aged; Multiple Sclerosis; Natalizumab; RNA, Viral; SARS-CoV-2; Seroepidemiologic Studies | 2021 |
COVID-19 in multiple sclerosis patients treated with dimethyl fumarate.
Topics: COVID-19; Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; SARS-CoV-2 | 2021 |
Human papillomavirus lesions in 16 MS patients treated with fingolimod: Outcomes and vaccination.
Topics: Alphapapillomavirus; Female; Fingolimod Hydrochloride; Humans; Male; Multiple Sclerosis; Papillomaviridae; Vaccination | 2021 |
Asymptomatic bradycardia after first fingolimod dose in a pediatric patient with multiple sclerosis - a case report.
Topics: Adolescent; Bradycardia; Child; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting | 2021 |
Hepatitis C during disease modifying therapy with Fingolimod for Relapsing Remitting Multiple Sclerosis: diagnosis and treatment.
Topics: Female; Fingolimod Hydrochloride; Hepatitis C; Humans; Immunosuppressive Agents; Middle Aged; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting | 2021 |
Comparative treatment effectiveness of oral fingolimod and conventional injectable disease-modifying agents in multiple sclerosis.
Topics: Administration, Oral; Adult; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Injections; Longitudinal Studies; Multiple Sclerosis; Retrospective Studies; Treatment Outcome | 2021 |
Long-term comparative analysis of no evidence of disease activity (NEDA-3) status between multiple sclerosis patients treated with natalizumab and fingolimod for up to 4 years.
Topics: Fingolimod Hydrochloride; Humans; Immunologic Factors; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Treatment Outcome | 2021 |
Fingolimod as first-line treatment in pediatric-onset multiple sclerosis: a case report.
Topics: Adolescent; Child; Disease Progression; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Treatment Outcome | 2021 |
Efficacy of fingolimod after switching from interferon β-1a in an adolescent with multiple sclerosis: case report.
Topics: Adolescent; Adult; Child; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunosuppressive Agents; Interferon beta-1a; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting | 2021 |
COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alemtuzumab; Azathioprine; Black or African American; Cladribine; Comorbidity; COVID-19; Crotonates; Cyclophosphamide; Cyclosporine; Databases, Factual; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Hospitalization; Humans; Hydroxybutyrates; Immunologic Factors; Immunosuppressive Agents; Incidence; Interferon-beta; Logistic Models; Lupus Erythematosus, Systemic; Male; Methotrexate; Middle Aged; Mitoxantrone; Multiple Sclerosis; Mycophenolic Acid; Natalizumab; Nitriles; Obesity; Risk Factors; Rituximab; SARS-CoV-2; Toluidines; United States; White People; Young Adult | 2021 |
Long-term fingolimod treatment in two pediatric patients with multiple sclerosis.
Topics: Child; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Interferon beta-1a; Male; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Treatment Outcome | 2021 |
Impact of COVID-19 on multiple sclerosis care and management: Results from the European Committee for Treatment and Research in Multiple Sclerosis survey.
Topics: COVID-19; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; SARS-CoV-2 | 2022 |
Long-Term Effectiveness of Fingolimod for Multiple Sclerosis in a Real-World Clinical Setting.
Topics: Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Quality of Life | 2021 |
Multiple sclerosis hospitalizations among users of oral disease-modifying therapies.
Topics: Aged; Crotonates; Dimethyl Fumarate; Fingolimod Hydrochloride; Hospitalization; Humans; Immunosuppressive Agents; Middle Aged; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Retrospective Studies; Toluidines; United States | 2021 |
Fingolimod as an effective therapeutic strategy for pediatric relapsing-remitting multiple sclerosis: two case reports.
Topics: Adult; Child; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Italy; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; United States | 2021 |
The outcome of a national MS-Covid-19 study: What the Turkish MS cohort reveals?
Topics: Adult; Cohort Studies; COVID-19; Female; Fingolimod Hydrochloride; Humans; Multiple Sclerosis; SARS-CoV-2 | 2021 |
Fingolimod in pediatric-onset multiple sclerosis.
Topics: Child; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting | 2021 |
Multiple sclerosis-like NMOSD patients suffer severe worsening of status after fingolimod initiation.
Topics: Aquaporin 4; Autoantibodies; Fingolimod Hydrochloride; France; Humans; Multiple Sclerosis; Neuromyelitis Optica | 2021 |
Challenges of switching towards anti-CD20 monoclonal antibodies in RR-MS: A monocentric study.
Topics: Adult; Antibodies, Monoclonal; Fingolimod Hydrochloride; Humans; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Retrospective Studies; Rituximab | 2021 |
Assessment of Macular Function by Multifocal Electroretinogram in Patients with Multiple Sclerosis Treated with Fingolimod.
Topics: Adult; Electroretinography; Fingolimod Hydrochloride; Humans; Middle Aged; Multiple Sclerosis; Retina; Retrospective Studies | 2021 |
Treatment-Induced BAFF Expression and B Cell Biology in Multiple Sclerosis.
Topics: Adult; Aged; B-Cell Activating Factor; B-Cell Activation Factor Receptor; B-Lymphocyte Subsets; Cells, Cultured; Cross-Sectional Studies; Female; Fingolimod Hydrochloride; Follow-Up Studies; Humans; Immunosuppressive Agents; Interferon-beta; Interleukin-10; Interleukins; Male; Middle Aged; Multiple Sclerosis; Precursor Cells, B-Lymphoid; RNA, Messenger; Signal Transduction; Transmembrane Activator and CAML Interactor Protein; Treatment Outcome | 2021 |
Potential risk of disease modifying therapies on neoplasm development and coadjutant factors in multiple sclerosis outpatients.
Topics: Adult; Aged; Alemtuzumab; Crotonates; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Hydroxybutyrates; Immunosuppressive Agents; Interferon-beta; Male; Middle Aged; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Neoplasms; Nitriles; Outpatients; Proportional Hazards Models; Risk Factors; Smoking; Spain; Toluidines | 2021 |
What happens after fingolimod discontinuation? A multicentre real-life experience.
Topics: Adult; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting | 2022 |
Fingolimod-related cryptococcal meningoencephalitis and immune reconstitution inflammatory syndrome in a patient with multiple sclerosis.
Topics: Fingolimod Hydrochloride; Humans; Immune Reconstitution Inflammatory Syndrome; Immunosuppressive Agents; Meningitis, Cryptococcal; Meningoencephalitis; Multiple Sclerosis | 2021 |
How to switch disease-modifying treatments in multiple sclerosis: Guidelines from the French Multiple Sclerosis Society (SFSEP).
Topics: Alemtuzumab; Cladribine; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab | 2021 |
Serological response to SARS-CoV-2 vaccination in multiple sclerosis patients treated with fingolimod or ocrelizumab: an initial real-life experience.
Topics: Antibodies, Monoclonal, Humanized; Antibodies, Viral; COVID-19; COVID-19 Vaccines; Fingolimod Hydrochloride; Humans; Immunity, Humoral; Italy; Multiple Sclerosis; Retrospective Studies; Vaccination | 2022 |
Five-year real-world data on fingolimod treatment's effects on cognitive function.
Topics: Cognition; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting | 2021 |
Fingolimod significantly reduces MRI activity in paediatric-onset multiple sclerosis (MS).
Topics: Child; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Multiple Sclerosis; Treatment Outcome | 2023 |
CKD-506: A novel HDAC6-selective inhibitor that exerts therapeutic effects in a rodent model of multiple sclerosis.
Topics: Animals; Antidepressive Agents; Blood-Brain Barrier; Cell Proliferation; Cytokines; Disease Models, Animal; Dose-Response Relationship, Drug; Encephalomyelitis, Autoimmune, Experimental; Female; Fingolimod Hydrochloride; Histone Deacetylase 6; Histone Deacetylase Inhibitors; Macrophages; Mice, Inbred C57BL; Multiple Sclerosis; Myelin-Oligodendrocyte Glycoprotein; Spinal Cord; T-Lymphocytes | 2021 |
Risk of depression in multiple sclerosis across disease-modifying therapies.
Topics: Depression; Fingolimod Hydrochloride; Humans; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Prospective Studies; Recurrence | 2022 |
Risk of multiple sclerosis relapses when switching from fingolimod to cell-depleting agents: the role of washout duration.
Topics: Adult; Alemtuzumab; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Middle Aged; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Recurrence | 2022 |
CXCL13 Levels Indicate Treatment Responsiveness to Fingolimod in MS Patients.
Topics: Chemokine CXCL13; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis | 2022 |
Therapeutic inertia in relapsing-remitting multiple sclerosis.
Topics: Adult; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Male; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Pregnancy | 2021 |
Indirect comparisons of siponimod with fingolimod and ofatumumab in multiple sclerosis: assessing the feasibility of propensity score matching analyses.
Topics: Antibodies, Monoclonal, Humanized; Azetidines; Benzyl Compounds; Clinical Trials, Phase III as Topic; Disease Progression; Feasibility Studies; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Propensity Score | 2021 |
Baseline characteristics and effects of fingolimod on cognitive performance in patients with relapsing-remitting multiple sclerosis.
Topics: Cognition; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting | 2021 |
Evaluation of the Effect of Fingolimod Treatment on Microglial Activation Using Serial PET Imaging in Multiple Sclerosis.
Topics: Adolescent; Adult; Aged; Carbon Radioisotopes; Female; Fingolimod Hydrochloride; Humans; Isoquinolines; Male; Microglia; Middle Aged; Multiple Sclerosis; Positron-Emission Tomography; White Matter; Young Adult | 2017 |
Evaluation and Optimization of
Topics: Algorithms; Animals; Crystallography, X-Ray; Drug Design; Fingolimod Hydrochloride; Humans; Immunologic Factors; Lysophospholipids; Molecular Structure; Multiple Sclerosis; Protein Structure, Secondary; Receptors, Lysosphingolipid; Sphingosine | 2017 |
Effect of Preventive and Curative Fingolimod Treatment Regimens on Microglia Activation and Disease Progression in a Rat Model of Multiple Sclerosis.
Topics: Animals; Disease Progression; Encephalomyelitis, Autoimmune, Experimental; Female; Fingolimod Hydrochloride; Immunosuppressive Agents; Microglia; Multiple Sclerosis; Rats | 2017 |
Sphingosine Toxicity in EAE and MS: Evidence for Ceramide Generation via Serine-Palmitoyltransferase Activation.
Topics: Animals; Ceramides; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Fingolimod Hydrochloride; Humans; Multiple Sclerosis; Myelin Sheath; Oligodendroglia; Rats; Serine C-Palmitoyltransferase; Sphingosine; Spinal Cord | 2017 |
Two studies in one: A propensity-score-matched comparison of fingolimod versus interferons and glatiramer acetate using real-world data from the independent German studies, PANGAEA and PEARL.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cohort Studies; Disease Progression; Female; Fingolimod Hydrochloride; Germany; Glatiramer Acetate; Humans; Interferons; Male; Middle Aged; Multiple Sclerosis; Young Adult | 2017 |
Effect of fingolimod (FTY720) on choroidal thickness in patients with multiple sclerosis.
Topics: Adolescent; Adult; Case-Control Studies; Choroid; Female; Fingolimod Hydrochloride; Humans; Immunologic Factors; Immunosuppressive Agents; Interferon-beta; Male; Multiple Sclerosis; Organ Size; Retrospective Studies; Tomography, Optical Coherence; Young Adult | 2017 |
Plasma neurofilament light chain levels in patients with MS switching from injectable therapies to fingolimod.
Topics: Adult; Biomarkers; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis; Neurofilament Proteins; Young Adult | 2018 |
Disease reactivation following fingolimod withdrawal in multiple sclerosis: Two case reports.
Topics: Adult; Brain; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Middle Aged; Multiple Sclerosis; Recurrence | 2017 |
The 'Field Hypothesis': rebound activity after stopping disease-modifying therapies.
Topics: Animals; Fingolimod Hydrochloride; Humans; Immunologic Factors; Multiple Sclerosis; Recurrence | 2017 |
Cryptococcal meningitis causing obstructive hydrocephalus in a patient on fingolimod.
Topics: Diagnosis, Differential; Female; Fingolimod Hydrochloride; Humans; Hydrocephalus; Immunosuppressive Agents; Meningitis, Cryptococcal; Middle Aged; Multiple Sclerosis; Treatment Outcome; Ventriculoperitoneal Shunt | 2017 |
Re-emergence of a tumefactive demyelinating lesion after initiation of fingolimod therapy.
Topics: Demyelinating Diseases; Female; Fingolimod Hydrochloride; Humans; Magnetic Resonance Imaging; Middle Aged; Multiple Sclerosis; Neuroimaging | 2017 |
Sphingomimetic multiple sclerosis drug FTY720 activates vesicular synaptobrevin and augments neuroendocrine secretion.
Topics: Animals; Cytosol; Excitatory Postsynaptic Potentials; Exocytosis; Fingolimod Hydrochloride; Glutamic Acid; Hippocampus; Male; Multiple Sclerosis; Neurons; Neurosecretory Systems; R-SNARE Proteins; Rats, Wistar; SNARE Proteins; Sphingosine; Synaptic Vesicles; Synaptosomes | 2017 |
Real-World Adherence and Persistence to Oral Disease-Modifying Therapies in Multiple Sclerosis Patients Over 1 Year.
Topics: Adolescent; Crotonates; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Immunosuppressive Agents; Male; Medicare; Medication Adherence; Multiple Sclerosis; Nitriles; Retrospective Studies; Toluidines; United States | 2017 |
Intermittent drug holidays in fingolimod therapy for multiple sclerosis.
Topics: Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting | 2018 |
Reconstitution of the peripheral immune repertoire following withdrawal of fingolimod.
Topics: Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis | 2017 |
Reconstitution of the peripheral immune repertoire following withdrawal of fingolimod.
Topics: Adult; Aged; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Female; Fingolimod Hydrochloride; Follow-Up Studies; Humans; Immunosuppressive Agents; Lymphocyte Count; Lymphopenia; Male; Middle Aged; Multiple Sclerosis | 2017 |
Five cases of malignant melanoma during fingolimod treatment in Dutch patients with MS.
Topics: Adult; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Melanoma; Middle Aged; Multiple Sclerosis; Netherlands; Young Adult | 2017 |
Persistence to oral disease-modifying therapies in multiple sclerosis patients.
Topics: Adult; Crotonates; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Follow-Up Studies; Humans; Hydroxybutyrates; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis; Nitriles; Retrospective Studies; Statistics, Nonparametric; Toluidines; Treatment Outcome | 2017 |
Adherence, persistence, and discontinuation among Hispanic and African American patients with multiple sclerosis treated with fingolimod or glatiramer acetate.
Topics: Adult; Black or African American; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Hispanic or Latino; Humans; Immunosuppressive Agents; Male; Medication Adherence; Middle Aged; Multiple Sclerosis; Retrospective Studies | 2018 |
Immune thrombocytopenic purpura associated with fingolimod.
Topics: Blood Platelets; Disease Management; Female; Fingolimod Hydrochloride; Glucocorticoids; Humans; Immunologic Factors; Immunosuppressive Agents; Middle Aged; Multiple Sclerosis; Natalizumab; Prednisolone; Purpura, Thrombocytopenic, Idiopathic; Receptors, Fc; Receptors, Lysosphingolipid; Recombinant Fusion Proteins; Thrombopoietin; Treatment Outcome; Young Adult | 2017 |
Therapy of highly active pediatric multiple sclerosis.
Topics: Adolescent; Child; Disease Progression; Female; Fingolimod Hydrochloride; Follow-Up Studies; Humans; Immunologic Factors; Magnetic Resonance Imaging; Male; Multiple Sclerosis; Natalizumab; Outcome Assessment, Health Care; Recurrence; Retrospective Studies; Severity of Illness Index | 2019 |
Multiple sclerosis treatment effects on plasma cytokine receptor levels.
Topics: Adolescent; Adult; Cytokine Receptor gp130; Female; Fingolimod Hydrochloride; Genetic Variation; Humans; Immunologic Factors; Immunosuppressive Agents; Interleukin-2 Receptor alpha Subunit; Interleukin-7 Receptor alpha Subunit; Male; Middle Aged; Multiple Sclerosis; Natalizumab; Pharmacogenomic Testing; Polymorphism, Single Nucleotide; Young Adult | 2018 |
S1P
Topics: Animals; Autoimmunity; Case-Control Studies; Disease Susceptibility; Encephalomyelitis, Autoimmune, Experimental; Fingolimod Hydrochloride; Gene Deletion; Humans; Inflammation; Lymphadenopathy; Lymphoid Tissue; Mice; Mice, Inbred C57BL; Multiple Sclerosis; Organ Specificity; Phenotype; Receptors, Lysosphingolipid; T-Lymphocytes, Regulatory; Th17 Cells; Transcription, Genetic | 2017 |
Merkel cell carcinoma with fingolimod treatment for multiple sclerosis: A case report.
Topics: Carcinoma, Merkel Cell; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Merkel cell polyomavirus; Middle Aged; Multiple Sclerosis; Polyomavirus Infections; Skin Neoplasms | 2017 |
Fingolimod induces BAFF and expands circulating transitional B cells without activating memory B cells and plasma cells in multiple sclerosis.
Topics: Adult; B-Cell Activating Factor; B-Cell Maturation Antigen; B-Lymphocytes; Case-Control Studies; Cross-Sectional Studies; Female; Fingolimod Hydrochloride; Humans; Immunologic Memory; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis; Plasma Cells; Precursor Cells, B-Lymphoid; Transmembrane Activator and CAML Interactor Protein; Young Adult | 2018 |
Assessing the cerebral gray matter volume in response to fingolimod therapy in multiple sclerosis: A more analytic view.
Topics: Cerebral Cortex; Fingolimod Hydrochloride; Gray Matter; Humans; Multiple Sclerosis | 2017 |
Remyelination modulators in multiple sclerosis patients.
Topics: Adult; Biomarkers; Brain-Derived Neurotrophic Factor; Demyelinating Diseases; Female; Fingolimod Hydrochloride; Humans; Insulin-Like Growth Factor Binding Protein 1; Lipocalin-2; Male; Middle Aged; Multiple Sclerosis; Natalizumab; Neurofilament Proteins; Remyelination; Sex Characteristics | 2017 |
Central Serous Chorioretinopathy Associated With Fingolimod Treatment.
Topics: Administration, Oral; Adult; Central Serous Chorioretinopathy; Choroid; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Multiple Sclerosis; Retina; Tomography, Optical Coherence; Visual Acuity | 2018 |
Fingolimod reduces neuropathic pain behaviors in a mouse model of multiple sclerosis by a sphingosine-1 phosphate receptor 1-dependent inhibition of central sensitization in the dorsal horn.
Topics: Anilides; Animals; Central Nervous System Sensitization; Disease Models, Animal; eIF-2 Kinase; Female; Fingolimod Hydrochloride; Immunosuppressive Agents; Male; Mice; Mice, Inbred C57BL; Motor Activity; Multiple Sclerosis; Myelin-Oligodendrocyte Glycoprotein; Neuralgia; Organophosphonates; Oxadiazoles; Pain Threshold; Peptide Fragments; Receptors, Lysosphingolipid; Sphingosine-1-Phosphate Receptors; Spinal Cord; Spinal Nerve Roots; Subcellular Fractions; Thiophenes | 2018 |
Cerebral toxoplasmosis in an MS patient receiving Fingolimod.
Topics: Adult; Brain; CD4 Lymphocyte Count; Diagnosis, Differential; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Toxoplasmosis, Cerebral | 2017 |
A two-year study using cerebral gray matter volume to assess the response to fingolimod therapy in multiple sclerosis.
Topics: Adult; Atrophy; Brain; Disability Evaluation; Female; Fingolimod Hydrochloride; Gray Matter; Humans; Linear Models; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Organ Size; Retrospective Studies; Time Factors; Treatment Outcome; Young Adult | 2017 |
Disease-modifying treatments modulate myeloid cells in multiple sclerosis patients.
Topics: Adult; Case-Control Studies; Cell Polarity; Cohort Studies; Extracellular Vesicles; Female; Fingolimod Hydrochloride; Humans; Immunologic Factors; Interferon beta-1a; Interleukin-1beta; Male; Membrane Glycoproteins; Middle Aged; Multiple Sclerosis; Myeloid Cells; Natalizumab; Receptors, Immunologic; Superoxide Dismutase; Time Factors | 2018 |
A Case of cutaneous large B-cell lymphoma during treatment of multiple sclerosis with fingolimod.
Topics: Aged; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Lymphoma, B-Cell; Multiple Sclerosis; Skin Neoplasms | 2018 |
Cutaneous anaplastic large cell lymphoma in a multiple sclerosis patient receiving Fingolimod.
Topics: Adult; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Lymphoma, Large-Cell, Anaplastic; Multiple Sclerosis | 2018 |
Fingolimod anti-inflammatory and neuroprotective effects modulation of RAGE axis in multiple sclerosis patients.
Topics: Adult; Anti-Inflammatory Agents; Antigens, Neoplasm; Arginine; Female; Fingolimod Hydrochloride; HMGB1 Protein; Humans; Lysine; Male; Middle Aged; Mitogen-Activated Protein Kinases; Multiple Sclerosis; Neuroprotective Agents; Receptor for Advanced Glycation End Products; Young Adult | 2018 |
Antibody response to seasonal influenza vaccination in patients with multiple sclerosis receiving immunomodulatory therapy.
Topics: Adult; Antibodies, Viral; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunogenicity, Vaccine; Immunologic Factors; Influenza Vaccines; Interferon beta-1b; Male; Middle Aged; Multiple Sclerosis; Natalizumab; Seasons | 2018 |
Factors Predictive of Severe Multiple Sclerosis Disease Reactivation After Fingolimod Cessation.
Topics: Adult; Brain; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Multiple Sclerosis; Prognosis; Recurrence; Severity of Illness Index; Young Adult | 2018 |
Clinical and Demographic Profile of Patients Receiving Fingolimod in Clinical Practice in Germany and the Benefit-Risk Profile of Fingolimod After 1 Year of Treatment: Initial Results From the Observational, Noninterventional Study PANGAEA.
Topics: Adult; Demography; Female; Fingolimod Hydrochloride; Germany; Humans; Immunosuppressive Agents; Male; Multiple Sclerosis; Observational Studies as Topic; Prospective Studies; Recurrence; Risk Assessment; Treatment Outcome | 2018 |
Predictors of hematological abnormalities in multiple sclerosis patients treated with fingolimod and dimethyl fumarate and impact of treatment switch on lymphocyte and leukocyte count.
Topics: Adult; Dimethyl Fumarate; Drug Substitution; Female; Fingolimod Hydrochloride; Follow-Up Studies; Humans; Immunosuppressive Agents; Leukocyte Count; Leukopenia; Lymphocyte Count; Lymphopenia; Male; Middle Aged; Multiple Sclerosis; Prognosis; Prospective Studies; Retrospective Studies | 2018 |
Transcriptome profiling of peripheral blood immune cell populations in multiple sclerosis patients before and during treatment with a sphingosine-1-phosphate receptor modulator.
Topics: Administration, Oral; Adult; Fingolimod Hydrochloride; Gene Expression Profiling; Humans; Immunosuppressive Agents; Lymphocytes; Middle Aged; Multiple Sclerosis; Receptors, Lysosphingolipid | 2018 |
Effectiveness and baseline factors associated to fingolimod response in a real-world study on multiple sclerosis patients.
Topics: Adult; Antibodies, Monoclonal, Humanized; Brain; Cohort Studies; Disability Evaluation; Female; Fingolimod Hydrochloride; Gadolinium; Humans; Immunosuppressive Agents; Italy; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis; Natalizumab; Time Factors; Treatment Outcome | 2018 |
Cardiac repolarization during fingolimod treatment in patients with relapsing-remitting multiple sclerosis.
Topics: Adult; Electrocardiography, Ambulatory; Female; Fingolimod Hydrochloride; Heart; Heart Rate; Humans; Immunosuppressive Agents; Male; Multiple Sclerosis | 2018 |
Serum anti-JCV antibody indexes in Japanese patients with multiple sclerosis: elevations along with fingolimod treatment duration.
Topics: Adult; Age Factors; Antibodies, Viral; Dimethyl Fumarate; Disability Evaluation; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunologic Factors; Interferon-beta; Japan; JC Virus; Longitudinal Studies; Male; Multiple Sclerosis; Retrospective Studies; Sex Factors; Time Factors | 2018 |
The value of including thalamic atrophy as a clinical trial endpoint in multiple sclerosis.
Topics: Atrophy; Fingolimod Hydrochloride; Gray Matter; Humans; Multiple Sclerosis; Thalamus; White Matter | 2018 |
Letter to the editor to the paper: "Acute and long-term effects of fingolimod on heart rhythm and heart rate variability in patients with multiple sclerosis".
Topics: Electrocardiography, Ambulatory; Fingolimod Hydrochloride; Heart Rate; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting | 2018 |
Health Care Cost for Multiple Sclerosis: The Case of a Health Insurer in Colombia.
Topics: Adult; Antiviral Agents; Female; Fingolimod Hydrochloride; Health Care Costs; Humans; Immunosuppressive Agents; Insurance Claim Review; Insurance, Health; Interferons; Male; Multiple Sclerosis | 2018 |
No evidence of disease activity in patients receiving fingolimod at private or academic centers in clinical practice: a retrospective analysis of the multiple sclerosis, clinical, and magnetic resonance imaging outcomes in the USA (MS-MRIUS) study.
Topics: Adult; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis; Retrospective Studies | 2018 |
Predicting therapeutic response to fingolimod treatment in multiple sclerosis patients.
Topics: Adolescent; Adult; Antigens, CD; Brain; Disability Evaluation; Female; Fingolimod Hydrochloride; Follow-Up Studies; Humans; Immunosuppressive Agents; Leukocytes, Mononuclear; Lymphocytes; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis; Predictive Value of Tests; Treatment Outcome; Young Adult | 2018 |
Beneficial Effects of the Calcium Channel Blocker CTK 01512-2 in a Mouse Model of Multiple Sclerosis.
Topics: Animals; Anti-Inflammatory Agents; Calcium Channel Blockers; Chemokines; Cognition Disorders; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Female; Fingolimod Hydrochloride; Hyperalgesia; Inflammation; Inflammation Mediators; Injections, Spinal; Mice, Inbred C57BL; Motor Activity; Multiple Sclerosis; Myelin Sheath; Myelin-Oligodendrocyte Glycoprotein; Nociception; omega-Conotoxins; Peptide Fragments | 2018 |
Comparisons of therapies in different scenarios help complete the puzzle.
Topics: Fingolimod Hydrochloride; Humans; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab | 2018 |
Acquired modification of sphingosine-1-phosphate lyase activity is not related to adrenal insufficiency.
Topics: Adrenal Glands; Adrenal Insufficiency; Adult; Aldehyde-Lyases; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis; Young Adult | 2018 |
Rebound disease in multiple sclerosis.
Topics: Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting | 2018 |
Disease Exacerbation after the Cessation of Fingolimod Treatment in Japanese Patients with Multiple Sclerosis.
Topics: Adult; Contrast Media; Dimethyl Fumarate; Disease Progression; Drug Substitution; Female; Fingolimod Hydrochloride; Gadolinium; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis; Withholding Treatment | 2018 |
Spontaneous regression of tumor-stage cutaneous T-cell lymphoma in a multiple sclerosis patient after discontinuing fingolimod.
Topics: Adult; Fingolimod Hydrochloride; Humans; Lymphoma, Large-Cell, Anaplastic; Lymphoma, T-Cell, Cutaneous; Multiple Sclerosis; T-Lymphocytes | 2018 |
Fingolimod's Impact on MRI Brain Volume Measures in Multiple Sclerosis: Results from MS-MRIUS.
Topics: Adult; Brain; Disease Progression; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis; Organ Size; Retrospective Studies | 2018 |
The impact of very short transition times on switching from Natalizumab to Fingolimod on imaging and clinical effectiveness outcomes in multiple sclerosis.
Topics: Adult; Contrast Media; Drug Administration Schedule; Female; Fingolimod Hydrochloride; Gadolinium; Humans; Immunologic Factors; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis; Natalizumab; Retrospective Studies; Survival Analysis; Time Factors; Treatment Outcome | 2018 |
Reply to: Comment on Y.D. Fragoso et al.: "Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod" [Mult. Scler. Relat. Disord. (2017)].
Topics: Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Lymphocyte Count; Multiple Sclerosis | 2018 |
Frequency and clinical characteristics of Multiple Sclerosis rebounds after withdrawal of Fingolimod.
Topics: Adult; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis; Recurrence; Retrospective Studies; Substance Withdrawal Syndrome | 2018 |
Effects of multiple sclerosis disease-modifying therapies on employment measures using patient-reported data.
Topics: Adult; Alemtuzumab; Dimethyl Fumarate; Employment; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunosuppressive Agents; Interferon-beta; Longitudinal Studies; Male; Middle Aged; Multiple Sclerosis; Natalizumab; Patient Reported Outcome Measures; Treatment Outcome | 2018 |
Multiple sclerosis: severe exacerbation after stopping disease-modifying drugs.
Topics: Fingolimod Hydrochloride; Humans; Multiple Sclerosis | 2018 |
Drug-associated progressive multifocal leukoencephalopathy in multiple sclerosis patients.
Topics: Adult; Cohort Studies; Female; Fingolimod Hydrochloride; Humans; Immunologic Factors; Leukoencephalopathy, Progressive Multifocal; Male; Middle Aged; Multiple Sclerosis; Natalizumab; Rituximab | 2019 |
Inhibition of RhoA and mTORC2/Rictor by Fingolimod (FTY720) induces p21-activated kinase 1, PAK-1 and amplifies podosomes in mouse peritoneal macrophages.
Topics: Actin Cytoskeleton; Animals; Cells, Cultured; Extracellular Matrix; Female; Fingolimod Hydrochloride; Macrophages, Peritoneal; Mechanistic Target of Rapamycin Complex 2; Mice; Mice, Inbred C57BL; Multiple Sclerosis; p21-Activated Kinases; Podosomes; Pregnancy; rac1 GTP-Binding Protein; Rapamycin-Insensitive Companion of mTOR Protein; rhoA GTP-Binding Protein | 2018 |
Shortening the washout to 4 weeks when switching from natalizumab to fingolimod and risk of disease reactivation in multiple sclerosis.
Topics: Adult; Brain; Disability Evaluation; Drug Substitution; Female; Fingolimod Hydrochloride; Follow-Up Studies; Humans; Immunologic Factors; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis; Natalizumab; Prohibitins; Statistics, Nonparametric; Time Factors; Young Adult | 2018 |
Application of the 2017 McDonald diagnostic criteria for multiple sclerosis in Korean patients with clinically isolated syndrome.
Topics: Adolescent; Adult; Crotonates; Demyelinating Diseases; Disease Progression; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Hydroxybutyrates; Immunologic Factors; Immunosuppressive Agents; Interferon-beta; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis; Nitriles; Oligoclonal Bands; Optic Neuritis; Quinolones; Reproducibility of Results; Republic of Korea; Sensitivity and Specificity; Time Factors; Toluidines; Young Adult | 2019 |
Immunogenicity and predictors of response to a single dose trivalent seasonal influenza vaccine in multiple sclerosis patients receiving disease-modifying therapies.
Topics: Adolescent; Adult; Aged; Cohort Studies; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H3N2 Subtype; Influenza B virus; Influenza Vaccines; Male; Middle Aged; Multiple Sclerosis; Natalizumab; Prospective Studies; Young Adult | 2019 |
Tumefactive multiple sclerosis lesions associated with fingolimod treatment: Report of 5 cases.
Topics: Adult; Disability Evaluation; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Multiple Sclerosis; Plasma Exchange; Retrospective Studies | 2018 |
Oral Disease-Modifying Treatments for Relapsing Multiple Sclerosis: A Likelihood to Achieve No Evidence of Disease Activity or Harm Analysis.
Topics: Adolescent; Adult; Aged; Cladribine; Clinical Trials, Phase III as Topic; Crotonates; Dimethyl Fumarate; Drug-Related Side Effects and Adverse Reactions; Female; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis; Nitriles; Recurrence; Toluidines; Young Adult | 2018 |
Unexpected high multiple sclerosis activity after switching from fingolimod to alemtuzumab.
Topics: Alemtuzumab; Antineoplastic Agents, Immunological; Drug Substitution; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Middle Aged; Multiple Sclerosis | 2018 |
The First Dose of Fingolimod Affects Circulating Extracellular Vesicles in Multiple Sclerosis Patients.
Topics: Adult; Extracellular Vesicles; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Lymphocyte Activation; MicroRNAs; Middle Aged; Multiple Sclerosis; Young Adult | 2018 |
Effect of fingolimod action on the release of monocyte-derived microvesicles in multiple sclerosis patients.
Topics: Adult; Cell-Derived Microparticles; Female; Fingolimod Hydrochloride; Humans; Leukocytes, Mononuclear; Male; Monocytes; Multiple Sclerosis | 2018 |
Exploring physicochemical space via a bioisostere of the trifluoromethyl and ethyl groups (BITE): attenuating lipophilicity in fluorinated analogues of Gilenya® for multiple sclerosis.
Topics: Animals; Drug Stability; Fingolimod Hydrochloride; Halogenation; Hepatocytes; Humans; Immunosuppressive Agents; Microsomes, Liver; Multiple Sclerosis; Rats | 2018 |
Impact of fingolimod on clinical and magnetic resonance imaging outcomes in routine clinical practice: A retrospective analysis of the multiple sclerosis, clinical and MRI outcomes in the USA (MS-MRIUS) study.
Topics: Adult; Brain; Cohort Studies; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis; Retrospective Studies; Treatment Outcome; United States | 2019 |
Comparative effectiveness of dimethyl fumarate versus fingolimod and teriflunomide among MS patients switching from first-generation platform therapies in the US.
Topics: Administration, Oral; Adolescent; Adult; Aged; Crotonates; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis; Nitriles; Recurrence; Secondary Prevention; Toluidines; Treatment Outcome; United States; Young Adult | 2019 |
Fingolimod-induced decrease in heart rate may predict subsequent decreasing degree of lymphocytes.
Topics: Adult; Case-Control Studies; Cells, Cultured; Female; Fingolimod Hydrochloride; Heart Rate; Humans; Immunosuppressive Agents; Leukopenia; Lymphocytes; Male; Multiple Sclerosis | 2018 |
Persistence and adherence to the new oral disease-modifying therapies for multiple sclerosis: A population-based study.
Topics: Adult; Crotonates; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Immunosuppressive Agents; Male; Medication Adherence; Middle Aged; Multiple Sclerosis; Nitriles; Toluidines | 2019 |
Real World Lab Data: Patterns of Lymphocyte Counts in Fingolimod Treated Patients.
Topics: Adult; B-Lymphocytes; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Female; Fingolimod Hydrochloride; Humans; Immunophenotyping; Male; Middle Aged; Multiple Sclerosis | 2018 |
Listeria monocytogenes rhombencephalitis in a patient with multiple sclerosis during fingolimod therapy.
Topics: Adult; Brain; Encephalitis; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Listeria monocytogenes; Listeriosis; Multiple Sclerosis | 2019 |
Study of the NR4A family gene expression in patients with multiple sclerosis treated with Fingolimod.
Topics: Adolescent; Adult; Aged; Animals; Down-Regulation; Female; Fingolimod Hydrochloride; Gene Expression; Humans; Immunosuppressive Agents; Male; Mice; Middle Aged; Multiple Sclerosis; Nuclear Receptor Subfamily 4, Group A, Member 1; Young Adult | 2019 |
Utilization Patterns of Oral Disease-Modifying Drugs in Commercially Insured Patients with Multiple Sclerosis.
Topics: Administration, Oral; Adult; Cohort Studies; Crotonates; Dimethyl Fumarate; Drug Prescriptions; Female; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Immunosuppressive Agents; Insurance, Pharmaceutical Services; Male; Medication Adherence; Middle Aged; Multiple Sclerosis; Nitriles; Patient Preference; Retrospective Studies; Toluidines; United States; Young Adult | 2019 |
The clinical and cost impact of switching to fingolimod versus other first line injectable disease-modifying therapies in patients with relapsing multiple sclerosis.
Topics: Adult; Female; Fingolimod Hydrochloride; Health Care Costs; Humans; Immunosuppressive Agents; Injections; Male; Middle Aged; Multiple Sclerosis; Recurrence; Retrospective Studies | 2019 |
Cerebrospinal fluid NCAM levels are modulated by disease-modifying therapies.
Topics: Adult; Biomarkers; CD56 Antigen; Enzyme-Linked Immunosorbent Assay; Female; Fingolimod Hydrochloride; Humans; Immunologic Factors; Male; Middle Aged; Mitoxantrone; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab | 2019 |
Effect of dosage reduction on peripheral blood lymphocyte count in patients with multiple sclerosis receiving long-term fingolimod therapy.
Topics: Adult; Drug Administration Schedule; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Leukoencephalopathy, Progressive Multifocal; Lymphocyte Count; Lymphocytes; Male; Middle Aged; Multiple Sclerosis | 2019 |
Comment on: "Oral Disease-Modifying Treatments for Relapsing Multiple Sclerosis: A Likelihood to Achieve No Evidence of Disease Activity or Harm Analysis".
Topics: Crotonates; Fingolimod Hydrochloride; Humans; Multiple Sclerosis | 2019 |
Fingolimod Alters Tissue Distribution and Cytokine Production of Human and Murine Innate Lymphoid Cells.
Topics: Animals; Cells, Cultured; Cytokines; Fingolimod Hydrochloride; Humans; Immunity, Innate; Lymphocytes; Mice; Mice, Inbred C57BL; Mice, Transgenic; Multiple Sclerosis; Sphingosine-1-Phosphate Receptors; Th1 Cells; Th17 Cells; Tissue Distribution | 2019 |
Benefit-risk Assessment of Cladribine Using Multi-criteria Decision Analysis (MCDA) for Patients With Relapsing-remitting Multiple Sclerosis.
Topics: Alemtuzumab; Cladribine; Crotonates; Decision Support Techniques; Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Nitriles; Recurrence; Risk Assessment; Toluidines | 2019 |
Natalizumab versus fingolimod and dimethyl fumarate in multiple sclerosis treatment.
Topics: Adult; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis; Natalizumab; Recurrence; Treatment Outcome; Young Adult | 2019 |
Expression Profile of Selected MicroRNAs in the Peripheral Blood of Multiple Sclerosis Patients: a Multivariate Statistical Analysis with ROC Curve to Find New Biomarkers for Fingolimod.
Topics: Adult; Biomarkers; Case-Control Studies; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; MicroRNAs; Middle Aged; Multiple Sclerosis; ROC Curve | 2019 |
Melanoma during fingolimod treatment for multiple sclerosis.
Topics: Back; Female; Fingolimod Hydrochloride; Humans; Immunologic Factors; Immunosuppressive Agents; Melanoma; Middle Aged; Multiple Sclerosis; Natalizumab; Risk Factors; Skin Neoplasms | 2019 |
The S1P mimetic fingolimod phosphate regulates mitochondrial oxidative stress in neuronal cells.
Topics: Animals; Antioxidants; Cell Death; Cell Line; Dopaminergic Neurons; Fingolimod Hydrochloride; Humans; Lysophospholipids; Membrane Potential, Mitochondrial; Mice; Mitochondria; Molecular Mimicry; Multiple Sclerosis; Neuroprotection; Oxidative Stress; Oxygen Consumption; Phosphates; Reactive Oxygen Species; Sphingosine; Sphingosine-1-Phosphate Receptors; Vitamin K 3 | 2019 |
Three cases of non-carryover fingolimod-PML: Is the risk in Japan increased?
Topics: Europe; Female; Fingolimod Hydrochloride; Humans; Immune Reconstitution Inflammatory Syndrome; Immunosuppressive Agents; Japan; Leukoencephalopathy, Progressive Multifocal; Male; Middle Aged; Multiple Sclerosis | 2019 |
Different MRI patterns in MS worsening after stopping fingolimod.
Topics: Adult; Disability Evaluation; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis; Recurrence; Retrospective Studies; Symptom Flare Up | 2019 |
Plasma protein profiling reveals candidate biomarkers for multiple sclerosis treatment.
Topics: Adult; Biomarkers; Cohort Studies; Female; Fingolimod Hydrochloride; Humans; Immunologic Factors; Immunosuppressive Agents; Male; Multiple Sclerosis; Natalizumab; Proteomics | 2019 |
Fingolimod for the treatment of multiple sclerosis in French West Indies, a real-world study in patients from African ancestry.
Topics: Adult; Disease Progression; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis; Recurrence; Retrospective Studies; Treatment Outcome; West Indies | 2019 |
Neurodevelopmental retardation in a baby born to a multiple sclerosis patient being treated with fingolimod.
Topics: Child, Preschool; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Infant, Newborn; Intellectual Disability; Multiple Sclerosis; Pregnancy; Pregnancy Complications; Pregnancy Trimester, First; Prenatal Exposure Delayed Effects | 2019 |
Combining secukinumab and fingolimod to successfully treat ankylosing spondylitis and multiple sclerosis - A novel approach.
Topics: Adult; Antibodies, Monoclonal, Humanized; Fingolimod Hydrochloride; Humans; Male; Multiple Sclerosis; Spondylitis, Ankylosing | 2019 |
Early central vs. peripheral immunological and neurobiological effects of fingolimod-a longitudinal study.
Topics: Adult; Biomarkers; Central Nervous System; Cerebrospinal Fluid; Female; Fingolimod Hydrochloride; Humans; Longitudinal Studies; Lysophospholipids; Male; Middle Aged; Multiple Sclerosis; Peripheral Nervous System; Sphingosine | 2019 |
Relapses and obstetric outcomes in women with multiple sclerosis planning pregnancy.
Topics: Adult; Disease Progression; Female; Fingolimod Hydrochloride; Follow-Up Studies; Glatiramer Acetate; Humans; Immunologic Factors; Interferon-beta; Multiple Sclerosis; Natalizumab; Pregnancy; Pregnancy Complications; Puerperal Disorders; Recurrence; Reproductive Behavior | 2019 |
Not all side effects are unwelcome ….
Topics: Adult; Fingolimod Hydrochloride; Humans; Insect Bites and Stings; Multiple Sclerosis; Sphingosine 1 Phosphate Receptor Modulators | 2020 |
Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosis.
Topics: Adult; Crotonates; Dimethyl Fumarate; Disease Progression; Female; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis; Nitriles; Recurrence; Toluidines; Treatment Outcome | 2019 |
[Increased disease activity in a case of multiple sclerosis after switching treatment from fingolimod to natalizumab].
Topics: Adult; Antibodies; Disease Progression; Drug Substitution; Female; Fingolimod Hydrochloride; Humans; Immunologic Factors; Immunosuppressive Agents; Injections, Intramuscular; Interferon-beta; Lymphocyte Count; Multiple Sclerosis; Natalizumab; Recurrence | 2019 |
Th1Th17
Topics: Adult; Biomarkers; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Humans; Kaplan-Meier Estimate; Male; Multiple Sclerosis; T-Lymphocyte Subsets; Th17 Cells | 2019 |
[Multiple sclerosis: new drugs and their molecular targets].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Fingolimod Hydrochloride; Humans; Molecular Targeted Therapy; Multiple Sclerosis; Natalizumab; Propylene Glycols; Sphingosine | 2012 |
Consensus guidelines for the diagnosis and treatment of multiple sclerosis.
Topics: Antibodies, Monoclonal, Humanized; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Interferon beta-1a; Interferon beta-1b; Interferon-beta; Middle East; Multiple Sclerosis; Myelitis; Natalizumab; Optic Nerve Diseases; Optic Neuritis; Propylene Glycols; Sphingosine; Spinal Cord Diseases | 2013 |
[Additional indicators of the assessment of efficacy of disease modifying drugs (preliminary results)].
Topics: Brain; Cytokines; Drug Therapy, Combination; Fingolimod Hydrochloride; Follow-Up Studies; Glatiramer Acetate; Humans; Immunologic Factors; Immunosuppressive Agents; Interferon-beta; Magnetic Resonance Imaging; Multiple Sclerosis; Peptides; Propylene Glycols; Secondary Prevention; Sphingosine; Time Factors; Treatment Outcome | 2013 |
Pharmacoepidemiology and the Australian regional prevalence of multiple sclerosis.
Topics: Antibodies, Monoclonal, Humanized; Australia; Drug Prescriptions; Fingolimod Hydrochloride; Geography; Humans; Immunologic Factors; Interferon-beta; Linear Models; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Neuroprotective Agents; Pharmacoepidemiology; Prevalence; Propylene Glycols; Pyridostigmine Bromide; Riluzole; Sphingosine | 2013 |
T-cell response against varicella-zoster virus in fingolimod-treated MS patients.
Topics: Adult; Aged; Drug Administration Schedule; Female; Fingolimod Hydrochloride; Herpes Zoster; Herpesvirus 3, Human; Herpesvirus 4, Human; Humans; Immunosuppressive Agents; Interferon-beta; Male; Middle Aged; Multiple Sclerosis; Propylene Glycols; Saliva; Sphingosine; T-Lymphocytes; Virus Activation | 2013 |
Reduction of the washout time between natalizumab and fingolimod.
Topics: Antibodies, Monoclonal, Humanized; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Multiple Sclerosis; Natalizumab; Propylene Glycols; Sphingosine | 2013 |
Severe auto-immune hemolytic anemia in a fingolimod-treated multiple sclerosis patient.
Topics: Anemia, Hemolytic, Autoimmune; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Propylene Glycols; Sphingosine; Young Adult | 2013 |
Comparative effectiveness of fingolimod versus interferons or glatiramer acetate for relapse rates in multiple sclerosis: a retrospective US claims database analysis.
Topics: Adult; Databases, Factual; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunosuppressive Agents; In Vitro Techniques; Insurance Claim Review; Interferons; Male; Middle Aged; Multiple Sclerosis; Peptides; Propylene Glycols; Recurrence; Retrospective Studies; Sphingosine; United States | 2013 |
Compliance to fingolimod and other disease modifying treatments in multiple sclerosis patients, a retrospective cohort study.
Topics: Adult; Aged; Cohort Studies; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Medication Adherence; Middle Aged; Multiple Sclerosis; Proportional Hazards Models; Propylene Glycols; Retrospective Studies; Sphingosine; Time Factors | 2013 |
Tumefactive multiple sclerosis and fingolimod: Immunotherapies and unintended consequences.
Topics: Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Immunotherapy; Multiple Sclerosis; Propylene Glycols; Sphingosine | 2013 |
A regenerative approach to the treatment of multiple sclerosis.
Topics: Animals; Antiparkinson Agents; Benztropine; Cell Differentiation; Coculture Techniques; Cuprizone; Encephalomyelitis, Autoimmune, Experimental; Female; Fingolimod Hydrochloride; Immune System; Mice; Mice, Inbred C57BL; Models, Biological; Multiple Sclerosis; Myelin Proteolipid Protein; Myelin Sheath; Oligodendroglia; Optic Nerve; Propylene Glycols; Rats; Receptor, Muscarinic M1; Receptor, Muscarinic M3; Recurrence; Regeneration; Sphingosine; Stem Cells | 2013 |
Basis for fluctuations in lymphocyte counts in fingolimod-treated patients with multiple sclerosis.
Topics: Adult; Cell Count; Cytokines; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Longitudinal Studies; Male; Middle Aged; Multiple Sclerosis; Propylene Glycols; Sphingosine; T-Lymphocytes | 2013 |
Effects of vitamin D3, calcipotriol and FTY720 on the expression of surface molecules and cytolytic activities of human natural killer cells and dendritic cells.
Topics: Calcitriol; Cell Line, Tumor; Cholecalciferol; Cytotoxicity, Immunologic; Dendritic Cells; Down-Regulation; Fingolimod Hydrochloride; Gene Expression Regulation, Neoplastic; Humans; Interleukin-2; K562 Cells; Killer Cells, Natural; Membrane Proteins; Multiple Sclerosis; Natural Cytotoxicity Triggering Receptor 2; Natural Cytotoxicity Triggering Receptor 3; NK Cell Lectin-Like Receptor Subfamily K; Propylene Glycols; Receptors, CCR6; Receptors, CCR7; Sphingosine; Up-Regulation | 2013 |
Progressive multifocal leukoencephalopathy in a patient taking the MS pill Gilenya.
Topics: Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Leukoencephalopathy, Progressive Multifocal; Multiple Sclerosis; Propylene Glycols; Sphingosine | 2013 |
[Cystoid macular oedema after fingolimod treatment in multiple sclerosis].
Topics: Adult; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Macular Edema; Multiple Sclerosis; Propylene Glycols; Sphingosine | 2014 |
[Usefulness of electronic drug registers: Spanish register of patients treated with fingolimod (Gilenya ®)].
Topics: Brain; Confidentiality; Drug Prescriptions; Drug Utilization; Electronic Health Records; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Informed Consent; Magnetic Resonance Imaging; Multiple Sclerosis; Patient Dropouts; Practice Patterns, Physicians'; Product Surveillance, Postmarketing; Propylene Glycols; Prospective Studies; Registries; Retrospective Studies; Risk Assessment; Severity of Illness Index; Socioeconomic Factors; Spain; Sphingosine; Treatment Outcome | 2014 |
Investigation of immune and CNS-mediated effects of fingolimod in the focal delayed-type hypersensitivity multiple sclerosis model.
Topics: Animals; Blood-Brain Barrier; Brain; Capillary Permeability; Disease Models, Animal; Disease Progression; Fingolimod Hydrochloride; Immunosuppressive Agents; Lymphocytes; Macrophages; Male; Microglia; Multiple Sclerosis; Propylene Glycols; Rats; Rats, Inbred Lew; Sphingosine | 2014 |
The pill times 2: what every woman with multiple sclerosis should know.
Topics: Abnormalities, Drug-Induced; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Pregnancy; Pregnancy Complications; Propylene Glycols; Sphingosine | 2014 |
Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis.
Topics: Abnormalities, Drug-Induced; Abortion, Spontaneous; Adult; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Middle Aged; Multiple Sclerosis; Pregnancy; Pregnancy Complications; Pregnancy Outcome; Propylene Glycols; Sphingosine | 2014 |
Fingolimod-associated amenorrhea: a report of three cases.
Topics: Adult; Amenorrhea; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Propylene Glycols; Sphingosine; Time Factors; Treatment Outcome | 2014 |
Paroxysmal atrial fibrillation after initiation of fingolimod for multiple sclerosis treatment.
Topics: Adult; Atrial Fibrillation; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Multiple Sclerosis; Propylene Glycols; Sphingosine | 2014 |
Differential effects of fingolimod on B-cell populations in multiple sclerosis.
Topics: ADP-ribosyl Cyclase 1; Adult; B-Lymphocyte Subsets; Biomarkers; Case-Control Studies; Cell Proliferation; Drug Resistance; Female; Fingolimod Hydrochloride; Flow Cytometry; Humans; Immunologic Memory; Immunosuppressive Agents; Ki-67 Antigen; Lymphocyte Activation; Male; Membrane Glycoproteins; Middle Aged; Multiple Sclerosis; Phenotype; Propylene Glycols; Receptors, Lysosphingolipid; RNA, Messenger; Sphingosine; Sphingosine-1-Phosphate Receptors; Syndecan-1; Time Factors; Treatment Outcome | 2014 |
Suppressed pro-inflammatory properties of circulating B cells in patients with multiple sclerosis treated with fingolimod, based on altered proportions of B-cell subpopulations.
Topics: Adult; B-Lymphocyte Subsets; B7-1 Antigen; Case-Control Studies; Chemotaxis, Leukocyte; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Inflammation; Interleukin-10; Male; Middle Aged; Multiple Sclerosis; Propylene Glycols; Receptors, CCR7; Sphingosine; Tumor Necrosis Factor-alpha | 2014 |
Successful treatment of fingolimod-associated macular edema with intravitreal triamcinolone with continued fingolimod use.
Topics: Aged; Anti-Inflammatory Agents; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Macular Edema; Middle Aged; Multiple Sclerosis; Triamcinolone | 2015 |
Healthcare resource use and relapses with fingolimod versus natalizumab for treating multiple sclerosis: a retrospective US claims database analysis.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Antibodies, Monoclonal, Humanized; Cohort Studies; Databases, Factual; Drug Therapy, Combination; Female; Fingolimod Hydrochloride; Health Services; Hospitalization; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Sclerosis; Natalizumab; Propensity Score; Propylene Glycols; Recurrence; Retrospective Studies; Sphingosine; United States; Young Adult | 2014 |
Polydermatomal perineal and gluteal herpes zoster infection in a patient on fingolimod treatment.
Topics: Adult; Buttocks; Female; Fingolimod Hydrochloride; Genital Diseases, Female; Herpes Zoster; Humans; Immunosuppressive Agents; Multiple Sclerosis; Perineum | 2015 |
Tumefactive multiple sclerosis and fingolimod.
Topics: Brain Injuries; Encephalitis; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Occipital Lobe; Propylene Glycols; Sphingosine | 2014 |
Tumefactive demyelination and a malignant course in an MS patient during and following fingolimod therapy.
Topics: Antigens, CD; Antigens, Differentiation, Myelomonocytic; Brain Injuries; Encephalitis; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Inflammation; Magnetic Resonance Imaging; Multiple Sclerosis; Occipital Lobe; Propylene Glycols; Sphingosine | 2014 |
Persistence with and adherence to fingolimod compared with other disease-modifying therapies for the treatment of multiple sclerosis: a retrospective US claims database analysis.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Drug Administration Routes; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunosuppressive Agents; Insurance Claim Review; Interferon beta-1a; Interferon beta-1b; Interferon-beta; Male; Medication Adherence; Middle Aged; Multiple Sclerosis; Natalizumab; Peptides; Proportional Hazards Models; Propylene Glycols; Retrospective Studies; Sphingosine; United States; Young Adult | 2014 |
Fingolimod may support neuroprotection via blockade of astrocyte nitric oxide.
Topics: Aged; Animals; Astrocytes; Cells, Cultured; Cerebrum; Encephalomyelitis, Autoimmune, Experimental; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Mice; Mice, Inbred C57BL; Middle Aged; Multiple Sclerosis; Neuroprotective Agents; Nitric Oxide; Propylene Glycols; Rats; Rats, Sprague-Dawley; Receptors, Interleukin-1 Type I; Receptors, Interleukin-17; Receptors, Lysosphingolipid; Signal Transduction; Sphingosine; Spinal Cord | 2014 |
Frequency and economic impact of comorbid cardiac conditions with multiple sclerosis.
Topics: Female; Fingolimod Hydrochloride; Health Care Costs; Heart Diseases; Hospitalization; Humans; Male; Middle Aged; Multiple Sclerosis; Propylene Glycols; Retrospective Studies; Sphingosine | 2014 |
Oral fingolimod to treat multiple sclerosis: see your cardiologist first.
Topics: Cardiovascular Diseases; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Multiple Sclerosis; Propylene Glycols; Sphingosine | 2014 |
The real-life experience with cardiovascular complications in the first dose of fingolimod for multiple sclerosis.
Topics: Adult; Aged; Bradycardia; Cardiovascular Diseases; Female; Fingolimod Hydrochloride; Heart Rate; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis; Propylene Glycols; Sphingosine; Time Factors; Young Adult | 2014 |
Experience with fingolimod in clinical practice.
Topics: Adult; Female; Fingolimod Hydrochloride; Follow-Up Studies; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis; Outcome Assessment, Health Care | 2015 |
From defining antigens to new therapies in multiple sclerosis: honoring the contributions of Ruth Arnon and Michael Sela.
Topics: Animals; Antibodies, Monoclonal, Humanized; Encephalomyelitis, Autoimmune, Experimental; Fingolimod Hydrochloride; Glatiramer Acetate; History, 20th Century; History, 21st Century; Humans; Immunosuppressive Agents; Multiple Sclerosis; Natalizumab; Peptides; Propylene Glycols; Sphingosine | 2014 |
Multiple sclerosis reactivation postfingolimod cessation: is it IRIS?
Topics: Adult; Antibodies, Monoclonal, Humanized; Drug Administration Schedule; Female; Fingolimod Hydrochloride; Humans; Immune Reconstitution Inflammatory Syndrome; Immunosuppressive Agents; Multiple Sclerosis; Natalizumab; Propylene Glycols; Recurrence; Sphingosine | 2014 |
Recognizing and overcoming potential barriers to oral medications for MS.
Topics: Administration, Oral; Crotonates; Dimethyl Fumarate; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Immunosuppressive Agents; Multiple Sclerosis; Nitriles; Propylene Glycols; Sphingosine; Toluidines | 2014 |
Fingolimod increases CD39-expressing regulatory T cells in multiple sclerosis patients.
Topics: Antigens, CD; Antigens, CD19; Apyrase; B-Lymphocytes; Basic Helix-Loop-Helix Transcription Factors; CD4-Positive T-Lymphocytes; Cytochrome P-450 CYP1B1; Cytokines; Fingolimod Hydrochloride; Gene Expression Regulation; Humans; Immunosuppressive Agents; Multiple Sclerosis; Receptors, Aryl Hydrocarbon; T-Lymphocytes, Regulatory | 2014 |
Visceral leishmaniasis infection in a fingolimod-treated multiple sclerosis patient.
Topics: Adult; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Leishmaniasis, Visceral; Multiple Sclerosis | 2015 |
[Fingolimod treatment in multiple sclerosis].
Topics: Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Lymphocyte Count; Lymphocytes; Multiple Sclerosis; Propylene Glycols; Sphingosine | 2014 |
Treatment of progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome with intravenous immunoglobulin in a patient with multiple sclerosis treated with fingolimod after discontinuation of natalizumab.
Topics: Adult; Antibodies, Monoclonal, Humanized; Female; Fingolimod Hydrochloride; Humans; Immune Reconstitution Inflammatory Syndrome; Immunoglobulins, Intravenous; Immunologic Factors; Leukoencephalopathy, Progressive Multifocal; Multiple Sclerosis; Natalizumab; Retreatment; Treatment Outcome | 2015 |
Epstein Barr virus infection reactivation as a possible trigger of primary biliary cirrhosis-like syndrome in a patient with multiple sclerosis in the course of fingolimod treatment.
Topics: Adult; Cholagogues and Choleretics; Epstein-Barr Virus Infections; Fingolimod Hydrochloride; Herpesvirus 4, Human; Humans; Immunocompromised Host; Immunosuppressive Agents; Liver Cirrhosis, Biliary; Male; Multiple Sclerosis; Recurrence; Treatment Outcome; Ursodeoxycholic Acid; Withholding Treatment | 2014 |
In vivo PET imaging demonstrates diminished microglial activation after fingolimod treatment in an animal model of multiple sclerosis.
Topics: Animals; Autoradiography; BCG Vaccine; Carrier Proteins; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Fingolimod Hydrochloride; Freund's Adjuvant; Immunohistochemistry; Immunosuppressive Agents; Inflammation; Ligands; Male; Microglia; Multiple Sclerosis; Positron-Emission Tomography; Propylene Glycols; Rats; Rats, Inbred Lew; Receptors, GABA-A; Sphingosine; Time Factors | 2015 |
Fingolimod efficacy in multiple sclerosis associated with Sjogren syndrome.
Topics: Adult; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Propylene Glycols; Sjogren's Syndrome; Sphingosine | 2015 |
Multiple sclerosis, immunomodulation, and immunizations: balancing the benefits.
Topics: Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Influenza Vaccines; Male; Multiple Sclerosis; Propylene Glycols; Sphingosine; Vaccination | 2015 |
Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis.
Topics: Adult; Cohort Studies; Female; Fingolimod Hydrochloride; Humans; Immunologic Factors; Immunosuppressive Agents; Interferon-beta; Magnetic Resonance Imaging; Male; Multiple Sclerosis; Propylene Glycols; Retrospective Studies; Sphingosine; Treatment Outcome | 2015 |
Knowledge retrieval from PubMed abstracts and electronic medical records with the Multiple Sclerosis Ontology.
Topics: Antineoplastic Agents; Antirheumatic Agents; Biological Ontologies; Computational Biology; Electronic Health Records; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Information Storage and Retrieval; Knowledge Discovery; Mitoxantrone; Multiple Sclerosis; PubMed; Rituximab | 2015 |
Subcellular distribution of FTY720 and FTY720-phosphate in immune cells - another aspect of Fingolimod action relevant for therapeutic application.
Topics: Animals; Cells, Cultured; Female; Fingolimod Hydrochloride; Lysophospholipids; Mice; Mice, Inbred C57BL; Multiple Sclerosis; Organophosphates; Phosphorylation; Phosphotransferases (Alcohol Group Acceptor); Sphingosine; Spleen; Tandem Mass Spectrometry | 2015 |
FTY720 (fingolimod) treatment tips the balance towards less immunogenic antigen-presenting cells in patients with multiple sclerosis.
Topics: Adult; Cytokines; Dendritic Cells; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Middle Aged; Monocytes; Multiple Sclerosis; Young Adult | 2015 |
Insight into the conformational polymorph transformation of a block-buster multiple sclerosis drug fingolimod hydrochloride (FTY 720).
Topics: Calorimetry, Differential Scanning; Crystallography, X-Ray; Fingolimod Hydrochloride; Models, Molecular; Molecular Conformation; Multiple Sclerosis; Spectrum Analysis, Raman; X-Ray Diffraction | 2015 |
Persistent headache in patients with multiple sclerosis starting treatment with fingolimod.
Topics: Adult; Female; Fingolimod Hydrochloride; Headache; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis; Time Factors; Treatment Outcome; Young Adult | 2015 |
Fingolimod prevents blood-brain barrier disruption induced by the sera from patients with multiple sclerosis.
Topics: Blood-Brain Barrier; Cell Line, Transformed; Claudin-5; Endothelial Cells; Fingolimod Hydrochloride; Gene Expression; Humans; Immune Sera; Immunosuppressive Agents; Multiple Sclerosis; NF-kappa B; Propylene Glycols; RNA, Messenger; Sphingosine; Vascular Cell Adhesion Molecule-1 | 2015 |
A pragmatic approach to dealing with fingolimod-related lymphopaenia in Europe.
Topics: Europe; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Lymphopenia; Multiple Sclerosis | 2015 |
Cbl-b-deficient mice express alterations in trafficking-related molecules but retain sensitivity to the multiple sclerosis therapeutic agent, FTY720.
Topics: Adaptor Proteins, Signal Transducing; Adoptive Transfer; Animals; Cell Movement; Encephalomyelitis, Autoimmune, Experimental; Fingolimod Hydrochloride; Homeodomain Proteins; Immunosuppressive Agents; Lymph Nodes; Lymphocyte Activation; Mice; Mice, Knockout; Multiple Sclerosis; Propylene Glycols; Proto-Oncogene Proteins c-cbl; Sphingosine; T-Lymphocytes | 2015 |
Ventricular tachycardia on chronic fingolimod treatment for multiple sclerosis.
Topics: Adult; Electrocardiography, Ambulatory; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Propylene Glycols; Sphingosine; Tachycardia, Ventricular | 2015 |
Kaposi sarcoma in a patient with relapsing-remitting multiple sclerosis receiving fingolimod.
Topics: Adult; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Leg; Male; Multiple Sclerosis; Propylene Glycols; Recurrence; Remission, Spontaneous; Sarcoma, Kaposi; Sphingosine; Treatment Outcome | 2015 |
Long-term cardiac safety and tolerability of fingolimod in multiple sclerosis: A postmarketing study.
Topics: Adult; Atrial Fibrillation; Atrioventricular Block; Blood Pressure; Electrocardiography; Female; Fingolimod Hydrochloride; Heart; Heart Rate; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis; Product Surveillance, Postmarketing | 2015 |
Peripheral blood T cell dynamics predict relapse in multiple sclerosis patients on fingolimod.
Topics: Adult; Case-Control Studies; CD4-Positive T-Lymphocytes; Cytokines; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis; Recurrence; Treatment Outcome; Young Adult | 2014 |
Comparative analysis of first-year fingolimod and natalizumab drug discontinuation among Swedish patients with multiple sclerosis.
Topics: Adult; Female; Fingolimod Hydrochloride; Humans; Immunologic Factors; Male; Middle Aged; Multiple Sclerosis; Natalizumab; Registries; Severity of Illness Index; Sex Factors; Sweden; Time Factors; Treatment Outcome | 2016 |
Sphingosine 1-phosphate signaling at the blood-brain barrier.
Topics: Animals; Astrocytes; Blood-Brain Barrier; Capillary Permeability; Endothelial Cells; Fingolimod Hydrochloride; Humans; Immunologic Factors; Lysophospholipids; Multiple Sclerosis; Receptors, Lysosphingolipid; Signal Transduction; Sphingosine | 2015 |
Fingolimod Prescribed for the Treatment of Multiple Sclerosis in Patients Younger Than Age 18 Years.
Topics: Adolescent; Brazil; Child; Child, Preschool; Disability Evaluation; Drug Prescriptions; Female; Fingolimod Hydrochloride; Follow-Up Studies; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Male; Multiple Sclerosis | 2015 |
Early relapse with tumefactive MS lesion upon initiation of fingolimod therapy.
Topics: Adult; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis; Neurologic Examination; Recurrence; Young Adult | 2016 |
[A case of multiple sclerosis who relapsed early after fingolimod therapy introduced].
Topics: Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Middle Aged; Multiple Sclerosis; Recurrence | 2015 |
Central Autonomic Dysfunction Delays Recovery of Fingolimod Induced Heart Rate Slowing.
Topics: Adult; Autonomic Nervous System; Blood Pressure; Bradycardia; Electrocardiography; Female; Fingolimod Hydrochloride; Hand Strength; Heart Rate; Humans; Immunosuppressive Agents; Male; Multiple Sclerosis; Valsalva Maneuver | 2015 |
Herpes zoster: a potential risk associated with fingolimod treatment.
Topics: Acyclovir; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fingolimod Hydrochloride; Follow-Up Studies; Herpes Zoster; Humans; Immunosuppressive Agents; Middle Aged; Multiple Sclerosis; Recurrence; Risk Assessment; Treatment Outcome; Valacyclovir; Valine | 2015 |
Sphingosine 1 Phosphate at the Blood Brain Barrier: Can the Modulation of S1P Receptor 1 Influence the Response of Endothelial Cells and Astrocytes to Inflammatory Stimuli?
Topics: Adult; Astrocytes; Blood-Brain Barrier; Cell Movement; Cell Survival; Cytokines; Endothelial Cells; Fingolimod Hydrochloride; Granulocyte-Macrophage Colony-Stimulating Factor; Healthy Volunteers; Humans; Inflammation; Leukocytes; Lysophospholipids; Microcirculation; Middle Aged; Multiple Sclerosis; Receptors, Lysosphingolipid; Signal Transduction; Sphingolipids; Sphingosine; Stress, Mechanical; Young Adult | 2015 |
Assessing PML risk under immunotherapy: if all you have is a hammer, everything looks like a nail.
Topics: Dimethyl Fumarate; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Leukoencephalopathy, Progressive Multifocal; Multiple Sclerosis; Risk | 2016 |
Dramatic recovery of steroid-refractory relapsed multiple sclerosis following Fingolimod discontinuation using selective immune adsorption.
Topics: Adsorption; Adult; Autoantibodies; Female; Fingolimod Hydrochloride; Humans; Immunoglobulin G; Immunologic Factors; Lymphopenia; Magnetic Resonance Imaging; Methylprednisolone; Multiple Sclerosis; Myelin Sheath; Natalizumab; Plasma Exchange; Steroids; Treatment Outcome | 2015 |
Natalizumab treatment reduces L-selectin (CD62L) in CD4+ T cells.
Topics: Adult; Aged; CD4-Positive T-Lymphocytes; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immune Reconstitution Inflammatory Syndrome; Immunologic Factors; Interferon-beta; L-Selectin; Leukocyte Count; Male; Middle Aged; Monocytes; Multiple Sclerosis; Natalizumab; Rituximab; Young Adult | 2015 |
Disseminated cryptococcosis in a patient with multiple sclerosis treated with fingolimod.
Topics: Brain; Cryptococcosis; Fingolimod Hydrochloride; Flucytosine; Humans; Male; Middle Aged; Multiple Sclerosis; Skin; Treatment Outcome | 2015 |
Emerging tumefactive MS after switching therapy from interferon-beta to fingolimod: A case report.
Topics: Adult; Diagnosis, Differential; Fingolimod Hydrochloride; Follow-Up Studies; Humans; Immunosuppressive Agents; Interferon-beta; Magnetic Resonance Imaging; Male; Multiple Sclerosis; Proton Magnetic Resonance Spectroscopy; Tomography | 2015 |
Optimizing treatment initiation: Effects of a patient education program about fingolimod treatment on knowledge, self-efficacy and patient satisfaction.
Topics: Adult; Aged; Female; Fingolimod Hydrochloride; Health Knowledge, Attitudes, Practice; Humans; Immunosuppressive Agents; Male; Medication Adherence; Middle Aged; Multiple Sclerosis; Patient Education as Topic; Patient Satisfaction; Perception; Self Efficacy; Surveys and Questionnaires; Time Factors; Treatment Outcome; Young Adult | 2015 |
Fingolimod-Associated Peripheral Vascular Adverse Effects.
Topics: Adult; Drug Monitoring; Fingers; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Multiple Sclerosis; Peripheral Vascular Diseases; Rheology; Treatment Outcome; Withholding Treatment | 2015 |
Response to letter regarding article 'Fingolimod effects on left ventricular function in multiple sclerosis'.
Topics: Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Sphingosine; Ventricular Function, Left | 2016 |
Comment on "Fingolimod effects on left ventricular function in multiple sclerosis" Mult Scler 2015.
Topics: Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine; Ventricular Function, Left | 2016 |
Adaptive Immune Responses in a Multiple Sclerosis Patient with Acute Varicella-Zoster Virus Reactivation during Treatment with Fingolimod.
Topics: Adaptive Immunity; Adult; Antibodies, Viral; Cytokines; Fingolimod Hydrochloride; Herpes Zoster; Herpesvirus 3, Human; Humans; Immunosuppressive Agents; Lymphocyte Count; Lymphocytes; Male; Multiple Sclerosis; Phenotype; Virus Activation | 2015 |
Sphingosine-1-phosphate receptor antagonism enhances proliferation and migration of engrafted neural progenitor cells in a model of viral-induced demyelination.
Topics: Animals; Axons; Cell Differentiation; Cell Movement; Cells, Cultured; Central Nervous System; Demyelinating Diseases; Fingolimod Hydrochloride; Immunosuppressive Agents; Mice, Transgenic; Mitogen-Activated Protein Kinases; Multiple Sclerosis; Murine hepatitis virus; Neural Stem Cells; Oligodendroglia; Receptors, Lysosphingolipid | 2015 |
Cryptococcal Meningoencephalitis in a Patient With Multiple Sclerosis Treated With Fingolimod.
Topics: Adult; Brain; Cryptococcosis; Cryptococcus; Fingolimod Hydrochloride; Humans; Male; Meningoencephalitis; Multiple Sclerosis; Treatment Outcome | 2015 |
[How to use Japanese guidelines for the treatment of multiple sclerosis].
Topics: Acute Disease; Asian People; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Practice Guidelines as Topic; Recurrence | 2015 |
[Fingolimod].
Topics: Clinical Trials as Topic; Fingolimod Hydrochloride; Humans; Immunologic Memory; Immunosuppressive Agents; Multiple Sclerosis; T-Lymphocytes | 2015 |
[Treatment for multiple sclerosis in patients with collagen diseases].
Topics: Adult; Autoantibodies; Collagen Diseases; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Interferon-beta; Male; Middle Aged; Multiple Sclerosis | 2015 |
Retinal hemorrhages following fingolimod treatment for multiple sclerosis; a case report.
Topics: Adult; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Macular Edema; Male; Multiple Sclerosis; Retinal Hemorrhage; Tomography, Optical Coherence | 2015 |
PML: The Dark Side of Immunotherapy in Multiple Sclerosis.
Topics: Alemtuzumab; Antibodies, Monoclonal, Humanized; Fingolimod Hydrochloride; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Immunosuppressive Agents; Immunotherapy; Leukoencephalopathy, Progressive Multifocal; Multiple Sclerosis; Natalizumab | 2015 |
AKP-11 - A Novel S1P1 Agonist with Favorable Safety Profile Attenuates Experimental Autoimmune Encephalomyelitis in Rat Model of Multiple Sclerosis.
Topics: Animals; Capillary Permeability; Cell Membrane; CHO Cells; Cricetulus; Cytokines; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Extracellular Signal-Regulated MAP Kinases; Female; Fingolimod Hydrochloride; Heart Rate; Lymphocyte Count; Multiple Sclerosis; Proteolysis; Proto-Oncogene Proteins c-akt; Rats; Receptors, Lysosphingolipid; T-Lymphocyte Subsets | 2015 |
Safety and efficacy of fingolimod in clinical practice: The experience of an academic center in the Middle East.
Topics: Adult; Cohort Studies; Disability Evaluation; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Middle Aged; Middle East; Multiple Sclerosis | 2015 |
Fingolimod ameliorates the development of experimental autoimmune encephalomyelitis by inhibiting Akt-mTOR axis in mice.
Topics: Animals; Encephalomyelitis, Autoimmune, Experimental; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Mice; Mice, Inbred C57BL; Multiple Sclerosis; Oncogene Protein v-akt; Receptors, Lysosphingolipid; Signal Transduction; TOR Serine-Threonine Kinases; United States; United States Food and Drug Administration | 2016 |
Therapeutic Potential of the Modulation of Sphingosine-1-Phosphate Receptors.
Topics: Fingolimod Hydrochloride; Humans; Immune System; Immunosuppressive Agents; Lysophospholipids; Multiple Sclerosis; Nervous System; Receptors, Lysosphingolipid; Sphingolipids; Sphingosine | 2016 |
Fingolimod targeting protein phosphatase 2A differently affects IL-33 induced IL-2 and IFN-γ production in CD8(+) lymphocytes.
Topics: Animals; CD8-Positive T-Lymphocytes; Cell Line, Tumor; DNA-Binding Proteins; Female; Fingolimod Hydrochloride; Histone Chaperones; Interferon-gamma; Interleukin-2; Interleukin-33; Lysophospholipids; Mice; Mice, Inbred C57BL; Multiple Sclerosis; Oncogene Proteins; Organophosphates; Phosphorylation; Phosphotransferases (Alcohol Group Acceptor); Protein Phosphatase 2; Sphingosine; Spleen | 2016 |
Fingolimod (FTY720-P) Does Not Stabilize the Blood-Brain Barrier under Inflammatory Conditions in an in Vitro Model.
Topics: Animals; Apoptosis; Blood-Brain Barrier; Capillary Permeability; Cells, Cultured; Drug Evaluation, Preclinical; Endothelial Cells; Fingolimod Hydrochloride; Immunosuppressive Agents; MAP Kinase Signaling System; Matrix Metalloproteinase 2; Microvessels; Multiple Sclerosis; Occludin; Rats | 2015 |
Identification of a novel mechanism of action of fingolimod (FTY720) on human effector T cell function through TCF-1 upregulation.
Topics: CD4-Positive T-Lymphocytes; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Multiple Sclerosis; T Cell Transcription Factor 1; Up-Regulation | 2015 |
Pulsed corticosteroid treatment in MS patients stabilizes disease activity following natalizumab withdrawal prior to switching to fingolimod.
Topics: Adrenal Cortex Hormones; Adult; Cohort Studies; Disability Evaluation; Female; Fingolimod Hydrochloride; Humans; Immunologic Factors; JC Virus; Leukoencephalopathy, Progressive Multifocal; Magnetic Resonance Imaging; Male; Methylprednisolone; Middle Aged; Multiple Sclerosis; Natalizumab; Time Factors | 2016 |
Primary Cutaneous Cryptococcus in a Patient With Multiple Sclerosis Treated With Fingolimod.
Topics: Cryptococcosis; Cryptococcus neoformans; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Middle Aged; Multiple Sclerosis; Wound Infection | 2016 |
The low EOMES/TBX21 molecular phenotype in multiple sclerosis reflects CD56+ cell dysregulation and is affected by immunomodulatory therapies.
Topics: Adult; Aged; Case-Control Studies; CD56 Antigen; Cell Movement; Dimethyl Fumarate; Epstein-Barr Virus Nuclear Antigens; Female; Fingolimod Hydrochloride; Gene Expression Regulation; Genetic Predisposition to Disease; Glatiramer Acetate; HLA-DRB1 Chains; Humans; Immunologic Factors; Immunosuppressive Agents; Interferon-beta; Longitudinal Studies; Male; Middle Aged; Multiple Sclerosis; Natalizumab; Polymorphism, Single Nucleotide; T-Box Domain Proteins; Young Adult | 2016 |
Comparative efficacy of fingolimod vs natalizumab: A French multicenter observational study.
Topics: Adult; Cohort Studies; Female; Fingolimod Hydrochloride; Follow-Up Studies; France; Humans; Immunologic Factors; Immunosuppressive Agents; Male; Multiple Sclerosis; Natalizumab; Treatment Outcome | 2016 |
Plasma levels of endothelial and B-cell-derived microparticles are restored by fingolimod treatment in multiple sclerosis patients.
Topics: Adult; B-Lymphocytes; Cell-Derived Microparticles; Endothelial Cells; Endothelium, Vascular; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis | 2016 |
The multiple sclerosis drug fingolimod (FTY720) stimulates neuronal gene expression, axonal growth and regeneration.
Topics: Actins; Animals; Axons; Axotomy; Cells, Cultured; Facial Nerve; Fingolimod Hydrochloride; Gene Expression; Genes, Immediate-Early; Growth Cones; Immunosuppressive Agents; Mice; Mice, Inbred C57BL; Multiple Sclerosis; Nerve Regeneration; Nerve Tissue Proteins; Neurites; Neurons; Transcription Factors | 2016 |
Topical Application of Fingolimod Perturbs Cutaneous Inflammation.
Topics: Administration, Topical; Animals; Capillary Permeability; Cell Movement; Cells, Cultured; Cytokines; Dermatitis; Disease Models, Animal; Fingolimod Hydrochloride; Histamine; Humans; Immunoglobulin E; Inflammation Mediators; Mice; Mice, Inbred C57BL; Mice, Knockout; Multiple Sclerosis; Neutrophils; Phosphotransferases (Alcohol Group Acceptor); Skin | 2016 |
Cerebrospinal fluid biomarkers of inflammation and degeneration as measures of fingolimod efficacy in multiple sclerosis.
Topics: Adult; Biomarkers; Chemokine CXCL13; Disease Progression; Enzyme-Linked Immunosorbent Assay; Female; Fingolimod Hydrochloride; Glial Fibrillary Acidic Protein; Humans; Inflammation; Male; Middle Aged; Multiple Sclerosis; Neurofilament Proteins; Treatment Outcome; Young Adult | 2017 |
The risk of varicella zoster virus infection in multiple sclerosis patients treated with fingolimod.
Topics: Adult; Aged; Female; Fingolimod Hydrochloride; Herpes Zoster; Humans; Immunocompromised Host; Immunosuppressive Agents; Incidence; Male; Middle Aged; Multiple Sclerosis; Recurrence; Secondary Prevention | 2016 |
The Swiss Multiple Sclerosis Cohort-Study (SMSC): A Prospective Swiss Wide Investigation of Key Phases in Disease Evolution and New Treatment Options.
Topics: Adult; Biomarkers; Brain; Cohort Studies; Demography; Female; Fingolimod Hydrochloride; Follow-Up Studies; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis; Natalizumab; Prognosis; Prospective Studies; Radiography; Recurrence; Switzerland | 2016 |
Lymphomatoid papulosis type D in a fingolimod-treated multiple sclerosis patient.
Topics: Fingolimod Hydrochloride; Humans; Lymphomatoid Papulosis; Multiple Sclerosis; Skin Neoplasms | 2016 |
Fingolimod therapy modulates circulating B cell composition, increases B regulatory subsets and production of IL-10 and TGFβ in patients with Multiple Sclerosis.
Topics: Adult; Antigen Presentation; B-Lymphocyte Subsets; Cell Differentiation; Cell Survival; Cytokines; Female; Fingolimod Hydrochloride; Gene Expression; Humans; Immunologic Memory; Immunophenotyping; Immunosuppressive Agents; Inflammation Mediators; Interleukin-10; Leukocyte Count; Lymphocyte Activation; Lymphocyte Count; Male; Middle Aged; Multiple Sclerosis; Plasma Cells; Receptors, Lysosphingolipid; Sphingosine-1-Phosphate Receptors; Transforming Growth Factor beta; Young Adult | 2016 |
A comparison of multiple sclerosis clinical disease activity between patients treated with natalizumab and fingolimod.
Topics: Adult; Disease Progression; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis; Natalizumab; Prospective Studies; Recurrence; Treatment Outcome | 2017 |
Dengue fever in patients with multiple sclerosis taking fingolimod or natalizumab.
Topics: Adult; Brazil; Dengue; Female; Fingolimod Hydrochloride; Humans; Immunologic Factors; Male; Multiple Sclerosis; Natalizumab; Severity of Illness Index | 2016 |
Rebound Syndrome in Patients With Multiple Sclerosis After Cessation of Fingolimod Treatment.
Topics: Adult; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Longitudinal Studies; Magnetic Resonance Imaging; Middle Aged; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; PubMed; Recurrence | 2016 |
Multimodal evoked potentials follow up in multiple sclerosis patients under fingolimod therapy.
Topics: Adult; Disability Evaluation; Electroencephalography; Electromyography; Evoked Potentials; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Male; Multiple Sclerosis; Physical Stimulation; Statistics, Nonparametric; Transcranial Magnetic Stimulation | 2016 |
Development of a primary cutaneous CD30(+) anaplastic large-cell T-cell lymphoma during treatment of multiple sclerosis with fingolimod.
Topics: Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Ki-1 Antigen; Lymphoma, Large-Cell, Anaplastic; Middle Aged; Multiple Sclerosis; Skin Neoplasms | 2016 |
Mobitz type I and II atrioventricular blocks during fingolimod therapy.
Topics: Adult; Atrioventricular Block; Electrocardiography; Electroencephalography; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Multiple Sclerosis; Retrospective Studies; Severity of Illness Index; Treatment Outcome; Young Adult | 2016 |
Difference-in-Differences Method in Comparative Effectiveness Research: Utility with Unbalanced Groups.
Topics: Adolescent; Adult; Chi-Square Distribution; Comparative Effectiveness Research; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunosuppressive Agents; Insurance Claim Review; Insurance, Health; Male; Middle Aged; Multiple Sclerosis; Probability; Recurrence; Regression Analysis; Retrospective Studies; United States; Young Adult | 2016 |
B Lymphocytes in Multiple Sclerosis: Bregs and BTLA/CD272 Expressing-CD19+ Lymphocytes Modulate Disease Severity.
Topics: Adult; Antigens, CD19; B-Lymphocytes, Regulatory; Cells, Cultured; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Interferon-gamma; Interleukin-10; Interleukin-12; Male; Middle Aged; Multiple Sclerosis; Receptors, Immunologic; Severity of Illness Index; Transforming Growth Factor beta; Tumor Necrosis Factor-alpha; Young Adult | 2016 |
Tp-Te interval predicts heart rate reduction after fingolimod administration in patients with multiple sclerosis.
Topics: Adult; Electrocardiography; Female; Fingolimod Hydrochloride; Heart Rate; Humans; Immunosuppressive Agents; Male; Multiple Sclerosis; Patient Admission; Predictive Value of Tests | 2016 |
Identification of gene expression patterns crucially involved in experimental autoimmune encephalomyelitis and multiple sclerosis.
Topics: ADP-ribosyl Cyclase 1; Animals; Cell Movement; Chemokine CXCL12; Encephalomyelitis, Autoimmune, Experimental; Female; Fingolimod Hydrochloride; Gene Expression Profiling; Gene Expression Regulation; Humans; Immunization; Lymph Nodes; Mice, Inbred C57BL; Multiple Sclerosis; Myelin-Oligodendrocyte Glycoprotein; Peptides; Rats; Receptors, CXCR4; RNA, Messenger; Spinal Cord | 2016 |
Rituximab versus fingolimod after natalizumab in multiple sclerosis: Also consider progressive multifocal leukoencephalopathy risk.
Topics: Fingolimod Hydrochloride; Humans; Immunologic Factors; Leukoencephalopathy, Progressive Multifocal; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Rituximab | 2016 |
Safety of switching from natalizumab straight into fingolimod in a group of JCV-positive patients with multiple sclerosis.
Topics: Adult; Drug Substitution; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; JC Virus; Leukoencephalopathy, Progressive Multifocal; Male; Multiple Sclerosis; Natalizumab; Prospective Studies; Treatment Outcome; Viral Load | 2016 |
Fingolimod suppresses bone resorption in female patients with multiple sclerosis.
Topics: Adult; Bone Resorption; Collagen Type I; Disability Evaluation; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis; Peptide Fragments; Peptides; Procollagen; Sex Characteristics; Tartrate-Resistant Acid Phosphatase | 2016 |
High-Resolution Expression Profiling of Peripheral Blood CD8
Topics: Adult; CD8-Positive T-Lymphocytes; Cytokines; Cytotoxicity, Immunologic; Female; Fingolimod Hydrochloride; Humans; Lysophospholipids; Male; Middle Aged; Multiple Sclerosis; Phenotype; Sphingosine | 2017 |
New oral drugs for the treatment of multiple sclerosis.
Topics: Administration, Oral; Crotonates; Dimethyl Fumarate; Drug Monitoring; Drug-Related Side Effects and Adverse Reactions; Fingolimod Hydrochloride; Humans; Hydroxybutyrates; Immunosuppressive Agents; Medication Therapy Management; Multiple Sclerosis; Nitriles; Toluidines; United Kingdom | 2016 |
Rebound Syndrome in Multiple Sclerosis After Fingolimod Cessation.
Topics: Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting | 2016 |
Rebound Syndrome in Multiple Sclerosis After Fingolimod Cessation.
Topics: Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting | 2016 |
Rebound Syndrome in Multiple Sclerosis After Fingolimod Cessation-Reply.
Topics: Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting | 2016 |
Effects of sphingosine-1-phosphate receptor 1 phosphorylation in response to FTY720 during neuroinflammation.
Topics: Animals; Encephalomyelitis, Autoimmune, Experimental; Fingolimod Hydrochloride; Immunosuppressive Agents; Mice; Mice, Inbred C57BL; Multiple Sclerosis; Phosphorylation; Receptors, CCR6; Receptors, Lysosphingolipid; Sphingosine-1-Phosphate Receptors | 2016 |
Impact of Minocycline on Extracellular Matrix Metalloproteinase Inducer, a Factor Implicated in Multiple Sclerosis Immunopathogenesis.
Topics: Animals; Anti-Bacterial Agents; Basigin; Central Nervous System; Clinical Trials, Phase III as Topic; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Fingolimod Hydrochloride; Fumarates; Humans; Interferon-beta; Lymphocyte Activation; Maleates; Matrix Metalloproteinase 9; Mice; Mice, Inbred C57BL; Minocycline; Monocytes; Multiple Sclerosis; T-Lymphocytes; Tissue Inhibitor of Metalloproteinase-1 | 2016 |
Safety and Efficacy of Fingolimod and Natalizumab in Multiple Sclerosis After the Failure of First-Line Therapy: Single Center Experience Based on the Treatment of Forty-Four Patients.
Topics: Adult; Disease Progression; Drug Therapy, Combination; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Recurrence | 2016 |
Real-world effectiveness of natalizumab and fingolimod compared with self-injectable drugs in non-responders and in treatment-naïve patients with multiple sclerosis.
Topics: Adult; Disability Evaluation; Drug Resistance; Female; Fingolimod Hydrochloride; Follow-Up Studies; Humans; Immunologic Factors; Italy; Kaplan-Meier Estimate; Male; Multiple Sclerosis; Natalizumab; Propensity Score; Proportional Hazards Models; Recurrence; Retrospective Studies; Self Administration; Tertiary Care Centers; Treatment Outcome | 2017 |
Biology: A degenerative affliction.
Topics: Alemtuzumab; Antibodies, Monoclonal, Humanized; Environment; Fingolimod Hydrochloride; Genetic Predisposition to Disease; Geography, Medical; Humans; Multiple Sclerosis | 2016 |
Computer design, synthesis, and bioactivity analyses of drugs like fingolimod used in the treatment of multiple sclerosis.
Topics: Cell Survival; Computer-Aided Design; Dose-Response Relationship, Drug; Fingolimod Hydrochloride; Humans; Molecular Docking Simulation; Molecular Structure; Multiple Sclerosis; Structure-Activity Relationship; Tumor Cells, Cultured | 2017 |
An Observational Study to Assess Brain MRI Change and Disease Progression in Multiple Sclerosis Clinical Practice-The MS-MRIUS Study.
Topics: Adult; Brain; Disease Progression; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Longitudinal Studies; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis; Retrospective Studies | 2017 |
Fingolimod Associated Bilateral Cystoid Macular Edema-Wait and See?
Topics: Adult; Clinical Trials as Topic; Female; Fingolimod Hydrochloride; Fluorescein Angiography; Fundus Oculi; Humans; Macular Edema; Multiple Sclerosis; Tomography, Optical Coherence | 2016 |
Fingolimod (Gilenya) and melanoma.
Topics: Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Melanoma; Melanoma, Cutaneous Malignant; Middle Aged; Multiple Sclerosis; Skin Neoplasms | 2016 |
Assessment of Serum Nitrogen Species and Inflammatory Parameters in Relapsing-Remitting Multiple Sclerosis Patients Treated with Different Therapeutic Approaches.
Topics: Adolescent; Adult; Biomarkers; Fingolimod Hydrochloride; Humans; Inflammation; Interferon beta-1a; Interferon beta-1b; Middle Aged; Multiple Sclerosis; Natalizumab; Nitric Oxide; Reactive Nitrogen Species | 2016 |
q-Space Myelin Map imaging for longitudinal analysis of demyelination and remyelination in multiple sclerosis patients treated with fingolimod: A preliminary study.
Topics: Adolescent; Adult; Age Factors; Brain; Disability Evaluation; Feasibility Studies; Female; Fingolimod Hydrochloride; Humans; Image Interpretation, Computer-Assisted; Immunosuppressive Agents; Longitudinal Studies; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis; Myelin Sheath; Pilot Projects; Retrospective Studies; Treatment Outcome; White Matter; Young Adult | 2017 |
Severe rebound after withdrawal of fingolimod treatment in patients with multiple sclerosis.
Topics: Adult; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Middle Aged; Multiple Sclerosis | 2017 |
From natalizumab to fingolimod in eight weeks - Immunological, clinical, and radiological data in quest of the optimal switch.
Topics: Adult; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Female; Fingolimod Hydrochloride; Humans; Male; Middle Aged; Multiple Sclerosis; Natalizumab; Radiography; Recurrence; Young Adult | 2017 |
Hepatitis E virus infection in a patient with suspected drug-induced liver injury.
Topics: Chemical and Drug Induced Liver Injury; Diagnosis, Differential; Female; Fingolimod Hydrochloride; Hepatitis E; Humans; Immunosuppressive Agents; Middle Aged; Multiple Sclerosis | 2017 |
Effect of Fingolimod on Neural Stem Cells: A Novel Mechanism and Broadened Application for Neural Repair.
Topics: Animals; Cell Differentiation; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Extracellular Signal-Regulated MAP Kinases; Fingolimod Hydrochloride; Humans; Mice; Multiple Sclerosis; Myelin Sheath; Nerve Regeneration; Neural Stem Cells; Oligodendroglia; Receptors, Lysosphingolipid; Signal Transduction; Stem Cell Transplantation; Treatment Outcome | 2017 |
Fingolimod alters the transcriptome profile of circulating CD4+ cells in multiple sclerosis.
Topics: Adult; CD4-Positive T-Lymphocytes; Cells, Cultured; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis; Transcriptome | 2017 |
Cutaneous cryptococcosis in a patient taking fingolimod for multiple sclerosis: Here come the opportunistic infections?
Topics: Adult; Cryptococcosis; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis; Opportunistic Infections; Recurrence | 2017 |
Fingolimod additionally acts as immunomodulator focused on the innate immune system beyond its prominent effects on lymphocyte recirculation.
Topics: Adult; Cell Proliferation; Dose-Response Relationship, Drug; Female; Fingolimod Hydrochloride; Flow Cytometry; Humans; Immunity, Innate; Immunologic Factors; Lymphocyte Activation; Male; Middle Aged; Multiple Sclerosis; Young Adult | 2017 |
Infections cast cloud over Novartis' MS therapy.
Topics: Drug Industry; Fingolimod Hydrochloride; Humans; Multiple Sclerosis; Propylene Glycols; Sphingosine; Virus Diseases | 2008 |
FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis.
Topics: Animals; Antigens, CD; Cell Proliferation; Cytokines; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Interferon-gamma; Interleukin-2; Lymphocyte Subsets; Multiple Sclerosis; Propylene Glycols; Sphingosine; T-Lymphocytes | 2008 |
Trial watch: Phase III promise for oral multiple sclerosis therapy.
Topics: Administration, Oral; Clinical Trials, Phase III as Topic; Double-Blind Method; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Propylene Glycols; Randomized Controlled Trials as Topic; Sphingosine | 2009 |
FTY720 ameliorates MOG-induced experimental autoimmune encephalomyelitis by suppressing both cellular and humoral immune responses.
Topics: Animals; Autoantibodies; Axons; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Female; Fingolimod Hydrochloride; Gene Expression; Immunosuppressive Agents; Lymphocytes; Multiple Sclerosis; Myelin Proteins; Myelin-Associated Glycoprotein; Myelin-Oligodendrocyte Glycoprotein; Propylene Glycols; Rats; Rats, Inbred Strains; Recombinant Proteins; Severity of Illness Index; Sphingosine; Spinal Cord; Time Factors | 2010 |
The future of multiple sclerosis therapy.
Topics: Administration, Oral; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Cladribine; Crotonates; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Immunologic Factors; Injections, Intravenous; Injections, Subcutaneous; Interferon-beta; Multiple Sclerosis; Nitriles; Propylene Glycols; Quinolones; Sphingosine; Toluidines | 2009 |
[Multiple sclerosis, the therapeutic arsenal of today and tomorrow].
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Causality; Cladribine; Disabled Persons; Fingolimod Hydrochloride; Forecasting; France; Humans; Immunologic Factors; Immunosuppressive Agents; Multiple Sclerosis; Propylene Glycols; Research; Sphingosine; Vaccination; Vaccines, DNA | 2009 |
New drugs may improve, complicate treatment for multiple sclerosis.
Topics: Cladribine; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Propylene Glycols; Sphingosine | 2010 |
Multiple sclerosis: closing in on an oral treatment.
Topics: Administration, Oral; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Clinical Trials, Phase III as Topic; Fingolimod Hydrochloride; Humans; Lysophospholipids; Mitoxantrone; Multiple Sclerosis; Natalizumab; Propylene Glycols; Randomized Controlled Trials as Topic; Sphingosine | 2010 |
The impact of fingolimod (FTY720) in neuroimmunologic diseases: mechanisms beyond immunomodulation.
Topics: Fingolimod Hydrochloride; Humans; Immunomodulation; Immunosuppressive Agents; Multiple Sclerosis; Neurons; Oligodendroglia; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine | 2010 |
Fingolimod (FTY720) enhances remyelination following demyelination of organotypic cerebellar slices.
Topics: Animals; Animals, Newborn; Astrocytes; Cerebellum; Demyelinating Diseases; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Lysophosphatidylcholines; Mice; Microglia; Multiple Sclerosis; Myelin Sheath; Oligodendroglia; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine; Stem Cells; Tissue Culture Techniques | 2010 |
[How rare is tuberculosis?].
Topics: Antitubercular Agents; Europe; Fingolimod Hydrochloride; Humans; Multiple Sclerosis; Orphan Drug Production; Propylene Glycols; Sphingosine; Tuberculosis | 2010 |
[Emerging treatments for multiple sclerosis].
Topics: Cladribine; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Prognosis; Propylene Glycols; Sphingosine | 2010 |
Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis.
Topics: Adult; Case-Control Studies; CD3 Complex; CD4 Antigens; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Female; Fingolimod Hydrochloride; Humans; Immunologic Factors; Immunologic Memory; Immunosuppressive Agents; Interferon-beta; Interleukin-17; Male; Multiple Sclerosis; Propylene Glycols; Prospective Studies; Receptors, CCR4; Receptors, CCR6; Sphingosine; T-Lymphocytes | 2010 |
FTY720 and central memory: out of sight, out of mind.
Topics: Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Propylene Glycols; Sphingosine; T-Lymphocyte Subsets; T-Lymphocytes | 2010 |
News & views in ... Immunotherapy.
Topics: Animals; Antibodies, Blocking; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Female; Fingolimod Hydrochloride; HIV Envelope Protein gp120; HIV Infections; Humans; Maximum Tolerated Dose; Multiple Sclerosis; Ovarian Neoplasms; Propylene Glycols; Sphingosine; Thymidylate Synthase; Virus Internalization | 2009 |
Sphingosine 1-phosphate receptor 1 and 3 are upregulated in multiple sclerosis lesions.
Topics: Adult; Aged; Aged, 80 and over; Astrocytes; Brain; Cells, Cultured; Chemokines; Enzyme-Linked Immunosorbent Assay; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine; Sphingosine-1-Phosphate Receptors; T-Lymphocytes; Up-Regulation | 2010 |
Update on emerging therapies for multiple sclerosis.
Topics: Cladribine; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem Cells; Multiple Sclerosis; Neurology; Propylene Glycols; Sphingosine; Treatment Outcome | 2010 |
Avoiding infusion therapy prime benefit of new MS drug.
Topics: Adult; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Infusions, Parenteral; Managed Care Programs; Multiple Sclerosis; Propylene Glycols; Sphingosine; United States; United States Food and Drug Administration; Young Adult | 2010 |
Novartis eyes oral MS drug as potential blockbuster.
Topics: Administration, Oral; Animals; Clinical Trials as Topic; Drug Approval; Drug Industry; Fingolimod Hydrochloride; Humans; Lymphocytes; Lysophospholipids; Multiple Sclerosis; Propylene Glycols; Sphingosine | 2010 |
FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation.
Topics: Animals; Astrocytes; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Female; Fingolimod Hydrochloride; Gene Expression Regulation; Immunosuppressive Agents; Lymphocytes; Mice; Mice, Inbred C57BL; Mice, Knockout; Multiple Sclerosis; Propylene Glycols; Receptors, G-Protein-Coupled; Receptors, Lysosphingolipid; Signal Transduction; Sphingosine | 2011 |
Non-phosphorylated FTY720 induces apoptosis of human microglia by activating SREBP2.
Topics: Animals; Apoptosis; Caspase 3; Caspase 7; Caspase Inhibitors; Cell Line; Fingolimod Hydrochloride; Gene Expression Profiling; Gene Regulatory Networks; Humans; Immunosuppressive Agents; Microarray Analysis; Microglia; Multiple Sclerosis; Pertussis Toxin; Phosphorylation; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine; Sterol Regulatory Element Binding Protein 2 | 2011 |
Transforming multiple sclerosis trials into practical reality.
Topics: Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Interferon beta-1a; Interferon-beta; Multiple Sclerosis; Placebos; Propylene Glycols; Randomized Controlled Trials as Topic; Research Design; Sphingosine | 2011 |
Relapse of experimental autoimmune encephalomyelitis after discontinuation of FTY720 (Fingolimod) treatment, but not after combination of FTY720 and pathogenic autoantigen.
Topics: Animals; Autoantigens; Cyclosporine; Demyelinating Diseases; Drug Therapy, Combination; Encephalomyelitis, Autoimmune, Experimental; Female; Fingolimod Hydrochloride; Glycoproteins; Immunosuppression Therapy; Immunosuppressive Agents; Lymphocyte Activation; Mice; Mice, Inbred C57BL; Multiple Sclerosis; Myelin-Oligodendrocyte Glycoprotein; Nerve Tissue Proteins; Peptide Fragments; Propylene Glycols; Remission Induction; Secondary Prevention; Specific Pathogen-Free Organisms; Sphingosine; Spinal Cord | 2011 |
Delayed fingolimod-associated asystole.
Topics: Administration, Oral; Antipsychotic Agents; Bradycardia; Electrocardiography; Fingolimod Hydrochloride; Heart Arrest; Humans; Immunosuppressive Agents; Male; Multiple Sclerosis; Propylene Glycols; Risperidone; Sphingosine; Time Factors; Young Adult | 2011 |
MS Forum/MS Over the Past 17 Years.
Topics: Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Interferon beta-1a; Interferon beta-1b; Interferon-beta; Mitoxantrone; Multiple Sclerosis; Recurrence | 2011 |
Multiple Sclerosis: The Big Questions- The MS Forum Workshop.
Topics: Canada; Cladribine; Fingolimod Hydrochloride; Humans; Multiple Sclerosis; Nervous System Diseases; Neurology; Societies, Medical | 2011 |
American academy of neurology annual meeting.
Topics: Academies and Institutes; Administration, Oral; Canada; Cladribine; Fingolimod Hydrochloride; Humans; Multiple Sclerosis; Nervous System Diseases; Neurology | 2011 |
The effect of FTY720 in the Theiler's virus model of multiple sclerosis.
Topics: Animals; Cardiovirus Infections; Disease Models, Animal; Female; Fingolimod Hydrochloride; Immunosuppressive Agents; Injections, Intraperitoneal; Mice; Multiple Sclerosis; Propylene Glycols; Sphingosine; Theilovirus; Viral Load | 2011 |
Oral fingolimod rescues the functional deficits of synapses in experimental autoimmune encephalomyelitis.
Topics: Animals; Dendritic Spines; Encephalomyelitis, Autoimmune, Experimental; Excitatory Postsynaptic Potentials; Female; Fingolimod Hydrochloride; Glutamic Acid; Glycoproteins; Immunosuppressive Agents; Mice; Mice, Inbred C57BL; Multiple Sclerosis; Myelin-Oligodendrocyte Glycoprotein; Peptide Fragments; Propylene Glycols; Sphingosine; Synapses; Synaptic Transmission | 2012 |
Multiple sclerosis: Cladribine--a contentious therapeutic contender for MS.
Topics: Cladribine; Clinical Trials as Topic; Device Approval; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine | 2011 |
Cost-effectiveness of natalizumab versus fingolimod for the treatment of relapsing multiple sclerosis.
Topics: Antibodies, Monoclonal, Humanized; Cost-Benefit Analysis; Fingolimod Hydrochloride; Health Care Costs; Humans; Immunosuppressive Agents; Multiple Sclerosis; Natalizumab; Propylene Glycols; Recurrence; Sphingosine; United States | 2011 |
Targeting synaptic pathology in multiple sclerosis: fingolimod to the rescue?
Topics: Animals; Encephalomyelitis, Autoimmune, Experimental; Fingolimod Hydrochloride; Immunosuppressive Agents; Mice; Multiple Sclerosis; Propylene Glycols; Sphingosine; Synapses | 2012 |
Branch retinal vein occlusion during fingolimod treatment in a patient with multiple sclerosis.
Topics: Blindness; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Middle Aged; Multiple Sclerosis; Propylene Glycols; Retinal Vein; Retinal Vein Occlusion; Sphingosine | 2011 |
Melanoma occurring during treatment with fingolimod for multiple sclerosis: a case report.
Topics: Adult; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Melanoma; Multiple Sclerosis; Propylene Glycols; Skin Neoplasms; Sphingosine | 2011 |
[Fingolimod treatment for multiple sclerosis patients. Infectiological aspects and recommendations for vaccinations].
Topics: Fingolimod Hydrochloride; Herpes Simplex; Humans; Immunization, Secondary; Immunosuppressive Agents; Multiple Sclerosis; Propylene Glycols; Sphingosine | 2012 |
Multiple sclerosis treatment: First oral drug, new antibody therapies.
Topics: Administration, Oral; Antibodies, Monoclonal; Fingolimod Hydrochloride; Humans; Immunologic Factors; Multiple Sclerosis; Propylene Glycols; Sphingosine | 2011 |
[A plan for risk management in the treatment of multiple sclerosis with gilenia (fingolimod)].
Topics: Contraindications; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Multiple Sclerosis; Propylene Glycols; Risk Management; Sphingosine | 2011 |
S1P(1) receptor modulation with cyclical recovery from lymphopenia ameliorates mouse model of multiple sclerosis.
Topics: Animals; Central Nervous System; Cytokines; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Fingolimod Hydrochloride; Immunosuppressive Agents; Indans; Lymphopenia; Mice; Multiple Sclerosis; Oxadiazoles; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine | 2012 |
Balancing the benefits and risks of disease-modifying therapy in patients with multiple sclerosis.
Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunosuppressive Agents; Interferon-beta; Mitoxantrone; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Peptides; Pharmacovigilance; Propylene Glycols; Risk Assessment; Sphingosine | 2011 |
[Neurology].
Topics: Antibodies, Monoclonal; Anticonvulsants; Atrial Fibrillation; Carbamates; Chronic Disease; Deep Brain Stimulation; Dopamine Agonists; Epilepsy; Fingolimod Hydrochloride; Genetic Therapy; Humans; Immunosuppressive Agents; Ischemic Attack, Transient; Multiple Sclerosis; Muscular Diseases; Neurology; Parkinson Disease; Phenylenediamines; Polyneuropathies; Propylene Glycols; Sphingosine; Stroke; Treatment Outcome; Valproic Acid | 2012 |
Agency is under fire for refusing to supply details of sudden deaths after first dose of multiple sclerosis drug.
Topics: Death, Sudden; Disclosure; Drug-Related Side Effects and Adverse Reactions; Europe; Fingolimod Hydrochloride; Government Agencies; Humans; Immunosuppressive Agents; Multiple Sclerosis; Propylene Glycols; Sphingosine | 2012 |
Drugs: An injection of hope.
Topics: Alemtuzumab; Animals; Antibodies, Monoclonal, Humanized; Cladribine; Clinical Trials, Phase III as Topic; Crotonates; Dimethyl Fumarate; Disease Progression; Drug-Related Side Effects and Adverse Reactions; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Inflammation; Multiple Sclerosis; Natalizumab; Nitriles; Propylene Glycols; Quinolones; Risk Assessment; Sphingosine; Toluidines; United States; United States Food and Drug Administration | 2012 |
Fingolimod: cardiovascular deaths.
Topics: Cardiovascular Diseases; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Propylene Glycols; Sphingosine | 2012 |
A patient with Leiden V mutation, multiple sclerosis, psoriasis, and sicca syndrome: could celecoxib and fingolimod adversely affect the heart?
Topics: Arthritis, Psoriatic; Atrial Fibrillation; Autoimmune Diseases; Celecoxib; Cyclooxygenase Inhibitors; Drug Therapy, Combination; Factor V; Fingolimod Hydrochloride; Heart; Heart Diseases; Heart Failure; Humans; Hypertension; Immunosuppressive Agents; Male; Middle Aged; Mitral Valve Insufficiency; Multiple Sclerosis; Mutation; Myocardium; Propylene Glycols; Pyrazoles; Sjogren's Syndrome; Sphingosine; Sulfonamides | 2012 |
[Basic mechanisms of action of fingolimod in relation to multiple sclerosis].
Topics: Animals; Atrophy; B-Lymphocytes; Brain; Cell Movement; Drug Evaluation, Preclinical; Encephalomyelitis, Autoimmune, Experimental; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; L-Selectin; Lysophospholipids; Mice; Molecular Structure; Multiple Sclerosis; Neuroglia; Propylene Glycols; Rats; Receptors, CCR7; Receptors, Lysosphingolipid; Sphingosine; T-Lymphocyte Subsets; Th17 Cells | 2012 |
Prolonged and symptomatic bradycardia following a single dose of fingolimod.
Topics: Adult; Bradycardia; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Propylene Glycols; Sphingosine | 2013 |
[Disease modifying drugs in multiple sclerosis and pregnancy].
Topics: Abnormalities, Drug-Induced; Abortion, Spontaneous; Antibodies, Monoclonal, Humanized; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunologic Factors; Immunosuppressive Agents; Infant, Newborn; Interferon-beta; Multiple Sclerosis; Natalizumab; Peptides; Pregnancy; Pregnancy Complications; Prenatal Exposure Delayed Effects; Propylene Glycols; Sphingosine; Stillbirth | 2012 |
New disease-modifying therapies and new challenges for MS.
Topics: Antibodies, Monoclonal, Humanized; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; JC Virus; Leukoencephalopathy, Progressive Multifocal; Multiple Sclerosis; Natalizumab; Propylene Glycols; Risk; Sphingosine | 2012 |
Targeting intracerebral inflammation in multiple sclerosis: is it feasible?
Topics: Animals; Astrocytes; Blood-Brain Barrier; Ceramides; Demyelinating Diseases; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Multiple Sclerosis; NF-kappa B; Oligodendroglia; Propylene Glycols; Quinolones; Sphingosine | 2012 |
Fingolimod attenuates ceramide-induced blood-brain barrier dysfunction in multiple sclerosis by targeting reactive astrocytes.
Topics: Adult; Aged; Aged, 80 and over; Astrocytes; Blood-Brain Barrier; Cell Movement; Cells, Cultured; Ceramides; Endothelial Cells; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Middle Aged; Monocytes; Multiple Sclerosis; Propylene Glycols; Sphingomyelins; Sphingosine | 2012 |
The safety risks of innovation: the FDA's Expedited Drug Development Pathway.
Topics: Anticoagulants; Antineoplastic Agents; Benzimidazoles; beta-Alanine; Carcinoma, Neuroendocrine; Clinical Trials as Topic; Dabigatran; Drug Approval; Efficiency, Organizational; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Patient Safety; Piperidines; Propylene Glycols; Quinazolines; Risk; Sphingosine; Stroke; Thyroid Neoplasms; Time Factors; United States; United States Food and Drug Administration | 2012 |
Fingolimod and multiple sclerosis: four cautionary tales.
Topics: Antibodies, Monoclonal, Humanized; Brain; Cerebrovascular Disorders; Encephalitis, Varicella Zoster; Female; Fingolimod Hydrochloride; Herpes Zoster; Humans; Immunosuppressive Agents; Leukoencephalopathy, Progressive Multifocal; Male; Multiple Sclerosis; Natalizumab; Nerve Fibers, Myelinated; Propylene Glycols; Sphingosine | 2012 |
Tumefactive multiple sclerosis lesions under fingolimod treatment.
Topics: Aspartic Acid; Brain; Choline; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Inositol; Magnetic Resonance Imaging; Multiple Sclerosis; Nerve Fibers, Myelinated; Propylene Glycols; Sphingosine; Young Adult | 2012 |
Multiple sclerosis rebound following herpes zoster infection and suspension of fingolimod.
Topics: Adult; Anti-Inflammatory Agents; Brain; Fingolimod Hydrochloride; Herpes Zoster; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Male; Methylprednisolone; Multiple Sclerosis; Propylene Glycols; Sphingosine | 2012 |
Gilenya safety update: cardiac and macula.
Topics: Bradycardia; Drug Monitoring; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Macular Edema; Multiple Sclerosis; Propylene Glycols; Sphingosine | 2012 |
Time to talk about timing--when to start, stop and change anti-migratory drugs in MS.
Topics: Antibodies, Monoclonal, Humanized; Drug Administration Schedule; Drug Substitution; Fingolimod Hydrochloride; Humans; Immunologic Factors; Multiple Sclerosis; Natalizumab; Patient Selection; Propylene Glycols; Sphingosine; Time Factors; Treatment Outcome | 2012 |
Emerging tumefactive multiple sclerosis after switching therapy from natalizumab to fingolimod.
Topics: Antibodies, Monoclonal, Humanized; Brain; Drug Administration Schedule; Drug Substitution; Fingolimod Hydrochloride; Humans; Immunologic Factors; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis; Natalizumab; Propylene Glycols; Recurrence; Sphingosine; Time Factors; Treatment Outcome | 2012 |
Disease reactivation after fingolimod discontinuation in two multiple sclerosis patients.
Topics: Adult; Disability Evaluation; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Middle Aged; Multiple Sclerosis; Propylene Glycols; Recurrence; Sphingosine; Substance Withdrawal Syndrome | 2013 |
Hepatitis E masquerading as drug-induced liver injury.
Topics: Adult; Chemical and Drug Induced Liver Injury; Diagnosis, Differential; Fingolimod Hydrochloride; Hepatitis E; Hepatitis E virus; Humans; Male; Multiple Sclerosis; Propylene Glycols; RNA, Viral; Sphingosine | 2012 |
[Fingolimod compassionate use program: case study on the concept of a therapy option for multiple sclerosis prior to marketing approval].
Topics: Adult; Case-Control Studies; Comorbidity; Compassionate Use Trials; Drug Approval; Drug-Related Side Effects and Adverse Reactions; Europe; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis; Prevalence; Propylene Glycols; Sphingosine; Treatment Outcome | 2012 |
Higher macular volume in patients with MS receiving fingolimod: positive outcome or side effect?
Topics: Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Macula Lutea; Male; Multiple Sclerosis; Propylene Glycols; Sphingosine | 2013 |
Fingolimod treatment in multiple sclerosis leads to increased macular volume.
Topics: Adult; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Linear Models; Longitudinal Studies; Macula Lutea; Male; Multiple Sclerosis; Propylene Glycols; Receptors, Lysosphingolipid; Retinal Neurons; Sphingosine; Tomography, Optical Coherence | 2013 |
[New therapies in multiple sclerosis].
Topics: Antibodies, Monoclonal, Humanized; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Natalizumab; Propylene Glycols; Sphingosine | 2012 |
Fingolimod reduces recurrence of disease activity after natalizumab withdrawal in multiple sclerosis.
Topics: Adult; Antibodies, Monoclonal, Humanized; Disability Evaluation; Drug Substitution; Female; Fingolimod Hydrochloride; Follow-Up Studies; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Propylene Glycols; Sphingosine; Time Factors; Young Adult | 2013 |
[New, effective immunomodulatory drug in treatment of multiple sclerosis: the fingolimod].
Topics: Cardiovascular System; Clinical Trials, Phase III as Topic; Controlled Clinical Trials as Topic; Fingolimod Hydrochloride; Humans; Immunologic Factors; Immunosuppressive Agents; Multiple Sclerosis; Propylene Glycols; Sphingosine; Treatment Outcome | 2012 |
In the coming year we should abandon interferons and glatiramer acetate as first-line therapy for MS: yes.
Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Clinical Trials as Topic; Crotonates; Dimethyl Fumarate; Fingolimod Hydrochloride; Fumarates; Glatiramer Acetate; Humans; Hydroxybutyrates; Immunologic Factors; Interferons; Multiple Sclerosis; Natalizumab; Nitriles; Peptides; Propylene Glycols; Sphingosine; Toluidines | 2013 |
Cystoid macular edema associated with fingolimod use for multiple sclerosis.
Topics: Administration, Oral; Female; Fingolimod Hydrochloride; Fluorescein Angiography; Humans; Immunosuppressive Agents; Macular Edema; Male; Middle Aged; Multiple Sclerosis; Propylene Glycols; Retrospective Studies; Sphingosine; Tomography, Optical Coherence; Visual Acuity | 2013 |
[Multiple sclerosis. A new oral immunomodulator].
Topics: Clinical Trials as Topic; Fingolimod Hydrochloride; Humans; Immunologic Factors; Multiple Sclerosis; Propylene Glycols; Sphingosine; T-Lymphocytes | 2005 |
Multiple sclerosis poses tough drug development challenges.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Clinical Trials as Topic; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Inflammation; Integrin alpha2; Multiple Sclerosis; Natalizumab; Propylene Glycols; Sphingosine | 2005 |
Fingolimod and sphingosine-1-phosphate--modifiers of lymphocyte migration.
Topics: Animals; Autoantigens; Cell Movement; Central Nervous System; Down-Regulation; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Lymph Nodes; Lysophospholipids; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Sphingosine; T-Lymphocytes | 2006 |
The curtain is drawn for both natalizumab and fingolimod (FTY720): a new era of multiple sclerosis therapy has arrived.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Clinical Trials as Topic; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Natalizumab; Practice Patterns, Physicians'; Propylene Glycols; Sphingosine | 2006 |
Multiple sclerosis: new insights and therapeutic progress.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Brain; Canada; Encephalomyelitis, Autoimmune, Experimental; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Interleukin-18; Multiple Sclerosis; Natalizumab; Propylene Glycols; Randomized Controlled Trials as Topic; Sex Factors; Sphingosine | 2007 |
Brain penetration of the oral immunomodulatory drug FTY720 and its phosphorylation in the central nervous system during experimental autoimmune encephalomyelitis: consequences for mode of action in multiple sclerosis.
Topics: Administration, Oral; Animals; Autoradiography; Brain; Encephalomyelitis, Autoimmune, Experimental; Female; Fingolimod Hydrochloride; Immunosuppressive Agents; Lymphocyte Count; Multiple Sclerosis; Phosphorylation; Propylene Glycols; Rats; Rats, Inbred Lew; Sphingosine | 2007 |